Targeting the Intrinsic Pathway of Coagulation with RNA Aptamers

by

Rebecca Leigh Smock Woodruff

University Program in Genetics and Genomics
Duke University

Date:_______________________
Approved:

___________________________
Bruce Sullenger, Supervisor

___________________________
Meta Kuehn

___________________________
Gow Arepally

___________________________
Barbara Shaw

___________________________
Richard Becker

Dissertation submitted in partial fulfillment of
the requirements for the degree of Doctor
of Philosophy in the University Program in Genetics and Genomics
in the Graduate School
of Duke University

2013
ABSTRACT

Targeting the Intrinsic Pathway of Coagulation with RNA Aptamers

by

Rebecca Leigh Smock Woodruff

University Program in Genetics and Genomics
Duke University

Date:_______________________

Approved:

___________________________
Bruce Sullenger, Supervisor

___________________________
Meta Kuehn

___________________________
Gow Arepally

___________________________
Barbara Shaw

___________________________
Richard Becker

An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the University Program of Genetics and Genomics in the Graduate School of Duke University

2013
Abstract

Thrombosis is associated with the occlusion of a blood vessel and can be triggered by a number of types of injury, such as the rupture of an atherosclerotic plaque on the artery wall, changes in blood composition, or blood stasis. The resulting thrombosis can cause major diseases such as myocardial infarction, stroke, and venous thromboembolic disorders that, collectively, account for the most common cause of death in the developed world. Anticoagulants are used to treat and prevent these thrombotic diseases in a number of clinical and surgical settings. Although commonly prescribed, currently approved anticoagulants have a major limitation of severe drug-induced bleeding, which contributes to the high levels of morbidity and mortality associated with use. The “holy grail” for antithrombotic therapy is to identify a drug that inhibits thrombus formation without promoting bleeding. Understanding the differences between thrombosis and hemostasis in the vascular system is critical to developing these safe and effective anticoagulants, as this depends on striking the correct balance between inhibiting thrombus formation (efficacy) and reducing the risk of severe bleeding (safety). While it is commonly thought that the same factors play a similar role in hemostasis and thrombosis, recent evidence points to differing functions for FXI and FXII in each of these settings. Importantly, these factors seem to contribute to pathological thrombus formation without being involved in normal hemostasis.
The overall goal of this project was to evaluate the inhibition of the intrinsic pathway of coagulation as a potential anticoagulant strategy utilizing the aptamer platform. Aptamers are short, highly structured nucleic acids that act as antagonists by binding to large surface areas on their target protein and thus tend to inhibit protein-protein interactions. High affinity binding aptamers have been isolated that specifically target a diverse range of proteins, including transcription factors, proteases, viral proteins, and growth factors, as well as other coagulation factors. As synthetic molecules, aptamers have a small molecular weight, are highly amenable to modifications that can control their bioavailability, and have not been found to elicit an immune response, thus making them ideal drug candidates. Importantly, aptamers can be rapidly and effectively reversed with either a sequence specific antidote that recognizes the primary sequence of the aptamer or a universal antidote that binds to their backbone and reverses all aptamer activity independent of sequence. This ability lends itself well to their therapeutic application in coagulation, as rapid reversal of a drug upon the onset of bleeding is a key property for increasing the safety of this class of drugs.

Aptamers targeting FXI/FXIa and FXII/FXIIa were isolated in two separate SELEX (systematic evolution of ligands by exponential enrichment) procedures: the FXII aptamer was isolated in a convergent SELEX approach and the FXIa aptamer was isolated from a purified protein selection. In both processes, 2’fluoropyrimidine
modified RNA with a 40-nucleotide random region was incubated with either the plasma proteome (in initial rounds of the convergent SELEX) or the purified protein target (FXII or FXIa). The nucleic acids that did not bind to the target were separated from those that bound, and these molecules were then amplified to generate an enriched pool with increased binding affinity for the target. This process was repeated under increasingly stringent conditions to isolate the aptamer that bound with the highest affinity to the purified target protein. Utilizing biochemical and in vitro coagulation assays, specific, high-affinity binding and functional anticoagulant aptamers were identified for both protein targets, and the mechanism of anticoagulation was ascertained for each aptamer.

Overall, both aptamers bound to an exosite on their target protein that was able to inhibit downstream activation of the next protein in the coagulation cascade. In order to specifically examine aptamer effects on several parameters of thrombin generation, a new assay was developed and fully characterized using aptamer anticoagulants targeting other coagulation factors. Aptamer inhibition of both FXI and FXII was able to decrease thrombin generation in human plasma. However, limited cross-reactivity in other animal species by both aptamers hindered our ability to assess aptamer inhibition in an in vivo setting. The further characterization and use of these aptamers in plasma and blood based settings will allow us to study the diverging functions of the intrinsic pathway in thrombosis and hemostasis.
A critical need exists for safe and effective anticoagulants to treat and prevent numerous thrombotic procedures and diseases. An ideal anticoagulant is one that strikes the correct balance between inhibiting thrombus formation and reducing drug-induced bleeding. Inhibition or depletion of factors XI and XII of the intrinsic pathway of coagulation have shown reduced thrombus formation without interruption of normal hemostasis in several models of thrombosis. By developing novel RNA aptamer anticoagulants to these factors, we have set the stage for evaluating the net therapeutic benefit of intrinsic pathway inhibition to effectively control coagulation, manage thrombosis, and improve patient outcome. As well as developing a safe anticoagulant, these agents can lead to important biological discoveries concerning the fundamental difference between hemostasis and thrombosis.
Dedication

I would like to first dedicate this work to my parents, Leonard Alfred Smock, PhD., and Ellen Gilinsky, PhD., who have taught me to have an inquisitive mind and have unquestionably supported me in everything I pursue to do in life. In addition, I would also like to dedicate this work to my grandfather, Stanley Ellis Gilinsky, who, during retirement, would read calculus and genetic textbooks for fun and taught me to never, ever stop learning.
Contents

Abstract ................................................................................................................................. iv

List of Tables ....................................................................................................................... xiii

List of Figures ..................................................................................................................... xiv

List of Abbreviations ........................................................................................................ xvii

Acknowledgements ........................................................................................................... xxi

1. Introduction .................................................................................................................... 1

1.1 Coagulation .................................................................................................................. 1

1.1.1 Thrombosis and Hemostasis .................................................................................... 1

1.1.2 Coagulation Cascade ............................................................................................... 2

1.2 Contact Pathway/Intrinsic pathway .......................................................................... 11

1.2.1 FXII ......................................................................................................................... 12

1.2.2 FXI ........................................................................................................................ 15

1.2.3 The roles of the contact pathway ........................................................................... 20

1.2.3.1 The Evolution of the Contact Pathway ............................................................... 22

1.2.3.2 Hemostasis and Thrombosis ............................................................................. 23

1.3.2.3 Fibrinolysis ....................................................................................................... 27

1.3.2.4 Platelets ............................................................................................................. 28

1.3.2.5 Inflammation .................................................................................................... 30

1.3.2.6 Angiogenesis .................................................................................................... 32

1.3.2.7 Inhibitors of the contact pathway .................................................................. 33

1.3 Antithrombotics ......................................................................................................... 35
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3.1 Cardiovascular Disease</td>
<td>35</td>
</tr>
<tr>
<td>1.3.2 Anticoagulant agents</td>
<td>40</td>
</tr>
<tr>
<td>1.3.3 Antiplatelet agents</td>
<td>44</td>
</tr>
<tr>
<td>1.3.4 Ideal Antithrombotic Agents</td>
<td>46</td>
</tr>
<tr>
<td>1.4 Aptamers and SELEX</td>
<td>50</td>
</tr>
<tr>
<td>1.4.1 Emergence of Aptamers &amp; SELEX</td>
<td>51</td>
</tr>
<tr>
<td>1.4.2 Aptamers as Therapeutics</td>
<td>56</td>
</tr>
<tr>
<td>1.4.3 Current aptamer therapeutics</td>
<td>62</td>
</tr>
<tr>
<td>1.4.4 Aptamers as antithrombotics</td>
<td>66</td>
</tr>
<tr>
<td>1.4.4.1 Inhibiting the common pathway</td>
<td>66</td>
</tr>
<tr>
<td>1.4.4.2 Inhibiting the extrinsic pathway</td>
<td>72</td>
</tr>
<tr>
<td>1.4.4.3 Inhibiting the intrinsic pathway</td>
<td>72</td>
</tr>
<tr>
<td>1.4.4.4 Inhibiting platelet pathways</td>
<td>79</td>
</tr>
<tr>
<td>2. Characterization of an anticoagulant aptamer against FXII</td>
<td>82</td>
</tr>
<tr>
<td>2.1 Introduction</td>
<td>82</td>
</tr>
<tr>
<td>2.2 Materials and Methods</td>
<td>84</td>
</tr>
<tr>
<td>2.3 Results</td>
<td>93</td>
</tr>
<tr>
<td>2.3.1 SELEX Pool Analysis and Lead Clone Selection</td>
<td>93</td>
</tr>
<tr>
<td>2.3.2 Lead aptamer binding affinity and specificity</td>
<td>98</td>
</tr>
<tr>
<td>2.3.3 Biochemical Characterization of aptamer inhibition</td>
<td>100</td>
</tr>
<tr>
<td>2.3.4 Truncation of aptamer</td>
<td>107</td>
</tr>
<tr>
<td>2.3.5 Functional Characterization of aptamer inhibition</td>
<td>110</td>
</tr>
</tbody>
</table>
2.4 Discussion .............................................................................................................116

3. Characterization of an anticoagulant aptamer targeting FXI..............................122
  3.1 Introduction ..........................................................................................................122
  3.2 Materials and Methods..........................................................................................126
  3.3 Results ..................................................................................................................135
    3.3.1 SELEX Pool Analysis and Lead Clone Selection ..............................................135
    3.3.2 Lead Aptamer Biochemical Characterization..................................................141
    3.2.3 Lead Aptamer Functional Analysis...................................................................146
  3.4 Discussion ............................................................................................................152

4. Comparing the sensitivity of coagulation assays for target validation ...............161
  4.1 Introduction ..........................................................................................................161
  4.2 Materials and Methods..........................................................................................164
  4.3 Results ..................................................................................................................168
    4.3.1 Modified TGA assay validation.........................................................................168
    4.3.2 Modified TGA parameter analysis upon aptamer inhibition..........................176
    4.3.3 Comparison of aptamer inhibition and mTGA validation in human plasma and
         blood-based coagulation assays..........................................................................184
    4.3.4 Comparison of aptamer inhibition and mTGA validation in animal plasma and
         blood-based coagulation assays..........................................................................187
  4.4 Discussion ............................................................................................................188

5. Conclusions and Perspectives ..............................................................................195
  5.1 The rationale behind developing aptamer inhibitors of the intrinsic pathway of
       coagulation..............................................................................................................195
5.2 Discovery and pre-clinical development of intrinsic pathway aptamer inhibitors .................................................................................................................. 198

5.3 Clinical development of aptamer therapeutics ................................................................................................................................. 205

5.4 Applications and the therapeutic potential of an intrinsic pathway inhibitor .... 207

5.5 Summary ......................................................................................................................................................................................... 210

References ...................................................................................................................................................................................... 216

Biography ..................................................................................................................................................................................... 244
List of Tables

Table 1. Current anticoagulant agents..........................................................................................41

Table 2. Current antiplatelet agents..........................................................................................44

Table 3. Aptamers in clinical trials............................................................................................64

Table 4. RNA aptamer sequences from FXII convergent SELEX.............................................95

Table 5. RNA aptamer binding to soluble FXII and FXIIa as determined by a nitrocellulose filter-binding assay ..........................................................................................................................96

Table 6. Truncation strategy for R4cXII-1 .................................................................................108

Table 7. RNA aptamer sequences from FXIa solution-based SELEX........................................139

Table 8. FXI aptamer screening results.......................................................................................141

Table 9. RNA aptamer binding to soluble FXI and FXIa as determined by a nitrocellulose filter-binding assay ..........................................................................................................................144

Table 10. Summary of aptamer properties..................................................................................170

Table 11. Summary of preliminary TEG parameters with the panel of aptamers in human whole blood ..........................................................................................................................186

Table 12. Summary of aptamer effects in clinical coagulation assays on human plasma or blood ........................................................................................................................................187

Table 13. Summary of aptamer effects in clinical coagulation assays on rabbit plasma or blood ........................................................................................................................................188
List of Figures

Figure 1. The cascade model of coagulation........................ .................................................. 4
Figure 2. The cell-based model of coagulation........................................................................6
Figure 3. The coagulation cascade, including the anticoagulant and fibrinolytic systems .......................................................... 11
Figure 4. A crystal structure of dimerized zymogen FXI .................................................. 16
Figure 5. A depiction of two types of thrombosis..................................................................38
Figure 6. Crystal structure of the RNA aptamer Tog25 to thrombin.................................70
Figure 7. The REG1 anticoagulation system.........................................................................75
Figure 8. Binding affinity of SELEX rounds against purified FXII.......................................94
Figure 9. Screen of FXII aptamers in a functional clotting assay, the aPTT ......................97
Figure 10. The M-fold predicted secondary structure of the full-length aptamer R4cXII-1 .......................................................................................................................... 98
Figure 11. Aptamer R4cXII-1 binds with high affinity to FXII and FXIIa ..........................99
Figure 12. Aptamer R4cXII-1 binds with reduced affinity to β-fXIIa............................ 100
Figure 13. Aptamer R4cXII-1 does not inhibit FXIIa cleavage of a small peptide substrate .............................................................................................................................. 101
Figure 14. Aptamer R4cXII-1 does not induce autoactivation of FXII but blocks the activities of several autoactivators of FXII ................................................................. 103
Figure 15. Aptamer R4cXII-1 dose dependently inhibits FXIIa-catalyzed activation of FXI ................................................................................................................................. 105
Figure 16. Aptamer R4cXII-1 does not inhibit the ability of FXII to activate prekallikrein ............................................................................................................................... 107
Figure 17. The M-fold predicted secondary structure of the truncated aptamer R4cXII-1T22 .......................................................................................................................... 109
Figure 18. Aptamer R4cXII-1t dose dependently anticoagulates human plasma in an aPTT, but not a PT clotting assay .................................................................111

Figure 19. Aptamer R4cXII-1t dose dependently inhibits FXIIa clotting times, but not FXIa clotting times.................................................................112

Figure 20. Aptamer R4cXII-1t dose dependently impairs thrombin generation in a TGA assay initiated with ellagic acid...........................................114

Figure 21. Analysis of R4cXII-1t cross-reactivity utilizing the aPTT across select animal species.................................................................................116

Figure 22. A schematic depicting the role of the FXII aptamer, R4cXII-1, in inhibiting FXII/FXIIa function .................................................................117

Figure 23. Analysis of FXIa SELEX rounds active site functionality and sequence diversity ..........................................................................................138

Figure 24. Representative secondary structures of clone families.................................140

Figure 25. Active site activity assay to determine lead clone candidates.......................142

Figure 26. Aptamer 11.7 binds preferentially to FXIa while aptamer 12.7 binds to both zymogen FXI and FXIa ........................................................................143

Figure 27. Both lead aptamers reduce FXIa-catalyzed activation of FIX.......................145

Figure 28. Both aptamers inhibit thrombin generation in a reconstituted cell-based model.......................................................................................146

Figure 29. Lead aptamer screening in functional clotting assays.................................148

Figure 30. Aptamer 12.7 dose dependently impairs thrombin generation in a TGA assay initiated with ellagic acid .....................................................150

Figure 31. FXI aptamers can impair clot strength parameters in a thromboelastogram activated with kaolin .................................................................151

Figure 32. A schematic depicting the role of the FXI aptamer, 12.7, in inhibiting FXI/FXIIa function .............................................................................153

Figure 33. Dose titrations of the panel of aptamers in the mTGA.....................................171
Figure 34. Comparison of the inhibition of the common pathway with the FX aptamer during the standard TF-activated TGA versus the modified ellagic acid-activated TGA .............................................................. 173

Figure 35. Comparison of the inhibition of the intrinsic pathway during the standard TF-activated TGA versus the modified ellagic acid-activated TGA ..................................................... 175

Figure 36. Comparison of the endogenous thrombin potential (ETP) during aptamer inhibition in the modified ellagic acid-activated TGA ................................................................. 177

Figure 37. Comparison of the peak amount of thrombin formed during aptamer inhibition in the modified ellagic acid-activated TGA ................................................................. 179

Figure 38. Comparison of the rate of thrombin generation during aptamer inhibition in the modified ellagic acid-activated TGA ................................................................. 181

Figure 39. Comparison of the lagtime during aptamer inhibition in the modified ellagic acid-activated TGA ................................................................. 183

Figure 40. Comparison of clotting times during aptamer inhibition in an aPTT and PT with human plasma ................................................................. 185

Figure 41. Decoupling hemostasis and thrombosis ................................................................. 197

Figure 42. Inhibiting the intrinsic pathway of coagulation with RNA aptamers .......... 199

Figure 43. Control RNA comparison in an aPTT assay ................................................................. 212

Figure 44. An RNA control exhibits antagonistic effects in a modified TGA assay ........ 213

Figure 45. Analysis of polyanions on FXIIa or FXIa clotting times ................................................................. 215
List of Abbreviations

16.3  FVIIa binding RNA aptamer
11F7t  FX binding RNA aptamer
2’F  Fluoro modification on the 2’ position of ribose
2’OMe  2’ O-methyl modification on the 2’ position of ribose
ACS  acute coronary syndrome
AF  atrial fibrillation
APC  activated protein C
aPTT  activated partial thromboplastin time
ARC1779  VWF binding RNA/DNA aptamer
AT  antithrombin
BK  bradykinin
BSA  bovine serum albumin
CAD  coronary artery disease
CTI  corn trypsin inhibitor
CVD  cardiovascular disease
DIC  disseminated intravascular coagulation
DVT  deep venous thrombosis
EPCR  endothelial protein C receptor
ETP  endogenous thrombin potential
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIX</td>
<td>factor IX</td>
</tr>
<tr>
<td>FIXa</td>
<td>activated factor IX</td>
</tr>
<tr>
<td>FVa</td>
<td>activated factor V</td>
</tr>
<tr>
<td>FVII</td>
<td>factor VII</td>
</tr>
<tr>
<td>FVIIa</td>
<td>activated factor VII</td>
</tr>
<tr>
<td>FVIII</td>
<td>factor VIII</td>
</tr>
<tr>
<td>FX</td>
<td>factor X</td>
</tr>
<tr>
<td>FXa</td>
<td>activated factor X</td>
</tr>
<tr>
<td>FXI</td>
<td>factor XI</td>
</tr>
<tr>
<td>FXII</td>
<td>factor XII</td>
</tr>
<tr>
<td>FXIIa</td>
<td>activated factor XII</td>
</tr>
<tr>
<td>GP1bα</td>
<td>glycoprotein 1b α-polypeptide</td>
</tr>
<tr>
<td>GPVI</td>
<td>glycoprotein VI</td>
</tr>
<tr>
<td>HAE</td>
<td>hereditary angioedema</td>
</tr>
<tr>
<td>HD1</td>
<td>thrombin binding DNA aptamer</td>
</tr>
<tr>
<td>HD22</td>
<td>thrombin binding DNA aptamer</td>
</tr>
<tr>
<td>HGFA</td>
<td>human growth factor activator</td>
</tr>
<tr>
<td>HIT</td>
<td>heparin-induced thrombocytopenia</td>
</tr>
<tr>
<td>HITT</td>
<td>heparin-induced thrombocytopenia with thrombosis</td>
</tr>
<tr>
<td>HK</td>
<td>high molecular weight kininogen</td>
</tr>
</tbody>
</table>
MI   myocardial infarction
mTGA  modified thrombin generation assay
NETs  neutrophil extracellular traps
NU172 thrombin binding DNA aptamer
PAD   peripheral artery disease
PAI-1 plasminogen activator 1
PCI   percutaneous coronary intervention
PCK   D-Pro-Phe-Arg chloromethyl ketone
PE    pulmonary embolism
PEG   polyethylene glycol
PK    prekallikrein
PSMA  prostate-specific membrane antigen
PT    partial thromboplastin time
R4cXII-1 FXII binding RNA aptamer
R9.14 VWF binding RNA aptamer
R9d14t thrombin binding RNA aptamer
RB006 FIXa binding RNA aptamer
RB007 FIXa aptamer antidote
REG1  FIXa aptamer and antidote system
RFLP  restriction fragment length polymorphism
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>SELEX</td>
<td>systematic evolution of ligands by exponential enrichment</td>
</tr>
<tr>
<td>TAFI</td>
<td>thrombin activated fibrinolysis inhibitor</td>
</tr>
<tr>
<td>TEG</td>
<td>thromboelastogram</td>
</tr>
<tr>
<td>TF</td>
<td>tissue factor</td>
</tr>
<tr>
<td>TFPI</td>
<td>tissue factor pathway inhibitor</td>
</tr>
<tr>
<td>TGA</td>
<td>thrombin generation assay</td>
</tr>
<tr>
<td>TM</td>
<td>thrombomodulin</td>
</tr>
<tr>
<td>tMCAO</td>
<td>transient middle cerebral artery stroke model</td>
</tr>
<tr>
<td>Tog25</td>
<td>thrombin binding RNA aptamer</td>
</tr>
<tr>
<td>tPA</td>
<td>tissue plasminogen activator</td>
</tr>
<tr>
<td>uPA</td>
<td>urokinase plasminogen activator</td>
</tr>
<tr>
<td>uPAR</td>
<td>urokinase plasminogen activator receptor</td>
</tr>
<tr>
<td>VKA</td>
<td>vitamin K antagonists</td>
</tr>
<tr>
<td>VTE</td>
<td>venous thromboembolism</td>
</tr>
<tr>
<td>VWF</td>
<td>von willebrand factor</td>
</tr>
</tbody>
</table>
Acknowledgements

First and foremost, I would like to thank my husband, Patrick Marshall Woodruff. During my graduate school career, we were engaged, got married, bought our first house, got our first dog, travelled to new continents, and had many, many wonderful memories. I could have never gotten through this process without you. Thank you for always being supportive of me, pretending to listen as I prattled on about sciency things, and never letting me take the easy way out. Everyday, I am more and more thankful of the love and relationship that we have.

A close second to thank would be my dog Bailey, who was by my side as I wrote every word of this dissertation, mainly sleeping on the couch. Loyal doesn’t even begin to describe her.

I would also like to thank my family, especially my parents to whom this work is dedicated. They met while in their respective PhD program’s at UNC, so I didn’t really have a chance of being anything else but a scientist. Although David and I hated stopping at every stream on our hikes to count the bugs underneath the rocks, I consider both of you my role models in how a scientist should balance work and life. You both were also models in your respective scientific career paths – with Dad’s respected and longtime position as chairman of the Biology Department at VCU and Mom’s path first in environmental consulting and then into government, culminating in her senior advisory position in Washington with the EPA. These different career paths gave me a
great perspective on the different paths that a scientist can take, even if our subject matters are completely opposite. I would also like to thank my brother David, who went as far away from science as possible, for giving the rest of our family some balance and someone to call if we ever have computer issues.

To my “new” family, the Woodruffs, thank you for making me mentally stronger – nothing could ever be as bad as Cub Creek! I really have enjoyed all the new experiences that you all have taken (dragged) me on – from cross country skiing to tubing down a freezing cold river to eating lunch on an Alaskan ridge with a spectacular view of Denali. All of these activities have gotten me out of my comfort zone, and I’m realizing that the rewards of doing so are unparalleled! Thank you for always supporting me in any endeavor and treating me like one of the family from the get go.

To my committee members – Meta Keuhn, Gow Arepally, Barbara Shaw, Rick Becker – thank you so much for your insight and guidance throughout my graduate school career. You’re different perspectives all have really helped to shape my project, and you all are fantastic scientific role models.

To the Sullenger Lab – past and present – thank you for making my lab experience amazing! To Kristi Viles, who I remember chatting with about advice on which lab to join as a young first year graduate students, thanks for getting me started in the lab, and I’m sorry that I dropped your thesis project! Aptamers (and especially those involved in blood clotting) are the way to go (as you have found out….). To Kristin
Bompiani, thanks for sharing my taste in sweets and always sharing your baking recipes!! Our trip to the ISTH conference in Japan was awesome – I’ll never forget our joy at finding a French restaurant where they served soup and bread and with a menu that we could understand! Your work ethic was inspiring, as well as your organizational skills in keeping the coag group working smoothly! To Jens Lohrmann, thanks for bringing me back German contraband chocolate eggs, fixing anything that was broken, and always being there if I ever needed help. To Jim Frederiksen, thank you for all your coagulation discussions – you came here a doctor and you will leave a scientist! To Angela Burnette – thank you for keeping the lab running and caring about each of us personally, it really sets the tone for the lab and truly makes a difference! To Liz Pratico – thanks for always knowing everything. Seriously, I think you could answer any questions that I had! Thank you for always taking the time to do so! To Dave B. – thanks for all the crazy random idea discussions – I’m glad that I seemed to keep you and Jon in line. Thanks for all the help and advice throughout my time in the lab. To all the “new” coag lab members – George Pitoc, Erin Soule, Kady-Ann Steen-Burrell, and Ruwan Gunaratne, I have really enjoyed working with each of you, helping as much as I can to get you set up with the coag assays, and learning a ton as you bring your backgrounds to the lab. We have an incredibly smart, gifted, and motivated group, and I am glad that I can call each of you my friend as well as coworker! I hope the snack bowl will be always filled with peanuts!
To Jon Kotula – you get your own paragraph! Thank you for getting me through graduate school. I am still convinced that one day we will start a crazy venture that may or may not be a home run (pretty sure that 99% of our ideas would be on the fail pile – but that 1% is going to be legendary). I am so grateful for all of our scientific and life discussions – those have really helped to shape what I want out of my scientific career. Patrick and I are so lucky to have found such awesome friends in you and Michelle – from the Traveling Nachos Doughman Team to making Bloomin’ Onions to Aspen vacations. It will be hard to find a group that will get along better than the six of us – Bailey and Meatball included. Our PhD Europe trip is going to be fantastic, and I can’t wait to take many more trips with you and Michelle in the future.

To Bruce: I can’t begin to tell you how much I admire you – both as a family man and as a scientist. In coming to graduate school, I wanted to find a mentor that mirrored the type of person that I wanted to be – and I have never once wavered in my decision to join your lab. Your commitment to family is unparalleled, especially in such a competitive academic environment. I will always appreciate how you allowed me to take time away from the lab to help my Dad during his cancer treatments, and I have also enjoyed getting to know your daughters and helping them with swimming! In the lab, you have always treated me as an equal, given me enough independence to find my own way as a scientist, and have supported me every step of the way. Thank you for teaching me the importance of collaboration, and also to think very far out of the box. I

xxiv
greatly appreciate all of the opportunities that you have encouraged me to do during my graduate school career – from attending scientific meetings or getting involved with collaborations, to giving back to my swimming community or starting a new competitive sport. I am not only a much smarter scientist, but also a better person after six years in your lab.

To the Duke Cycling Team: What an amazing, smart, talented, motivated and gifted group of people. After missing that competitive edge after five years away from serious sport, I came to the team in January 2012 looking for a way to try out a sport that I didn’t know much about, but looked fairly fun. Four months later, I find myself flying across the country to compete in the Collegiate National Championships. I would not have made it there, and still be racing today, if it wasn’t for the help several patient and just plain nice guys: Jeff Reid, Matt Rinehart, Kurtis Gruters, Kaleb Naegali, Matt Howe, Gael Hagen, Eoin and Kevin McDonnell, Jacob Timmerman, Coach Rusty, and the rest of the entire team. Thanks for fixing my bike multiple times, answering text messages about how to fix my bike, keeping me out of the wind on long training rides, allowing me to tag along on said training rides, and teaching me all the crazy details of bikes and bike etiquette. Thank you for all the crazy conversations that happen when you get an abundance of smart people from all different backgrounds together. I never had a question go unanswered without a thoroughly research answer: whether that be a graph plotting the categorized climbs to the percent salinity in the Great Salt Lake! Chatting
with everyone about their respective research has put mine in perspective, and also
aided my broader thinking of my project.

A special thanks is in order to my Carolina family. Thanks for letting me go to
Duke, and not giving me too much lip about it. I still maintain to this day, that I never
bought a shirt or other article of clothing that said Duke on it. Exceptions of course to
Duke Cycling, as I proudly wear my Duke kit (absolutely no relation what so ever to
Duke basketball).

And to all of the many, many amazing North Carolina friends that we have
made… Thank you for you support! Patrick and I are so lucky to have such a wonderful
group of friends.
1. Introduction

1.1 Coagulation

1.1.1 Thrombosis and Hemostasis

Hemostasis is the process that occurs to maintain the integrity of the vascular system after injury by keeping blood contained within the circulatory system and to sustain patency of a blood vessel. This process is crucial for life and is highly conserved throughout organisms, from worms to zebrafish to humans (1). Thrombosis, or the formation of a blood clot which can grow to occlude or partially occlude a blood vessel, is thought to result from pathological processes that ultimately overwhelm the normal regulatory systems of hemostasis (2). Thrombosis is responsible for the three most common vascular diseases: myocardial infarction (MI), ischemic stroke, and venous thromboembolism (VTE), which collectively include deep venous thrombosis (DVT) and pulmonary embolism (PE). Including other abnormalities in blood coagulation (such as inherited bleeding disorders) and other coronary diseases, cardiovascular disease (CVD) is the leading cause of death worldwide (3).

The process of thrombosis is often described using Virchow’s triad, which states that changes in blood flow, blood composition, or the endothelial cell lining of the vessel walls all contribute to thrombosis (4). In the development of a thrombus, reduced blood flow, stasis, and the resulting decreased oxygen tension can allow for the buildup of procoagulant proteases and mechanisms that can overcome the natural anticoagulant
processes present at that site. A number of disease states and environmental and genetic risk factors, such as age, cancer, pregnancy, obesity, and the use of hormone replacement therapy or contraceptives, which can all result in thrombophilia, can alter the composition of blood. Thrombophilia is a blood disorder in which blood has an increased tendency to clot, generally caused by either an increase in clotting proteins, procoagulant mutations in clotting proteins, decreases in natural anticoagulant proteins, or decreased fibrinolysis. The endothelial cells lining the vessel walls are normally found in an anticoagulant state, with the expression of protein anticoagulants and a dampened ability to attach to proteins and cells present in flowing blood. Changes in the endothelial cells, upon reduced oxygen tension or mechanical injury, can drastically alter their ability in adhering to and activating inflammatory cells, platelets, and coagulation proteases and thus initiate clotting. While a defect in one of these elements can go unnoticed, the addition of a second abnormality could be additive or even synergistic in causing thrombosis, and effective clinical diagnosis and treatment relies on the simultaneous consideration of all soluble, cellular, and physiological markers (5).

1.1.2 Coagulation Cascade

The ability of blood to coagulate, or form clots, has been documented from the time of Hippocrates, where it was noted that blood removed from the body congealed upon cooling (6). This view was widely accepted until the mid 1850’s, when scientists showed that blood clotting could be accelerated in the body with the addition of foreign
substances, therefore, the ability of blood to clot was “intrinsic” to itself. Throughout the next century, the various components of the clotting cascade were discovered, beginning with the four basic factors: fibrinogen, prothrombin, thromboplastin (now called tissue factor), and calcium. At the turn of the century, Paul Morawitz first described the “classic theory” of coagulation, whereby, in the presence of tissue factor (TF) and calcium, prothrombin was converted to thrombin, which would then convert fibrinogen to fibrin to achieve clotting (6). Throughout the next century, the other clotting factors were discovered, mainly through the examination of coagulopathic patients deficient in one of these factors.

By the mid-1960s, a “waterfall”(7) or “cascade”(8) schematic of coagulation was organized, whereby an activated serine protease sequentially activates the next zymogen in the overall sequence, culminating in thrombin production and fibrin clot formation. These processes were known to proceed in the presence of a lipid and calcium (Factor IV). This cascade has become slightly more defined since the publication of those seminal papers, as the discovery of the action of cofactors, naturally occurring inhibitors, feedback loops, and multiple ways to activate the cascade have slightly altered the original format.
Today, this model describes two converging pathways initiated by either exposure of TF on the vessel wall at the site of injury (extrinsic pathway) or by activation of blood-borne components in the vasculature (intrinsic, or contact activation, pathway) (Figure 1). The extrinsic pathway is essential for localized fibrin clot formation at the site of injury, and is triggered by the binding and subsequent activation of factor VII (FVII) to exposed endothelial TF, thus forming the extrinsic tenase complex. The intrinsic, or ‘contact’ pathway, is activated when factor XII (FXII) is exposed to negatively charged surfaces, causing autoactivation of FXII to FXIIa. FXIIa then activates factor XI (FXI), which can then activate factor IX (FIX). FIXa can then complex with its cofactor,
activated factor VIII (FVIIIa), leading to the formation of the intrinsic tenase complex. The extrinsic and intrinsic pathways converge with the activation of factor X (FX) by either the extrinsic tenase or the intrinsic tenase. FXa then binds to its cofactor factor Va (FVa), forming the prothrombinase complex, which can then activate prothrombin to thrombin, leading to the conversion of fibrinogen to fibrin (1).

While this cascade models elegantly depicts the series of reactions necessary to form a clot, it does not explain several clinical observations. First, this model does not depict why patients with hemophilia A or B (FVIII or FIX deficiency) have severe bleeding phenotypes, even though the extrinsic pathway in these patients is intact. In addition, patients with deficiencies of the two initiating members of the intrinsic pathway, FXII and FXI (hemophilia C), either have no bleeding tendencies or an injury-related variable bleeding tendency, respectively. Thus, the extrinsic pathway could seemingly compensate for the loss of FXII or FXI, but not FIX or FVIII, an observation that the current cascade model did not explain (9).

To address these and other observations regarding platelet and endothelial cell interactions with coagulation factors, a revised, cell-based model of coagulation was presented in which TF-bearing cells and activated platelets serve as a scaffold for procoagulant proteins to interact and ultimately form a localized fibrin clot to repair the vessel wall (10). In this system, coagulation occurs in three overlapping stages: initiation, amplification, and propagation (Figure 2).
Figure 2. The cell-based model of coagulation
Adapted from Hoffman and Monroe, Hematol Oncol Clin North Am, 2007 (9)

Initiation occurs primarily through the exposed TF/VIIa extrinsic complex on the surface of an endothelial cell at the site of injury. This complex can then activate FIX, thus linking the extrinsic and intrinsic pathways, which can then diffuse from the surface of the cell and localize on the platelet surface. The extrinsic tenase can also activate FXa on the surface of the TF-bearing cell. This activation is localized by TF pathway inhibitor (TFPI) or antithrombin (AT), which rapidly inhibits any FXa that diffuses away from the site of injury. FXa then combines with FVa on the surface of the
TF-bearing cell to form the prothrombinase complex. In this stage, FV can become activated by two ways: 1) by FXa or non-coagulation proteases and 2) the release of FVa from α-granules of partially activated platelets. The resulting prothrombinase complex on the surface of exposed, TF-bearing cells then activate low levels of thrombin (9).

In the amplification stage, this small amount of thrombin can feedback and prime the coagulation cascade for rapid thrombin generation. Thrombin has several roles in this stage. First, thrombin can bind to receptors on the platelet surface, thus accelerating platelet activation. In addition, thrombin activates FVIII, FXI, and additional FV in feedback loops that result in high levels of activated coagulation proteases on the platelet surface. It is this augmentation and activation of various cofactors (FVIII, FV) that leads into the propagation stage, where activated FIX, formed from both FXIa and TF/VIIa, can complex with FVIIIa to activate FX on the surface of the platelet. The resulting prothrombinase complex can then produce the burst of thrombin necessary to form a stable fibrin clot. This generated thrombin can also activate other mechanisms (platelet receptors, FXIII, inhibitors of fibrinolysis) to stabilize the clot (10).

With this model, it is clear that the extrinsic and intrinsic pathways are not redundant; in fact, the extrinsic pathway initiates thrombin generation on exposed TF bearing cells, whereas the intrinsic pathway amplifies thrombin generation on the surface of the platelet to form and stabilize the clot. A notably absent coagulation factor in this scheme is FXII, as thrombin feedback of FXI on the surface of platelet provides
sufficient amounts of FXIa to boost the production of FIX (11). These observations fit with clinical data, as FXII does not seem to be essential for hemostasis. However, recent observations, discussed in more detail later in this chapter, suggest that FXII might have a mechanism in thrombus formation, as continued FXIa and subsequent thrombin generation on the surface of a clot may contribute to continued thrombus stability.

While the numerous coagulation proteases work primarily to generate thrombin and form a fibrin clot, platelets, which are anuclear cells circulating at high concentration in the blood, also become activated at the site of vascular injury and form an integral part of the clot that seals the vasculature. At the site of vessel wall injury, there is numerous crosstalk between coagulation proteases, platelets, and endothelial cells. While platelet activation is a complex topic reviewed extensively (1, 12), platelets offer a procoagulant surface for coagulation proteases to generate thrombin, as well as providing stable adhesion to the vessel wall and mediating signaling activities to enhance thrombus formation. That platelets are essential for coagulation is evident by the severe bleeding phenotypes in patients with thrombocytopenia (decreased amount of platelets in the blood) or genetic disorders affecting platelet pathways.

While the process described above outlines how coagulation occurs to repair injury to the vascular system, an important physiological concept includes the process of anticoagulation, which continually works to regulate and localize coagulation to the site of injury, and also fibrinolysis, which breaks down the clot once it is no longer needed in
order to keep blood vessels patent. While these two mechanisms will not be outlined in
detailed, a brief mention of these systems is important in understanding the entire
hemostatic system.

Natural anticoagulant mechanisms are critical in preventing widespread clot
formation. This is evident by the fact that mice lacking one of the three major
anticoagulant pathways, protein C (inhibiting FVIIa and FVa), TFPI (inhibiting FXa), and
AT (inhibiting FIXa, FXa and thrombin), are not compatible with life (13). Protein C
becomes activated by increasing amounts of thrombin binding to thrombomodulin (TM)
on the surface of endothelial cells, which can then cleave protein C held in complex with
the endothelial protein C receptor (EPCR). Activated protein C (APC) can then complex
with Protein S to effectively inhibit the action of the important cofactors FVIIIa and FVa.
Dysfunction of this pathway is implicated in disseminated intravascular coagulation
(DIC), which results in widespread clotting and subsequent bleeding from consumption
of coagulation factors. TFPI limits the initiation of coagulation by directly inhibiting free
FXa, and also interacting with the TF/FVIIa/FX complex. TFPI function seems to be
partially dependent on Protein S. AT inhibits three key coagulation proteases, FIXa,
FXa, and thrombin, and is as such is one of the more important inhibitors of thrombin
generation. True AT deficiency has never been observed in humans, while homozygous
deficient mice die in utero, suggesting that AT deficiency is lethal (1).
In order to maintain blood flow, the fibrinolytic pathway degrades fibrin clots once they are no longer needed to seal a site of injury. Plasminogen, the protease that degrades fibrin into soluble fibrin degradation products, is activated by tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). While tPA actually binds to fibrin and aids in the lysis of clots, uPA acts on the cellular level. There are several inhibitors of fibrinolysis, including plasminogen activator 1 (PAI-1), α2-antiplasmin, and thrombin activated fibrinolysis inhibitor (TAFI). The importance of these proteins are evident, as patients deficient in plasminogen have an increased likelihood of clotting, and deficiencies of PAI-1 result in an increased tendency to bleed (14). A more complete view of the coagulation cascade, including anticoagulant and fibrinolytic mechanisms, are detailed in Figure 3.
1.2 Contact Pathway/Intrinsic pathway

Portions of this section have been adapted from the manuscript entitled “The many faces of the contact pathway and their role in thrombosis” published in the Journal of Thrombosis and Thrombolysis on July 2011, 32(1): 9-20 and authored by Rebecca Woodruff, Bruce Sullenger, and Richard Becker, as well as a second manuscript entitled “Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?” published in Current Cardiology Reports on July 2010, 12(4): 315-20 and authored by Rebecca Woodruff, Bruce Sullenger, and Richard Becker.
1.2.1 FXII

Human FXII is an 80kDa glycoprotein that, upon activation, forms α-FXIIa comprised of a 50kDa amino acid heavy chain and a 30kDa light chain linked by a disulfide bond (15). While the light chain contains the catalytic domain capable of activating FXI and prekallikrein (PK), the heavy chain consists of several conserved domains that mediate binding to other proteins and surfaces, including fibronectin type I and II domains, two EGF-like domains, a kringle domain, and a proline rich region (16). The gene for FXII (F12) is closely related to human growth factor activator (HGFA) (17), and contains considerable homologous structural regions, including epidermal growth factor domains, with the fibrinolytic proteins tPA and uPA (18-20).

Binding by the heavy chain to a negatively charged surface, such as dextran sulfate or kaolin, induces a conformational change that allows FXII to be more susceptible to cleavage (21, 22). This cleavage can occur slowly by FXII autoactivation or more efficiently by kallikrein in a feedback loop (23, 24). Biologically, a number of negatively charged substances, including polyphosphates, nucleic acids, mast cell heparin, and collagen, among others, have been found to activate FXII in vivo (25-28).

Once activated, surface bound α-FXIIa can cleave FXI and PK, and plasma kallikrein can then reciprocally activate FXII in a positive feedback loop (29, 30). Further cleavage of FXII leads to a smaller 30kDa fragment, β-FXII, which retains catalytic activity for PK but not FXI, and can diffuse away from the activating surface (22, 31).
FXII has also been shown to bind to the surface of endothelial cells (mediated through the urokinase plasminogen activator receptor (uPAR) (32), as well as platelets (32, 33), and can thus affect other systems aside from coagulation. Binding of zymogen FXII to uPAR on endothelial cells can stimulate angiogenesis (34). FXII-mediated activation of PK leads to activation of the bradykinin (BK) proinflammatory signaling pathway that can induce vasodilation, chemotaxis of neutrophils, and increase vascular permeability. In addition, FXII can activate the complement pathway through activation of the C1 esterase (35), as well as trigger the fibrinolytic system through urokinase activation. The main physiologic inhibitor for FXII is the C1 esterase inhibitor (36), although FXII activation by platelets seems to be regulated by antithrombin (37). While FXII can influence a number of systems in vitro, FXII’s contribution to these systems in vivo is unclear.

Recognition that thrombin can directly activate FXI and bypass the need for FXII-mediated activation may explain the absence of a bleeding phenotype in FXII-deficient patients and also supports an emerging theory that FXII-mediated thrombin generation and fibrin formation is not an absolute prerequisite for normal hemostasis (38, 39). However, FXII-deficient mice are protected against thrombus formation in several models of arterial and venous thrombosis, but maintain normal hemostatic capacity. Intravital microscopy and blood flow monitoring suggest that while thrombus initiation proceeds following vascular injury, the thrombi themselves are unstable and disperse
rather developing to the point of occlusion (40). Infusion of human FXII into these mice recovers the wild type phenotype, suggesting that the observed effects are highly dependent on plasma levels of FXII (40). Protection from thrombosis is not limited to arterial injury, as FXII-deficient mice have reduced brain infarct volume following transient middle cerebral artery stroke model (tMCAO) model without an increase in hemorrhage (41). Therefore, in mice, it is evident that FXII plays a role in pathological thrombus formation. A search for the primary (or dominant) activator in vivo has been challenging, as a number of negatively charged substances commonly found at the site of a thrombus, such as polyphosphates, nucleic acids, sulfatides, fatty acids, protein aggregates, and activated platelets have each been found to activate FXII in vitro (27, 42-44). It is well known that activated platelets can accelerate FXII-mediated fibrin formation, and the discovery that platelet released polyphosphate can directly activate FXII may serve as this link (45).

While FXII deficiency in mice confers thrombotic protection, full deficiency of FXII is rare, and thus not well described. However, there is a history of anecdotal reports suggesting that complete deficiency of FXII is prothrombotic, including the first recorded FXII deficient patient, John Hageman, who died from a pulmonary embolism (46). Other studies have argued against FXII as an independent risk factor for thromboembolism, but cite other risk factors in a FXII deficient background (47). Interestingly, a large Viennese patient study (n=8936) showed that all-cause mortality of
patients severely deficient in FXII (<10%) was similar to patients with 100% FXII plasma levels, suggesting a dual role of FXII in thrombosis (48). Because FXII deficiency causes unstable thrombi in mice, it may interfere with thrombosis in areas with high shear stress that can break apart the thrombus before it grows to a larger size. However, venous thrombi can still develop in areas with low shear stress, and perhaps have a larger tendency to embolize during FXII deficiency. In addition, other functions of FXII, such as its growth factor activity or role in inflammation, could also affect mortality rates in severely deficient patients. Future epidemiologic studies will need to be carried out to further elucidate FXII’s role in humans.

1.2.2 FXI

Human FXI(a) is a 160-kDa serine protease glycoprotein that circulates as a disulfide linked homodimer of two identical 607 amino acid subunits. Each polypeptide consists of a 35-kDa C-terminal light chain containing the trypsin-like catalytic domain, and an N-terminal 45-kDa heavy chain with four ~90 amino acid tandem repeats termed apple domains (49). These apple domains confer binding to other proteins: A1 contains binding sites to high molecular weight kininogen (HK) and thrombin (50), A2 & A3 to FIX (51), A3 to the platelet receptor GP1bα and heparin (52), and A4 to FXII and the other subunit of FXI (53, 54). FXI circulates in complex with HK, and is structurally related to PK, as both are hallmarked by the PAN-related apple domains forming a disc-like structure around the base of the catalytic domain (55) (Figure 4).
Figure 4. A crystal structure of dimerized zymogen FXI

In this topology diagram, the catalytic domain is in white, and sites of interactions are highlighted. H1 and H2 denote heparin binding sites, T is thrombin, HK is high molecular weight kininogen, Gp1b is the platelet receptor GP1bα, FIX is factor IX, AL is the activation loop cleavage site, and AS is the active site residues. This figure is adapted from Emsley, Blood, 2010 (55).

FXI can be activated by FXIIa and thrombin, both of which cleave at the same site on FXI, and activation proceeds through an intermediate structure with one activated subunit (1/2FXIa) which can be detected in plasma and may represent the predominant active species (56). FXIa subsequently activates FIX to FIXαβ by the sequential cleavage of two activation sites on FIX (56-59). Dimerization seems to be required for FXI activation, as it is thought that the proteases bind to one subunit while activating the other (60). In addition, dimerization might be important in tethering FXI to the site of injury, as the zymogen subunit can bind to the platelet receptor GP1bα, and leave the
active subunit free to bind to and activate FIX. Zymogen FXI binds to platelets better than FXIa, with approximately 1500 binding sites per platelet (61). Whereas optimal binding requires HK, zinc ions, residues in the apple 3 domain of FXI, and the N-terminal domain of GP1bα, recent work has suggested that FXI binds to the platelet receptor ApoER2, which colocalizes with GP1bα (55). FXIa also binds to platelets, but with a much lower frequency of 250 binding sites per platelet (62). FXI and FXIa bind to platelets through a separate binding site and mechanism, as FXIa binding to platelets seemingly requires the catalytic domain, but not the apple 3 domain, whereas the apple 3 domain is required for FXI binding (55).

Early observations revealed that FXI could be activated by thrombin as well as FXIIa and suggested that this route of bioamplification was favored in vivo over FXII-mediated activation (38). Subsequent experiments revealed that FXI-mediated activation of thrombin was essential for continued thrombin generation in the presence of low levels of TF, but not when higher levels of TF were present, such as that found at the endothelial cell sites of injury (63). This continued thrombin generation is important for the activation of TAFI, which can protect the clot from fibrinolysis degradation (63). In addition, the GP1bα receptor on the surface of platelets contains binding sites for FXII, thrombin and FXI, bringing these proteins into close proximity on the platelet surface and allowing FXI to be activated and subsequently activate FIX in the presence of calcium ions, thus amplifying coagulation and thrombin generation (56-59).
The effect of FXI concentration on thrombin kinetics varies widely among individuals (64), likely reflecting the several unique functional characteristics of the protease, as well as the dependency on the levels of other procoagulant proteases, and mirroring the variable bleeding phenotype seen in FXI deficient patients. In a cell based model system, as little as 5% of normal plasma levels of FXI led to some thrombin generation, with a maximal amount of thrombin generated at 50% of normal FXI levels(59). These observations lend to the fact that FXI deficiency, or hemophilia C, has historically been difficult to predict bleeding tendency as there has been a poor correlation between bleeding phenotype and plasma FXI levels. Hemophilia C is a rare bleeding disorder that affects approximately one in 10,000 people worldwide, but is more common in distinct populations, such as Ashkenazi Jews (65). While hemophilia C does not normally result in spontaneous bleeding, it is a mild to moderate bleeding disorder with increased bleeding tendencies in tissues with high fibrinolytic activity. With over 190 reported mutations in the F11 gene (www.factorxi.com), there are two main types of mutation: CRM- (Type I) are mutations causing low FXI plasma levels while CRM+ (Type II) are mostly functional mutations correlating with normal FXI levels but reduced coagulant activity.

Studies on human patients with FXI deficiency have been similarly muddled. While severe deficiency of FXI is rare, there is some evidence that these patients may be protected against VTE and even ischemic stroke (66, 67). The Leiden Thrombophilia
study, a large, population based study, identified high FXI activity levels as a risk factor for DVT (68). In addition, a retrospective analysis of patients reported that FXI activity above 95% was associated with a heightened risk of ischemic stroke (68, 69). Patients with acute coronary syndrome (ACS), compared to patients with stable angina pectoris, have higher levels of FXIa-C1 inhibitor complexes, reflecting acute activation of FXI (70).

Overall, while FXI is considered a “procoagulant” and elevated levels have been associated with prothrombotic phenotypes, FXI plasma activity in humans correlates poorly with bleeding risk (71).

The potential uncoupling of FXI’s role in thrombosis and hemostasis is supported by observations from several models of arterial thrombosis, venous thrombosis and stroke in FXI- deficient mice and higher species. FXI deficient mice exhibit prolonged aPTT clotting times and reduced FXI plasma activity levels, but had no evidence of a bleeding phenotype. Several studies using a ferric chloride model of arterial injury with these mice demonstrated that FXI deficiency protected from thrombus occlusion at a level comparable to FIX deficiency or high concentrations of unfractionated heparin, but without uncontrolled bleeding as measure by a tail vein bleeding assay (40, 72, 73). The thrombi that did form were unstable and failed to occlude the vessel (40). FXI deficiency also conferred a thromboprotective effect in a tMCAO, with a lower volume of infarcted brain tissue and less fibrin deposition in distal microvessels compared to wild type mice without any detectable hemorrhage (41).
potential antithrombotic effect of FXI depletion or inhibition has also been observed in species other than mice. Antibody-mediated FXI inhibition in rabbits increased clot lysis in jugular veins and reduced thrombus propagation on injured neointima of the iliac artery (74, 75), while infusion of FXI antibodies in baboons prevented growth of occlusive thrombi in arterio-venous shunt and vascular graft occlusion models (76, 77). Administration of a FXI specific antisense oligonucleotide in mice reduced levels of FXI while conferring an antithrombotic effect similar to warfarin without abnormal bleeding times (78).

1.2.3 The roles of the contact pathway

The relevance of the contact activation pathway in vivo for maintaining hemostatic capacity has been debated as patients deficient in FXII, PK, or HK do not typically present with a bleeding phenotype, and FXI deficiency (hemophilia C), is a mild to moderate, tissue-specific bleeding disorder. In contrast, patients deficient in the downstream intrinsic pathway factors, such as FIX or FVIII, demonstrate more severe bleeding tendencies, including spontaneous bleeding, while patients completely deficient in TF, FX or FII have not been described. Upholding these observations, it is widely accepted that activation of the extrinsic pathway is the main pathway responsible for hemostasis. In addition, the actions of FXII can be bypassed by other constituents of the coagulation pathway, including thrombin, which can directly activate FXI, leading to continued thrombin generation (38, 79). This mechanism is thought to be
increasingly important in settings where extrinsic activation, or the amount of TF present, is low, such as on the surface of a growing clot.

In the past decade, *in vitro* and animal model studies have suggested a larger role in FXII-mediated activation of FXI in contributing to stable thrombus formation from continued thrombin generation on the surface of a growing thrombus. In thrombosis, substances that are present at a developing thrombus, such as aggregated proteins, extracellular RNA or other nucleotides, collagen, and polyphosphate, could contribute to the continued activation of FXII and FXI, leading to excessive thrombin generation and platelet activation to attenuate the growth of the thrombus. The role of FXII and FXI in thrombosis could vary depending on the event, and while the contact pathway might play a large role in thrombus formation where or when the extrinsic pathway has been inhibited, such as on the extended surface of a platelet rich thrombus, FXII and FXI might not be required for thrombosis at a ruptured plaque, where a large amount of TF can trigger thrombin generation independently (80).

The procoagulant environment contributing to thrombus formation is not solely influenced by activation of the coagulation cascade and platelets, but is also affected by the activity of other systems, including inflammatory or fibrinolytic systems, that FXI and FXII can also influence. Full understanding of the systems that the contact pathway affects is essential as many vascular disorders, such as atherosclerosis, are influenced by a number of these processes. In fact, activated FXII is found at the site of an early
atherosclerotic lesion, and could contribute to the inflammatory and angiogenic processes that help to develop an atherosclerotic plaque (81). Additional fibrinolytic and/or inflammatory properties of FXII and FXI could also play a role in pathological thrombus formation. Therefore, a detailed exploration into all of the contributions of the contact pathway can provide insight into the mechanisms of thrombosis and guide future drug development.

1.2.3.1 The Evolution of the Contact Pathway

It is widely thought that a series of gene duplications throughout evolution led to the complete clotting cascade as it is seen in humans. Thus, all clotting factors contain many of the same conserved domains and are closely related to one another (19). A simple version of the clotting cascade appeared in the earliest vertebrates, and as vertebrates themselves have become more complex with more intricate and contained cardiovascular systems, the clotting cascade has evolved similarly. While thrombin was the first coagulation factor to emerge before the appearance of the first vertebrates, the contact pathway was the last to evolve, as genes for HK, FXII and a single paralog of PK/XI are found later in vertebrate development (19). A duplication event of the FXI/PK predecessor gene led to the separation of these factors during the development of early mammals, with all placental mammals carrying two distinct genes for PK and FXI (18). Because of this late emergence, these proteins are 58% similar with the same overall domain structure (82, 83). Interestingly, the gene for FXII has been lost in some species
during evolution as some marine mammals, such as whales and dolphins, as well as birds, lack a gene for FXII, supporting the view that this protein is not needed for hemostasis (19, 84). Similarly, the gene for FXI is absent in birds, such as the chicken, duck, and vulture (85).

1.2.3.2 Hemostasis and Thrombosis

In the coagulation cascade, FXI can be activated either by FXIIa or in a feedback loop by thrombin, and these two routes may have diverging functions. FXI-mediated activation of thrombin is essential for continued thrombin generation in the presence of low levels of TF, but, when higher levels of TF are present, thrombin generation is FXI, and also FXII, independent (63, 86). To this end, preliminary studies show that low TF/FXI deficient mice die in utero, while FXI deficient nice have no bleeding phenotype, suggesting that FXI is essential for hemostasis while the extrinsic pathway is impaired (87). Because the thrombin-mediated FXI activation pathway seems to be favored in vivo over FXII-mediated activation it is widely considered that FXII-mediated thrombin formation did not have a significant role in maintaining normal hemostasis (38, 88).

The site at a growing thrombus, however, is quite different from a hematological challenge, and could differ from thrombus to thrombus. A number of negatively charged substances found in the body and at sites of vascular injury, such as polyphosphates (26, 45), extracellular oligonucleotides (27, 89), collagen (25), laminin (90), and aggregated proteins (44), have been found to activate FXII. While all of these
substances could contribute the FXII activation, the main *in vivo* physiological activator of FXII, if there is just one, has not been fully elucidated. Polyphosphate released from activated platelets is a logical FXII activator contained to the site of thrombus formation. However, polyphosphate can act as a cofactor to augment thrombin’s ability to activate FXI itself and therefore bypass the requirement for FXII. However, there is mounting *in vivo* evidence that FXII-mediated FXI activation contributes to thrombus formation.

A growing clot at the site of a ruptured plaque could be exposed to larger amounts of inflammatory proteins or the contents of dead and dying cells, all which could contribute the activation of FXII. To this end, while mice deficient in FXI or FXII do not exhibit spontaneous or abnormal bleeding, these mice are protected against thrombus formation in several models of arterial and venous thrombosis, as well as stroke. In several models of thrombotic injury, intravital microscopy work and blood flow monitoring suggest that, while thrombus initiation is not interrupted on the vessel wall in both FXI and FXII deficient mice, thrombi that are formed are unstable and break up before occlusion of a blood vessel can occur (40, 72, 73, 91). Protection from thrombosis is not limited to arterial injury, as FXII and FXI deficiency also confer a thromboprotective effect in a tMCAO, with a lower volume of infarcted brain tissue and less fibrin deposition in distal microvessels without any hemorrhaging detected (41). MRI’s performed in FXII deficient mice undergoing tMCAO found that, while both groups show severe hypoperfusion in the first two hours after removing the occluding
thread, the FXII deficient mice show an increase in cerebral blood flow from 2–24 hours compared to wild type mice (92). The antithrombotic effect of FXI deficiency is also seen across species, as inhibition of FXI with antibodies in rabbits resulted in increased clot lysis in jugular veins and reduced thrombus propagation on injured neointima of the iliac artery (74, 75). In addition, infusion of FXI antibodies in baboons prevented the growth of occlusive thrombi in arterio-venous shunts and vascular graft occlusion (76, 77). Even at low shear rates in an endothelial denudation rabbit jugular vein model, FXI was found to contribute to platelet aggregation and fibrin formation (93).

Activation of FXII can lead to activation of FXI, and thus coagulation, but FXIIa can also activate PK. PK circulates in plasma bound to HK, and once activated, kallikrein cleaves the nonapeptide BK from HK. BK is a vasoactive peptide that mediates several inflammatory responses, including vasodilation and vascular permeability. In order to elucidate which pathway, FXII-mediated FXI activation or FXII-mediated PK activation, plays a larger role in thrombosis, thrombosis models with animals deficient in these contact pathway proteins were undertaken. In murine studies with deletions of other constituents of the contact pathway, BK B2 receptor (the main receptor for BK) and kininogen gene 1 (encodes for HK) knockout mice caused a delayed time to vessel occlusion in a Rose Bengal/laser injury carotid artery thrombosis model (94, 95). This model causes less endothelial damage and collagen exposure than a applying the free radical FeCl₃. While FXI and FXII deficient mice were able to prolong the time to vessel
occlusion in this model (96), pharmacologic inhibition of plasma kallikrein was shown to be prothrombotic, as shorter occlusion times in the carotid artery after laser injury were observed (97). Conversely, BK2 knockout mice in different strain backgrounds demonstrated opposing phenotypes in an experimental stroke model, with one having reduced infarct volumes and improved motor skills (98), whereas another study showed an increase in infarct volumes and mortality rates (99). While the role of some of the contact pathway proteins in thrombosis has not completely been elucidated, the in vivo evidence suggests that FXII and FXI, though not involved in initiating fibrin formation, are involved in stabilizing occlusive thrombi in several animal models.

If FXI and FXII deficiency protect from thrombosis in an animal model, than human should follow suite. In fact, either FXI or FXII deficient humans present with a more complex phenotypic picture. Elevated levels of FXI have been found to be prothrombotic, as FXI levels are considered to be a risk factor for deep venous thrombosis and ischemic stroke (68, 69), and FXI deficiency reduced the incidence of ischemic stroke (67). FXI deficiency does not seem to offer protection against acute myocardial infarction (100), but high FXI levels were found to increase the risk of myocardial infarction. Interestingly, in this same study, low levels of FXII increased the risk of myocardial infarction. FXII plasma activity has been found to exhibit a U-shaped curve with respect to mortality, with the lowest 10% of plasma levels associated with mortality rates comparable to 100% FXII levels (48). However, FXII has not been found
to be an independent prothrombotic risk factor, and no studies have been conducted to
determine if FXII deficiency offers thromboprotection (101). These findings highlight
the difference between mice and human, and also point to the probable importance of
other functions of the contact pathway in modulating thrombosis.

1.3.2.3 Fibrinolysis

In addition to its role in the coagulation cascade, the contact pathway has also
been shown to influence fibrinolysis. In vitro, it was recognized that the presence of FXI
was able to inhibit clot lysis in plasma (63). Further studies found that thrombin
mediated feedback activation of FXI contributes to sustained thrombin generation and
TAFI production, thus stabilizing and protecting the clot from fibrinolysis (102, 103).
TAFI inhibits fibrinolysis of the formed clot by removing carboxy-terminal lysine
residues from fibrin, thereby altering the ability of plasminogen to bind to fibrin, and
thus preventing the breakdown of the fibrin clot (104). The importance of FXI-mediated
continued TAFI production is evident from the increased risk of bleeding in FXI
deficient patients undergoing surgeries in tissues with high local fibrinolytic activity.
Additionally, inhibition of FXI in a rabbit jugular vein model caused a two-fold increase
in endogenous thrombolysis and clot lysis, presumably through reduced activation of
TAFI (74).

While FXI acts indirectly as an antifibrinolytic by attenuating thrombin mediated
TAFI activation, FXII has been shown to directly and indirectly promote fibrinolysis.
FXII structurally resembles the fibrinolytic proteins tPa and uPa, and FXIIa and kallikrein can activate plasminogen directly in plasma to contribute to wound healing and tissue remodeling (105, 106). Kallikrein can also directly activate uPa and tPa, and enhance the activation of tPa on endothelial cells by releasing BK, which stimulates tPa release (107). In addition, a recent study showed that FXII could bind to and inactivate PAI-1 to enhance fibrinolysis in an in vitro assay (108). Overall, the contact pathway seems to be involved in both pro and antifibrinolytic mechanisms, although the relative efficiency and importance of each system in vivo has yet to be determined.

1.3.2.4 Platelets

Activated platelets are known to promote FXII activation and FXII-mediated thrombin generation, although the mechanism of activation in vivo has been debated (43, 109). Polyphosphates released from the dense granules of activated platelets can directly activate FXII, trigger coagulation and inflammation, and delay clot lysis, possibly through FXI-mediated TAFI activation (26, 43, 45). Mice deficient in FXII were protected from a lethal pulmonary embolism model triggered by infusion of polyphosphates and exhibited reduced fibrin formation in the lungs, while infusion of human FXII protein corrected thrombosis susceptibility in this model (45). Collagen, a strong platelet activator itself, is also able to independently bind to and activate FXII to induce thrombin generation and clotting in a FXI-dependent manner (25, 40). Under flow conditions, collagen-initiated thrombin formation in reconstituted platelet rich
plasma was highly dependent on the presence of FXII and FXI, and this dependence was abolished by adding tissue factor, suggesting that FXII- and FXI- mediated thrombin generation is particularly important in conditions where the extrinsic pathway has been impaired (25). The relative importance of polyphosphate-mediated activation of FXII versus collagen activation, as well as the possibility of FXII activation from other materials present in a developing thrombus such as RNA and aggregated proteins, will require detailed investigation, although the unstable thrombi in FXII deficient mice suggest that one or possibly all of these factors effect FXII- mediated coagulation (26, 27, 40).

Binding to platelets serves as an important mechanism for FXI-mediated FIX activation, as thrombin can activate enough FXI on the platelet surface without any FXII contribution to sustain thrombin generation (59). A naturally occurring FXI mutant that cannot bind platelets has a severely reduced rate of activation by thrombin (110), whereas thrombin activates FXI at a 5-10,000 fold enhancement when bound to the platelet surface (61). This enhancement could be due to the recent finding that polyphosphates release from activated platelets serve a cofactor to greatly increase thrombin activation of FXI (111). While there are ~1500 binding sites for FXI on the surface of the platelet (61), FXIa binds to only ~250 sites (112), suggesting that FXI and FXIa bind in a different mechanism. In fact, FXI and FXIa do not compete for binding on the platelet surface (62), and biochemical studies suggest that FXI binds to GP1bα in
complex with either HK or prothrombin through its exposed A3 domain, but, once
activated, residues in the catalytic domain are required for binding (112). Dimeric FXI
seems to be required for binding, as monomeric FXI has a reduced activity in activated
platelet dependent clotting assays, suggesting that FXI binds to GP1bα with one subunit
and to FIX with the other (58). In addition, FXI has recently been shown to bind to
ApoER2, a receptor that co-localizes with GP1bα on the platelet surface, and FXI or FXIa
can induce platelet aggregation and intracellular signaling events on wild type, but not
ApoER2-deficient platelets (113). Binding of FXI to the platelet surface can help to
localize hemostasis to only the site of injury, as the FXI inhibitor protein nexin 2 released
from activated platelets inhibits only free FXIa (112, 114). Thus, platelets can accelerate
the activation of both FXII and FXI in several respects, and may serve as important
mediator of intrinsic pathway activation at the site of a growing thrombus.

1.3.2.5 Inflammation

Activation of the contact system can induce inflammatory reactions through
activation of the classical cascade of the complement system, leading to anaphylatoxin
production causing smooth muscle cell contraction, enhanced vascular permeability and
recruitment of inflammatory cells to produce a local immune response. Mast cells are
commonly found at sites of infection, and are associated with increased vascular
permeability in host defense of allergic reactions. Heparin released by these mast cells
has been shown to activate FXII, thus leading to release of BK, a small peptide that is
cleaved from HK by kallikrein which induces vascular permeability (28, 35). BK can also bind to its receptor on endothelial cells to promote nitric oxide and prostacyclin release, inducing smooth muscle cell relaxation and vasodilation (115). FXII seems to play an integral part of contact-stimulated BK generation, as plasma levels of BK are reduced in FXII deficient mice, even though kallikrein can be activated independent of FXII by other proteins (heat shock protein 90, prolylcarboxypeptidase) (116). Activation of both of these systems causes the signs and symptoms seen in septic shock and hereditary angioedema. In septic shock, FXII can be activated by bacterial cell walls, endotoxin, polyphosphate, and various microbial proteases present from bacteria in the blood, leading to a rapid decrease in blood pressure and possibly disseminated intravascular coagulation, a thrombotic and hemorrhagic disorder resulting from widespread misregulation of the clotting and fibrinolytic systems (117-120). Unregulated contact pathway and complement activation is also implicated in hereditary angioedema (HAE), a condition caused by a deficiency or defect in the main inhibitor of these two pathways, C1-inhibitor (121). HAE is marked by the recurrent episodes of acute, localized increase in vascular permeability in the skin and various mucosal tissues, mediated through the action of BK and complement anaphylatoxin. HAE-TypeIII is caused by a mutation in the FXII gene, however, plasma concentrations and aPTT clotting times are both normal in these patients (101). Kallikrein and BK may also be involved in cross-talk with the renin-angiotensin system involved in regulating blood pressure and fluid balance.
Constituents of the contact system can also bind to and activate immune cells directly, as kallikrein can induce neutrophil homing, aggregation, and degranulation (115, 122, 123), and FXII mobilizes leukocytes to the site of injury by activating the chemoattractant chemerin (124). FXII also stimulates monocytes to produce the cytokine interleukin-1 (125). In addition, activated HK can bind to receptors on monocytes and neutrophils, stimulating the release of cytokines and inhibiting their migration, keeping them at the site of injury, and contributing to a chronic inflammatory response (115).

Overall, these studies indicate that all of the contact factors, except FXI, may play an important role in modulating the inflammatory response pathway. Thus, inhibition of FXI is touted to have less potential off-target effects, and therefore be a more attractive therapeutic target.

1.3.2.6 Angiogenesis

Binding of contact pathway proteins to endothelial cells can also induce angiogenesis, and this generation of new blood vessels can be important in tumor progression and wound healing. HK and PK bind to endothelial cells through a multiprotein receptor complex, including complement receptor gC1qR, uPAR, and cytokeratin 1 (126). While activation of PK can occur on the surface of endothelial cells without FXII by the enzyme prolylcarboxypeptidase (95), FXII can bind to gC1qR and increase the rate of kallikrein formation (127). Assembly of contact factors in the presence of Zn^{2+} ions on endothelial cells results in the release of BK, which, through the
action of its receptors, stimulates cell migration and proliferation by increasing the concentration of angiogenic mediators (32, 128, 129). In addition, BK was recently shown to enhance the homing of circulating endothelial progenitor cells, a mechanism also important in forming new blood vessels (130).

Zymogen FXII is also directly implicated in angiogenesis, as FXII can bind to uPAR and induce cell proliferative intracellular signaling events at levels just 12.5% of its normal plasma concentration (34, 128). In addition, FXII induced aortic sprouting in mice at concentrations as low as 3.2% of normal levels, and FXII deficient mice had fewer vessels in skin biopsies compared to wild type (34). While FXII is not essential for developmental angiogenesis as FXII deficiency is not lethal, it could contribute to the repair process after injury or inflammation. HK and FXII compete for the same binding region on the gC1qR-uPAR-cytokeratin 1 complex, and plasma concentrations of HK inhibit FXII binding and thus inhibit FXII-mediated signaling. Activated HK itself inhibits angiogenesis by preventing endothelial cell migration and adhesion through disruption of the uPA-uPAR signaling complex that regulates these processes (32, 34, 131).

1.3.2.7 Inhibitors of the contact pathway

Inhibition strategies aimed at FXIa include antisense oligonucleotides, neutralizing antibodies, and peptide and small molecule inhibitors. Several antibodies have been tested in higher animals, including rabbits and baboons, and all were
efficacious in preventing thrombus occlusion without any reported effects on bleeding times (76, 77, 96). Administration of a FXI specific antisense oligonucleotide in mice reduced levels of FXI while conferring an antithrombotic effect similar to warfarin without abnormal bleeding times (78). A selective small molecule inhibitor has recently been described that prevents activation of FIX and prolongs clotting times (132).

Novel 3-carboxamide-coumarin inhibitors were developed to be potent and selective inhibitors of FXIIa (133); however, they did not protect mice from ischemic stroke in a tMCAO at the given concentration (134). D-Pro-Phe-Arg chloromethyl ketone (PCK) inhibits the amidolytic activity of FXIIa, was able to increase clotting time in a dose-dependent manner, and protect mice against ischemic brain stroke in a tMCAO (41). However, PCK is not completely selective for FXIIa, as it is a more potent inhibitor of kallikrein (135), and PCK treatment was prothrombotic in a Rose Bengal murine thrombosis model (97). The fourth domain of a specific thrombin inhibitor, infestin, that was isolated from the insect *Triatoma infestans*, can specifically inhibit FXIIa (136). This protein, termed infestin-4, was fused to recombinant human albumin, and was highly specific for FXIIa. This compound protected mice from ischemic stroke and protected rats and mice from arterial thrombosis without affecting hemostasis (136). Several inhibition strategies against both proteins mirror the data seen with factor deficient mice and encouragingly protect against thrombosis without affecting bleeding.
1.3 Antithrombotics

1.3.1 Cardiovascular Disease

CVD includes any disease of the heart or blood vessels and is the leading cause of morbidity and mortality, accounting for one in three deaths in the United States. While mortality trends have declined since 2000, CVD has accounted for more deaths that any other major cause of death since the early 1900s. Currently one in three adults have one or more types of CVD, with the prevalence higher amongst men and increasing with age. Thus, CVD costs more than any other major diagnostic group and currently constitutes over 17% of overall national health expenditures. Unfortunately, by 2030, 40.5% of the population is predicted to have a CVD, with direct medical costs expected to triple to an estimated $818 billion (3, 137).

The three most common CVDs include acute coronary syndromes (ACS), stroke, and VTE. ACS includes an array of symptoms relating to an obstruction of the coronary arteries, including MI and unstable angina. In coronary artery disease (CAD), insufficient amounts of oxygen are reaching the myocardium, most commonly due to arteriosclerosis, or the buildup of a lipid-filled plaque in the endothelium of one or up to all three coronary arteries. This plaque can slowly grow over the course of years to occlude the blood vessel, or rupture, thus immediately forming a thrombus that can occlude blood flow, and thus oxygenation of the myocardial tissue. Prolonged occlusion can cause death of the myocardium, resulting in an MI. Angina pectoris is chest pain
associated with temporary myocardial ischemia that does not occur long enough for
death of the heart tissue to occur. While stable angina is associated with chest pain due
to increased oxygen requirements of the myocardium when coronary blood flow is
reduced, most likely due to an atherosclerotic plaque, unstable angina is associated with
a partially occlusive thrombus and can lead to MI.

Atrial Fibrillation (AF) is the most common heart arrhythmia and can be caused
by a number of different risk factors, including hypertension and CAD. In AF, the left
atrium is not contracting properly, leading to blood stasis and an increased probability
for thrombus formation. AF greatly increases the risk of stroke, as thrombi formed in
the atrium can travel to the cerebral artery to result in an ischemic event. Ischemic
strokes account for 85% of all strokes, and stroke, as a whole, is the leading cause of
severe disability (137).

VTE occurs with blood clots forming in the large veins, oftentimes in the legs, a
process termed deep vein thrombosis (DVT). While there are approximately 1-3 cases
per 1000 people per year, the prevalence of VTE increases with age, with approximately
1 in every 100 people per year over the age of 50 presenting with a VTE (4). Long
periods of immobilization, such as that which occurs on long plane flights or leading a
sedentary lifestyle, results in blood stasis, which can increase the risk for VTE. In
addition, orthopedic surgery, such as hip or knee replacements, can increase the risk for
VTE up to two months. A pulmonary embolism (PE) is an embolized thrombus,
oftentimes from a DVT, that travels to and blocks the pulmonary artery. PE is the third most common cause of hospital-related death, and one-quarter of PE’s result in sudden death (137).

While arterial thrombosis is largely responsible for ACS, including MI, stroke, and peripheral artery disease (PAD), which occlude obstructions in other large arteries (excluding coronary, aortic or brain), venous thrombosis is primarily responsible for VTE, including DVT and PE. These two types of thrombosis differ in mechanism, as outlined below, and thus in the types of agents used to treat them (Figure 5).
Arterial thrombosis is associated with atherosclerosis, and often occurs on the surface of a ruptured atherosclerotic plaque. Exposure of procoagulant material, such as collagen, von willebrand factor (VWF), lipid-rich macrophages, TF and subendothelial cells in the high shear arterial environment rapidly recruits platelets to the site of injury and activates procoagulant proteases, thus forming platelet-rich “white” clots. These clots can grow to occlude an artery, where they can cause disrupted blood flow to the tissue supplied by the artery. Arterial thrombi are the most common cause of MI and stroke, collectively the most common cause of death in the world. Risk factors associated with arterial thrombi include hypertension, diabetes, smoking, and hypercholesterolemia. Interestingly, the risk factors for arterial thrombosis only
modestly increase VTE risk, and vice versa, thus supporting that these thrombotic disorders have different mechanisms (5).

Venous thrombosis usually occurs with “red” clots in the large veins in the legs, where part or all of this thrombus can break away and travel to the lungs, possibly forming a PE and disrupting the flow of blood in the pulmonary artery. Prolonged immobilization, such as that which occurs during bed rest after surgery or prolonged periods of sitting, can cause blood stasis and decreased oxygen tension, especially in sinus valve pockets in the large leg vein. Decreased oxygen tension can induce endothelial cell stress response systems, resulting in activation of cell adhesion molecules on the surface of the cell that recruit platelets, microparticles, and inflammatory cells, all of which carry low levels of TF. This local increase in TF, in addition to a higher number of procoagulant proteases present due to blood stasis, leads to activation of the coagulation cascade, thrombin generation and fibrin clot formation. In addition, inflammatory cells release neutrophil extracellular traps (NETs), DNA, RNA, and platelet-released polyphosphate, thus activating the intrinsic pathway through FXII, and contributing to more thrombin generation (139). While immobilization alone might not cause DVT, genetic factors including deficiencies in anticoagulant proteases or prothrombotic mutations, and other acquired risk factors such as age, surgery, hormone replacements or contraceptives, and obesity, can increase the risk for developing a DVT.
In general, arterial thrombosis is treated with a class of drugs called antiplatelets, which prevent platelet activation and aggregation, while venous thrombosis is treated with anticoagulants, which prevent fibrin clot formation. Collectively, these two classes of drugs are called antithrombotics, and are divided into classes based on their mechanism of action. Antithrombotics are also used to prevent blood coagulation in surgical settings, where catheter insertions, stent placements, extracorporeal circuits or orthopedic surgery can present a highly thrombogenic environment.

1.3.2 Anticoagulant agents

Anticoagulants are generally used to prevent the generation, growth and embolization of a thrombus, although they do not dissolve an already present clot. There are several classes of anticoagulants, including the vitamin K antagonists (VKA), FXa inhibitors, and direct and indirect thrombin inhibitors. A partial list of the currently approved anticoagulants, including their targets, mechanism of action, and indication, are outlined in Table 1.
### Table 1. Current anticoagulant agents
All information was obtained from www.fda.gov

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Type of Drug</th>
<th>Route</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect Thrombin Inhibitors</td>
<td>Heparin</td>
<td>Heparin</td>
<td>Glycosaminoglycan</td>
<td>Parental</td>
<td>Prophylaxis &amp; Treatment of DVT; PCI; CABG</td>
</tr>
<tr>
<td></td>
<td>Enoxaparin</td>
<td>Lovenox</td>
<td>Glycosaminoglycan</td>
<td>Parental</td>
<td>Prophylaxis &amp; Treatment of DVT</td>
</tr>
<tr>
<td></td>
<td>Fondaparinux</td>
<td>Arixtra</td>
<td>Pentasaccharide</td>
<td>Parental</td>
<td>Prophylaxis &amp; Treatment of DVT</td>
</tr>
<tr>
<td>VKA</td>
<td>Warfarin</td>
<td>Coumadin</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis &amp; Treatment of DVT; Prophylaxis &amp; Treatment of VTE in valve replacement &amp; AF; Prophylaxis of recurrent MI or stroke</td>
</tr>
<tr>
<td>Direct Thrombin Inhibitors</td>
<td>Argatroban</td>
<td>Acova</td>
<td>Small Molecule</td>
<td>Parental</td>
<td>Prophylaxis &amp; Treatment of DVT; PCI</td>
</tr>
<tr>
<td></td>
<td>Bivalirudin</td>
<td>Angiomax</td>
<td>Peptide</td>
<td>Parental</td>
<td>Prophylaxis &amp; Treatment of DVT; PCI</td>
</tr>
<tr>
<td></td>
<td>Dabigatran</td>
<td>Pradaxa</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of VTE &amp; stroke in nonvalvular AF</td>
</tr>
<tr>
<td>Direct FXa Inhibitors</td>
<td>Apixaban</td>
<td>Eliquis</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of VTE &amp; stroke in nonvalvular AF</td>
</tr>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>Xarelto</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis &amp; Treatment of DVT; Prophylaxis of stroke in nonvalvular AF</td>
</tr>
</tbody>
</table>

There are two routes of administration of anticoagulants: parental or oral.

Parental anticoagulants are traditionally used in acute care settings when a rapid onset is necessary, such as a patient presenting with unstable angina or MI, during cardiac operations, or for short-term prophylaxis of VTE after orthopedic surgery (140). The indirect thrombin inhibitor heparin is a glycosaminoglycan that enhances antithrombin’s inhibition of thrombin and FXa. Heparin has been a mainstay of anticoagulation since the 1940s. Because of its rapid and predictable mode of action, heparin is oftentimes used to initiate anticoagulant therapy. In addition, heparin is commonly used in
surgical settings, such as cardiopulmonary bypass (CPB), because of its strong anticoagulant effect and its ability to be reversed by a small, positively charged protein, protamine. Heparin, while effective, is associated with several complications, including heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT), which results when heparin interacts with other extracellular proteins, such as platelet factor 4, to cause immune reactions (138). Lower molecular weight heparins, such as enoxaparin (Lovenox) or fondaparinux (Arixtra), are safer and easier to administer and monitor, and have thus replaced heparin for prophylactic treatment of VTE. However, these heparin derivatives cannot be reversed by protamine, and are thus not used for surgical procedures (141). The parental direct thrombin inhibitors, such as argatroban (Acova) and bivalirudin (Angiomax), have recently been introduced to replace the indirect thrombin inhibitors in patients with or at risk of developing HIT or HITT, who cannot be given heparin, during percutaneous coronary intervention (PCI, or “angioplasty”) surgery or as a prophylactic treatment of VTE. While these parental anticoagulants are effective, they all confer a high risk of bleeding, with no direct antidote available to reverse their action.

For long-term anticoagulation therapy, an oral anticoagulant is administered after initial treatment with a rapidly acting parental anticoagulant. In general, oral anticoagulants are easier to administer and have higher patient compliance for chronic therapy, as parental anticoagulants require repeated injections. The oral VKA, warfarin
(Coumadin), has been the mainstay of oral anticoagulant therapy for the past 65 years. While effective, warfarin has several drawbacks that have led to a search for new oral anticoagulants. Namely, warfarin has numerous food and drug interactions, a narrow therapeutic window, and is difficult to dose and monitor, with over half of patients failing to maintain an acceptable level of anticoagulation (140). This puts a high number of patients at risk for bleeding events (over-anticoagulation) or thrombotic events (under-anticoagulation).

Recent advances have led to emergence of new oral anticoagulants directly targeting either thrombin or FXa that will likely begin to replace warfarin. These compounds include rivaroxaban (Xarelto), apixaban (Eliquis) and dabigatran (Prada xa), which all show efficacy in preventing short-term VTE for surgical indications such as hip or knee replacement. These oral anticoagulants have also shown efficacy in long-term anticoagulant therapy for the life-long prevention of stroke in patients with AF, which represent a large and growing population (142). While dabigatran has already been licensed for this indication, other direct FXa inhibitors are in advanced stages of development. These new anticoagulants show comparable efficacy to warfarin with less bleeding incidents, indicating that the field has made a large step in replacing warfarin in this at-risk population (142).
1.3.3 Antiplatelet agents

Chronic antiplatelet therapy is used to treat a range of cardiovascular diseases associated with arterial thrombosis, including treating patients with MI, stroke, or angina, as well as prevention in patients at-risk for these events and others, such as PAD or AF. In addition, antiplatelet agents are also used as a rapid onset anticoagulant in cardiac surgeries, especially PCI, where insertion of foreign bodies, such as a catheter or a stent, can cause thrombosis. Several of the currently used antiplatelet agents are summarized in Table 2.

<table>
<thead>
<tr>
<th>Target</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Type of Drug</th>
<th>Route</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDE</td>
<td>Cilostazol</td>
<td>Pletal</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Treatment of PAD</td>
</tr>
<tr>
<td></td>
<td>Dipyridamole</td>
<td>Persantine</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of thrombosis in valve replacement</td>
</tr>
<tr>
<td>P2Y12</td>
<td>Prasugrel</td>
<td>Effient</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of thrombotic CV events in ACS; Prophylaxis of stent thrombosis</td>
</tr>
<tr>
<td></td>
<td>Clopidogrel</td>
<td>Plavix</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of thrombotic CV events in ACS; Prophylaxis of stroke, MI, or PAD</td>
</tr>
<tr>
<td></td>
<td>Ticagrelor</td>
<td>Brilinta</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of thrombotic CV events in ACS</td>
</tr>
<tr>
<td></td>
<td>Ticlopidine</td>
<td>Ticlid</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of stroke; Prophylaxis of stent thrombosis</td>
</tr>
<tr>
<td>GP/IIb-IIIa</td>
<td>Abciximab</td>
<td>ReoPro</td>
<td>Monoclonal Antibody</td>
<td>Parental</td>
<td>PCI</td>
</tr>
<tr>
<td></td>
<td>Eptifibatide</td>
<td>Integrilin</td>
<td>Peptide</td>
<td>Parental</td>
<td>Prophylaxis of thrombotic CV events in ACS; PCI</td>
</tr>
<tr>
<td></td>
<td>Tirofiban</td>
<td>Aggrastat</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Prophylaxis of thrombotic CV events in ACS</td>
</tr>
<tr>
<td>COX</td>
<td>Aspirin</td>
<td>Aspirin</td>
<td>Small Molecule</td>
<td>Oral</td>
<td>Low Dose: Long term prophylaxis of MI &amp; stroke</td>
</tr>
</tbody>
</table>

All information was obtained from www.fda.gov
Aspirin has been the gold standard for chronic oral antiplatelet agent use, as it is effective in reducing the incidence of MI and stroke without increasing the risk of bleeding (142). Clopidogrel (Plavix) is more recent antiplatelet agent that has shown widespread tolerance across patient populations with ACS, as well as slightly more efficacy than aspirin in reducing serious vascular events. However, both of these agents were only able to reduce the incidence of these events by approximately 20%, leaving a wide proportion of the population at risk, and a high probability for breakthrough thrombotic events (12, 142).

The limited efficacy of aspirin and clopidogrel, which only target one receptor on the platelet surface, respectively, suggests that the redundancy of the platelet activation pathway, where any number of pathways can be activated by different stimuli and lead to platelet aggregation, is important, and that only inhibiting one pathway or receptor might not be efficacious (142). To this end, combination therapy, either combining an antiplatelet and an anticoagulant agent, or two antiplatelet agents (such as aspirin and clopidogrel), is hampered by an increase in major bleeding, thus not leading to a clinical benefit for chronic use. This type of therapy is reserved for use in high-risk populations, as well as inhibitors against the platelet receptor GPIIb-IIIa, which is the key receptor in mediating platelet aggregation. These inhibitors exhibit high bleeding risk, but are still used in certain settings, such as in PCI to inhibit catheter and stent-mediated thrombosis, where their use can be highly monitored and controlled (12).
Newer antiplatelet agents have been developed that have higher potency than clopidogrel, but target the same pathway. Prasugrel (Effient) is P2Y12 receptor antagonist that exhibits more potent and consistent inhibition of platelet aggregation (142). Unlike clopidogrel, ticagrelor (Brilinta) does not have to be metabolized, and thus has a fast onset of action, a characteristic that lends itself well to surgery, where anticoagulation needs to occur quickly. The challenge of both of these agents, however, is their increased risk of bleeding compared to clopidogrel (142).

Overall, antiplatelet therapy has suffered due to a narrow therapeutic window, where too much inhibition can cause bleeding and too little inhibition can cause breakthrough thrombotic events. Another problem with antiplatelet therapy is that irreversible inhibitors are present for the life of a platelet, so a patient on antiplatelet drugs ideally should stop therapy for several days before surgery to decrease the risk of bleeding. Oftentimes, this is not possible for this subset of the population, as urgent surgery in ACS patients is often necessary (141). The combination of the correct dose and target is important, and further studies into the inhibition of alternative platelet receptors has been underway to attempt to identify new, safer antiplatelet agents.

1.3.4 Ideal Antithrombotic Agents

While cardiovascular disease is already the leading cause of death in many westernized countries, the global incidence of cardiovascular disease is expected to
continue to increase, as more cultures are changing their lifestyle to lead more sedentary lives and eat higher fat diets. As such, the antithrombotic market is expected to increase from approximately 4 billion in 2010 to 12 billion in 2016 in the United States alone, from a combination of increased patient population for long term therapy due to rising incidence of obesity and atherosclerosis, and an increase of cardiac procedures performed in the aging population (143). While a number of new agents have been introduced into the market that have more favorable profiles than the standard of care, there is still a large unmet need for convenient and effective antithrombotics that do not incur a bleeding risk. This risk of bleeding associated with antithrombotic drug therapy can be caused by many factors, including narrow therapeutic windows (the balance between inhibiting thrombosis and causing bleeding), patient drug metabolism variability, an undefined threshold of anticoagulation needed for clinical benefit, complex interactions between the drug and multiple hemostatic factors, and limited control of the drug’s pharmacodynamics (144). As in the example of antiplatelet therapy, increased potency does not always mean increased efficacy, and increased risks of bleeding can actually decrease the clinical benefit of a more potent therapeutic.

There are several ways to design an antithrombotic with a more favorable safety profile. The first strategy is to formulate a drug that has a rapid onset and offset of action. After drug administration is halted, the compound is rapidly cleared from the body and anticoagulation values quickly return to baseline in the absence of drug
administration. This strategy requires a large amount of compound, and is not viable for a chronic therapy setting. An alternative drug design strategy is to develop a stable compound that can be rapidly controlled with an antidote. Antidote reversal of stabilized drugs reduces the amount of compound required (and therefore the cost), increases the number of indications that the drug can be used for, and enhances the safety profile (145). In addition, an active antidote can be appropriately dosed to reverse some, but not all, of the circulating drug, allowing for a higher level of anticoagulant control. This ability of antidotes to modulate, rather than completely neutralize the therapeutic compound offers clinicians the ability to fine-tune the drug’s titratability and the level of clinical anticoagulation in real time (145). Currently, the only antidote-reversible antithrombotic available is the heparin/protamine pair, which is the standard for clinical anticoagulation despite dangerous side effects and complex and unpredictable pharmacodynamics that make dosing a challenge. Other, newer anticoagulant agents that have potentially less bleeding risk than heparin, such as enoxaparin or argatroban, do not have an antidote, making their clinical use limited (146).

Because of the wide range of cardiovascular events and the different mechanism contributing to each, a “magic bullet” therapy that is universally effective is not likely (12). Instead, therapeutics designed to treat closely related cardiovascular events and settings are needed. For example, cardiologists in a hospital setting need an effective
antithrombotic for highly thrombogenic settings, including cardiology procedures and critical care settings, where the risk of bleeding might not offset the clinical benefit. This antithrombotic ideally has a rapid onset of action, is most often parentally administered, is highly effective at anticoagulation, and can be instantly reversed after surgery or if bleeding complications arise. In contrast, a parental antithrombotic for a long term chronic setting might not be feasible (141). A long-term antithrombotic must be conveniently administered, is most often orally administered, be highly tolerable in a wide range of patient populations, have a predictable pharmacokinetic and pharmacodynamics response, have compatibility with other reagents, and be effective without causing bleeding or have an antidote readily available if bleeding complications arise. While there are similarities between these two strategies, in general, the most important characteristics involved in designing a successful antithrombotic is reliability, convenience, and safety (143).

Another strategy in striking the balance between inhibiting thrombus formation (efficacy) and reducing the risk of severe bleeding (safety) of an antithrombotic includes inhibiting the correct target. While most of the factors involved in hemostasis and thrombosis are conserved, determining the differences between these two states, and subsequently only inhibiting those factors involved in thrombosis, can lead to an effective antithrombotic with a reduced bleeding risk. In general, targeting of the downstream, essential coagulation factors interrupts both thrombosis and hemostasis to
ensure that blood clotting cannot occur. In these settings, an antidote is needed in order to control potential bleeding for this strategy to be safely administered. While most of the currently approved antithrombotics target these downstream factors, their use is limited due to the high risk of bleeding associated with therapy, and no antidote to reverse it. However, recent studies have suggested that, at least in animal models, inhibition of the upstream, intrinsic coagulation factors XI and XII can hinder thrombosis without affecting normal hemostatic events. While these factors are associated with the stability of a pathological thrombus, they are not essential for hemostasis in humans, as deficiencies of FXI and FXII do not confer a severe bleeding phenotype. Therefore, pharmacological inhibition of FXI and FXII, or other factors not involved in hemostasis, could produce an effective anticoagulant to treat and prevent thromboembolic disorders without a high risk of bleeding.

1.4 Aptamers and SELEX

Portions of this section have been adapted from the manuscript entitled “Antidote-control of aptamer therapeutics: The road to a safer class of drug agents” published in Current Pharmaceutical Biotechnology on August 2012, 13(10):1924-34 and co-authored by Kristin Bompiani and Rebecca Woodruff, as well as Richard Becker, Shahid Nimjee, and Bruce Sullenger.

Other portions of this section were adapted from the manuscript entitled “Application of
aptamers for targeted therapeutics” published in Arch Immunol Ther Exp (Warsz) on April 2013, and co-authored by Partha Ray, Kristi Viles, Erin Soule and Rebecca Woodruff.

1.4.1 Emergence of Aptamers & SELEX

The central dogma of molecular biology states: “DNA makes RNA makes protein.” While the oligonucleotides in this equation are responsible for information storage and transfer, proteins actually carry out all the functions of the cell. A clue that this might not precisely be the case was discovered when the structure of tRNA was solved, and it was determined that highly structured RNA’s serve a function other than information storage in the translation process. The discovery of catalytic RNAs was so groundbreaking that it was later awarded the Nobel Prize. Out of this oligonucleotide revolution came the idea of an RNA world, where more diverse oligonucleotides than what is present today could have been able to both encode and carry out complex functions until amino acids took over part of their job. To do this, oligonucleotides would have needed to evolve diverse shapes and affinities towards different substrates, and this information inherently would have been encoded by their linear sequence. By screening large libraries of single stranded oligonucleotides, scientists can identify the exact sequences responsible for binding to molecules, including nucleic-acid binding proteins (147).

The process of SELEX (systematic evolution of ligands by exponential enrichment) was first developed to quickly discover the specific nucleotide sequence(s)
essential for binding to a DNA or a single stranded RNA binding protein. In their groundbreaking paper, Tuerk and Gold demonstrated that large libraries of randomized oligonucleotide (RNA or DNA) sequences could be screened in vitro for ligands that bind with the highest affinity to T4 DNA polymerase (148). Using this process, their group discovered that T4 DNA polymerase recognizes eight specific nucleotides. Two aptamers, or specific sequences of DNA, dominated the finished pool and bound with equal affinity: one with the exact nucleotide sequence of its natural DNA binding site and one with four differences. These binding sequences were termed “aptamer” after the Greek aptus, meaning “to fit” (149). Early on, it was determined that SELEX could actually select sequences that bind with higher affinity than those that are present in nature (150). Because the in vitro SELEX process is not constrained by biological fitness, these additional, and sometimes truncated, sequences that bind with higher affinity can be isolated. This process was therefore exploited, and during the last twenty years, has been used to isolate aptamers to a diverse number of proteins, including transcription factors, proteases, viral proteins, growth factors and cell adhesion molecules, among others.

The starting pool of a selection is a combinatorial nucleic acid library containing a certain number of randomized nucleotides, flanked on either end with constant regions to aid with molecular biology techniques. The randomized region is essential for library diversity, and can range from a few nucleotides up to hundreds of nucleotides,
and can be continuous or found in blocks. Importantly, enough randomization of the library needs to occur in order to form enough unique stable aptamer structures (or oligonucleotide sequences) to perform the selection. A library with approximately 25 randomized nucleotides yields \(~10^{15}\) different aptamer sequences, which allows for almost all sequences present in the starting pool to be examined (147).

Traditionally, the SELEX process begins by incubating this nucleic acid library with a purified protein target or molecule. Oligonucleotides that bind to the protein or molecule are separated from the unbound aptamers through various techniques (nitrocellulose filtration, column chromatography, immunoprecipitation, \textit{etc.}) and are subsequently amplified to generate an enriched pool with increased binding affinity for the target. The entire process of incubation, partitioning, elution, and amplification completes one round of SELEX. This process is repeated under increasingly stringent conditions to isolate a pool of oligonucleotide sequences that bind with the highest affinity for the target. Increased stringency is generated by creating greater competition for binding to the target in a round; this is facilitated by either increasing the RNA to protein ratio, increasing salt concentrations, or decreasing the overall amount of protein used. The number of rounds required to drive a selection to completion depends on both the innate ability of the target to bind to the library oligonucleotide and how much stringency is increased in each round. Importantly, stringency is often kept minimal during the beginning rounds to reduce the risk of losing a high affinity binder when
there are many aptamer sequences present and limited number of areas on the protein to bind. After significant increases in binding affinity by the pool are made, and weak or non-binders have been selected out, stringency can be increased to quickly drive the selection to completion (147).

Several variations on the traditional SELEX procedure have since been derived from the original method described by Tuerk and Gold. For example, “toggle” SELEX was developed to isolate an aptamer that can bind to conserved regions on two homologous proteins, primarily between a protein from two different species (151). This method was developed to facilitate aptamer cross-reactivity for pre-clinical studies.

“Complex” selection is used to create a pool of aptamers that can bind to multiple targets in a complex mixture, such as the plasma proteome or red blood cell membranes, to create a focused library (152, 153). This focused pool can be amplified and used to isolate aptamers from nearly any protein found in the complex mixture in approximately half the number of rounds compared to traditional SELEX (152). Other types of SELEX have been developed with cells or a whole organism as the target, not just soluble proteins or molecules. Cell-based SELEX can be employed in the cancer biomarker setting to discover aptamers that selectively bind to cancer cells, but not normal cells (154). Similarly, aptamers have been isolated that can detect differences between pancreatic cancerous cell secretomes versus non-cancerous secretomes (155). In
addition, SELEX has been performed in vivo in a mouse to identify aptamers that bound specifically to cancer metastases (156).

The SELEX process generates an enriched pool of aptamer sequences that demonstrate high affinity binding toward the target. After completion of SELEX, the oligonucleotide pool is cloned and sequenced, yielding individual aptamer sequences. Enriched pools at the end of a selection often have “structural families”, or sequences that share common stretches of nucleotide composition or common structural motifs. If SELEX has been driven to completion, the final pool is comprised of a single aptamer sequence. While SELEX completion produces an obvious candidate compound for further testing, generation of sequence families can yield valuable information as conserved structural domains across structural families may indicate a region of sequence that is important for target binding and/or functionality.

Once several aptamer sequences have been identified, in vitro studies are used to compare the individual aptamer sequences for their binding affinity and intended functionality toward the therapeutic target (enzyme inhibition, receptor-mediated signaling, etc.). The aptamer with a combination of the tightest binding and most potent functionality is selected for optimization and further studies.
1.4.2 Aptamers as Therapeutics

In essence, aptamers are designer ligands that can be made toward theoretically any target molecule of interest. As a novel class of compounds that has rapidly gained clinical interest over the past twenty years, aptamers combine the best characteristics of small molecules and antibodies and have some additional unique characteristics of their own.

As small, single-stranded oligonucleotides, aptamers form specific three-dimensional structures that allow them to bind to their targets with high affinity and specificity. Crystal structures of aptamer-protein binding have shown that aptamers fold into a tertiary structure and present an extended conformational surface that is complementary to the target protein, thus binding and concealing a large surface area on the protein (157). There are numerous electrostatic, hydrophilic, and van der Waals interactions within the extended aptamer/protein binding interface, including hydrogen and pi-bond stacking with the amino side chains of the proteins. Because of these specific interactions, aptamers often bind their targets with dissociation constants (KdS) that are typically in the low nanomolar (10^-9) to high picomolar range (10^-12). The unique surface, shape, and charge of the aptamer-binding region on the target profoundly influences the affinity of aptamer-target binding and thus dictates specificity. A single substitution of an amino acid or nucleic acid base in the binding region can completely disrupt aptamer binding and thus function (158). Since a large part of the target protein
is concealed by aptamer binding, aptamers tend to act as antagonists by blocking protein-protein interactions.

Unlike small molecules or antibodies, aptamers can easily be pharmacokinetically manipulated, thus controlling their duration of action from a few hours to days. Unmodified oligonucleotides, especially RNA, are rapidly degraded in biological fluids by endogenous endonucleases. Therefore, internal modification strategies with chemically synthesized bases are oftentimes utilized to increase resistance to enzymatic hydrolysis. Modified bases are typically introduced at the beginning of the SELEX process, since a change in chemical structure can influence aptamer folding and target binding. Commonly, the 2’ ribose position of the pyrimidine nucleotides is modified to include functional groups such as an amine (2’N), O-methyl (2’OMe) or fluoro (2’F), as substitutions at this position are effective at increasing nuclease resistance (159). These modifications can easily be incorporated during in vitro transcription by using a mutant form of RNA polymerase (RNAP) that can recognize its respective modified base. While all of these modifications greatly increase the half-life of an aptamer in biological fluids, there are subtle unique advantages and disadvantages to each type of modification. Overall, many aptamers have been generated with 2’fluopyrimidines, as higher transcription yields incorporating this modification makes the development process easier. However, 2’OMe modifications have traditionally been less expensive than any of the other common modifications, and are thus attractive in
clinical development of aptamers (159). Although internal modification of the aptamer sequence protects against endonuclease cleavage, a 3’end cap of deoxythimidine is often incorporated to protect the end of the aptamer from exonuclease cleavage.

Because aptamers are relatively small (8-15 kDa) and thus are rapidly cleared by the kidneys, bulky, inert moieties, such as cholesterol or polyethylene glycol (PEG), are typically conjugated to the 5’ end of an aptamer to increase the molecular weight, thereby decreasing the clearance rate and increasing the half-life of an aptamer in vivo. Cholesterol conjugation of an aptamer can increase the half-life to several hours (160), while PEG conjugation can extend the half-life to days or even weeks, depending on the mode of administration (161). Therefore, the bioavailability of a specific aptamer can be easily manipulated.

Similar to small molecule therapeutics, aptamers can be chemically synthesized by solid-phase oligonucleotide synthesis to generate large, homogenous and highly purified quantities of compound. Shorter aptamers, like other custom oligonucleotides, have higher yields and are most cost effective to produce; thus, aptamers are typically truncated to less than 50 nucleotides or the smallest functional sequence possible. Additionally, as synthetic molecules, the chemical composition of individual bases in the aptamer sequence can be altered to increase the yield or decrease the cost of manufacturing, as long as the changed modification does not disrupt the aptamer’s structure or function. Previously, 2’F modified nucleotides could often be substituted
with the less expensive 2’OMe nucleotides, resulting in a functional aptamer that is more cost effective to produce in high quantities. However, the cost of 2’F modified nucleotides has recently been reduced to a similar cost as 2’OMe nucleotides, allowing for the feasibility of developing a therapeutic 2’F modified aptamer.

In addition to being chemically synthesized, aptamers have a stable shelf life and can recover their folded structure after wide temperature fluctuations. Moreover, aptamers are well tolerated in the body, and can thus be repeatedly administered (162). Overall, ribonucleic acids are non-immunogenic, with extensive analysis in clinical trials. The incidence of allergic reactions have been low, and thought to be caused by antibody generation to the PEG group appended to the aptamer (163).

While the above properties of aptamers highlight their flexibility and utility as potential therapeutics, the most unique characteristic of aptamers over antibodies or small molecules is their ability to be functionality controlled with antidotes. Two types of antidote control have been developed: a sequence specific antidote that recognizes the primary sequence of the aptamer and disrupts the aptamer’s structure, and a universal antidote that nonspecifically binds to an oligonucleotide and can reverse the activity of any aptamer, independent of sequence or shape (164, 165).

A matched oligonucleotide aptamer antidote takes advantage of the fact that aptamers form stable secondary conformations, such as hairpins and pseudoknots, which fold into a stable tertiary structure to bind to a complementary surface on their
target (157). Theoretically, a molecule that binds to and alters the tertiary structure of an aptamer should disrupt the ability of an aptamer to bind to its target protein. Because oligonucleotides inherently bind to each other through simple Watson-Crick base pairing, a short, complementary “antisense” oligonucleotide disrupts the structural elements essential for binding and abolishes aptamer activity (164).

Although matched oligonucleotide antidotes can successfully modulate the function of aptamer anticoagulants, there are a few drawbacks of this strategy. First, this method of antidote design is labor intensive and costly, because custom antidotes must be designed and tested for each new aptamer. Moreover, it can be challenging to develop oligonucleotide antidotes to highly structured aptamers (unpublished data). Finally, because aptamer-oligonucleotide antidote complexes are double-stranded RNA, they may trigger an innate immune response through activation of toll-like receptors, although there has been no direct evidence of this to date.

Because of these potential limitations of oligonucleotide antidotes, a universal antidote strategy was developed. In theory, a universal antidote is a molecule that can bind to and control the activity of any aptamer, regardless of sequence or conformational shape. In healthy individuals, no endogenous oligonucleotides circulate in the blood; therefore, an antidote that can recognize and bind to any oligonucleotides will be able to neutralize the administered aptamers, regardless of sequence. Because all aptamers are oligonucleotides and thus negatively charged, the most obvious choice for
a universal antidote is a positively charged molecule that can bind an aptamer through electrostatic interactions. Several compounds were shown to be successful universal antidotes, including protamine and a number of nucleic acid binding polymers, both \textit{in vitro} and \textit{in vivo}. In contrast to the specific base pairing mechanism required for oligonucleotide antidotes, binding of a universal antidote to the oligonucleotide backbone is thought to envelope the aptamer, thus providing a barrier around the folded aptamer to prevent binding to the therapeutic target. In essence, a universal antidote functions like a “molecular sponge” by binding and sequestering any systemically administered oligonucleotides.

Both types of antidotes have several benefits that led themselves well to therapeutic administration. Because of their specificity and ability to modulate aptamer functionality, matched oligonucleotide antidotes can allow clinicians to fine-tune therapy to the degree required, rather than turn it on or off. This level of drug control can allow clinicians to respond immediately to urgent clinical needs and is a valuable advance in drug therapy. In addition, if two aptamers are administered simultaneously, one could use an oligonucleotide antidote to specifically turn off a single aptamer, thus reinstating the functionality of a single pathway while leaving the other pathway(s) inhibited. However, the clear advantage of a universal antidote lies in its simplicity and cost-effectiveness - one antidote compound can be used for any aptamer.
therapeutic. Additionally, a universal antidote could simultaneously reverse the activity of any aptamer combinations.

The high binding affinity and specificity of aptamers allow for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Thus the aptamer platform offers a promising therapeutic.

1.4.3 Current aptamer therapeutics

The concept of using nucleic acids to modify protein function originated from the study of viruses, where short, structured RNAs encoded by the virus bound to proteins to either assist with virus replication or inhibit antiviral responses. In the first study testing the idea of a therapeutic aptamer, Sullenger et al. demonstrated that the single stranded RNA TAR aptamer could successfully inhibit HIV virus replication by binding to the natural nucleic acid binding site of the viral protein Tat, and thus act as a decoy to block normal Tat function (166, 167). Coupled with the emergence of SELEX, it was recognized that this process could be used to rapidly generate oligonucleotide designer ligands to essentially any therapeutic target, including soluble proteins and enzymes, prions (pathogenic misfolded proteins), cellular surface receptors, and transcription factors (168).
While a number of therapeutic aptamers have been developed, only one aptamer has gained FDA approval: an anti-VEGF aptamer, Macugen, for treatment of age-related macular degeneration (169). Since its approval in 2004, a number of novel aptamers have been introduced into clinical trials, as summarized in Table 3.
Table 3. Aptamers in clinical trials
Only the most recent trial for each aptamer was included. Data from www.clinicaltrials.gov.

<table>
<thead>
<tr>
<th>Aptamer (company)</th>
<th>Target</th>
<th>Condition</th>
<th>Phase (status)</th>
<th>Identifier (<a href="http://www.Clinical">www.Clinical</a> Trials.gov)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARC1905 (Ophthotech Corporation)</td>
<td>Factor C5 of the complement cascade</td>
<td>Age-Related Macular Degeneration</td>
<td>Phase 1 (unknown)</td>
<td>NCT00950638</td>
</tr>
<tr>
<td>E10030 (Ophthotech)</td>
<td>Platelet-derived growth factor-B (PDGF-B)</td>
<td>Neovascular Age-Related Macular Degeneration</td>
<td>Phase 2 (completed)</td>
<td>NCT01089517</td>
</tr>
<tr>
<td>NOX-A12 (Noxxon Pharma AG)</td>
<td>Stromal cell-derived factor-1 (SDF-1)</td>
<td>Multiple Myeloma</td>
<td>Phase 2 (recruiting)</td>
<td>NCT01521533</td>
</tr>
<tr>
<td>NOX-E36 (Noxxon Pharma AG)</td>
<td>Monocyte chemotactic protein-1 (MCP-1)</td>
<td>Type 2 Diabetes Mellitus, Albuminuria</td>
<td>Phase 2 (recruiting)</td>
<td>NCT01547897</td>
</tr>
<tr>
<td>Pegaptanib sodium (Valeant Pharmaceuticals International, Inc.)</td>
<td>Vascular endothelial growth factor (VEGF-165)</td>
<td>Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema</td>
<td>Phase 4 (active, recruiting)</td>
<td>NCT01573572</td>
</tr>
<tr>
<td>REG1 (Regado Biosciences)</td>
<td>Factor IX</td>
<td>Acute Coronary Syndrome</td>
<td>Phase 2 (completed)</td>
<td>NCT00932100</td>
</tr>
<tr>
<td>AS1411 (Antisoma Research)</td>
<td>Nucleolin</td>
<td>Acute Myeloid Leukemia</td>
<td>Phase 2 (terminated)</td>
<td>NCT01034410</td>
</tr>
<tr>
<td>ARC1779 (Archemix Corp.)</td>
<td>Von Willebrand Factor</td>
<td>Von Willebrand Disease</td>
<td>Phase 2 (withdrawn)</td>
<td>NCT00694785</td>
</tr>
<tr>
<td>ARC19499 (Archemix Corp.)</td>
<td>Tissue Factor Pathway Inhibitor (TFPI)</td>
<td>Hemophilia</td>
<td>Phase 1/2 (unknown)</td>
<td>NCT01191372</td>
</tr>
</tbody>
</table>
While aptamers function well as antagonists due to their propensity to inhibit protein-protein interactions, they can also be used to stimulate protein function. A multimerized aptamer targeting the immune surface costimulatory receptor 4-1BB was generated that mimicked natural ligand binding to active 4-1BB and promoted T-cell proliferation, survival, and expansion in vitro and led to tumor rejection when administered in vivo (170).

In addition to functioning as antagonists or agonists, it was quickly realized that the ability to easily manipulate aptamers offers a platform for targeted delivery. Aptamers can be made as chimeras, with a small molecule, nanoparticle, toxin, splice-switching oligonucleotide, or siRNA, to name a few, appended to the end of the aptamer sequence, to act as a delivery molecule for targeted therapy (171). While the aptamer targets a certain protein and offers specificity, the cargo attached to the end of the aptamer imparts a function. While there are several examples in the literature of this, one of the first displaying this concept was for targeting prostate-specific membrane antigen (PSMA) positive prostate cancer cells in vitro (172). An aptamer targeting PSMA was hybridized with an anti-PLK1 or anti-BCL2 siRNA and the complex was shown to specifically bind to PSMA receptor on the surface of the cancer, be internalized, and silence PLK1 or BCL2 function, resulting in apoptosis and decreased cell proliferation. This technology has wide application in the cancer field, offering a tumor-specific targeting device for other therapeutic agents, hopefully leading to targeted cancer
therapy. While there are many aptamers targeting tumor markers available, each aptamer has to be validated individually, as internalization rates and methods differ from receptor to receptor. Identifying a single aptamer that can internalize into many cancerous cell types would be advantageous in further developing this therapeutic (173).

Aside from direct applications as therapeutics, aptamers have been designed to have clinical diagnostic functions ranging from the detection of tumor cells or cancerous secretomes to uses in imaging, flow cytometry, and microarray detection. The multiple functions of therapeutic aptamers have been extensively reviewed (168, 171, 174)

1.4.4 Aptamers as antithrombotics

While the use of antithrombotics will only increase as more of the population is expected to have a cardiovascular disease, the field itself has been hampered by nonselective agents with narrow therapeutic windows and no dosing flexibility or reversal agent. As a therapeutic, aptamers lend themselves well as anticoagulants, as aptamers targeting coagulation factors can be systemically delivered with rapid onset in a highly reproducible and readily measurable manner, as well as be rapidly modulated or completely reversed within minutes after the administration of an antidote. Thus, aptamers targeting several members of the coagulation pathway have been developed, and a few of those compounds have progressed into clinical trials.

1.4.4.1 Inhibiting the common pathway

Prothrombin/Thrombin
Thrombin is the final step in the blood coagulation pathway, and mediates many important features of blood coagulation, from cleaving fibrinogen into fibrin to activating platelets. Thrombin has three main binding sites: the catalytic active site, and two anionic bindings sites: exosite I and II, which are located on opposite sides of the protein. Exosite I is present on both prothrombin and thrombin, and binds to fibrinogen, FV, FVIII, thrombomodulin, and platelet PAR receptors. In this way, exosite I mediates fibrinogen cleavage, feedback activation of clotting cofactors, and platelet activation. The other anion binding site, exosite II, binds to heparin and also to a platelet surface receptor. Therefore, exosite II mediates platelet activation, as well as inhibition by heparin. Thus, inhibitors targeting different sites on thrombin have different modes of action, and combining inhibitors to both exosites can result in a very potent inhibition of thrombin function (175).

Because of thrombin’s central role in coagulation, this well-characterized protein has been the target for some of the first in vitro aptamer selections. The first aptamer to be isolated to a non-nucleic acid binding protein was termed HD1, or is also known as ARC183. This aptamer is a unmodified 15 nucleotide single-stranded DNA aptamer that forms a stable G-quadruplex and binds to exosite I, thus inhibiting exosite I functions, including fibrinogen cleavage (176, 177). Due to its anticoagulant activity, this aptamer was explored in several animal models as a cardiopulmonary bypass agent. In cynomolgous monkeys, HD1 has a very short half-life (108 seconds) and rapid clearance.
by the body (2-4 minutes); therefore, a continuous infusion was needed to achieve efficacious anticoagulation (178). Once administration was halted, coagulation values returned to baseline in approximately 10 minutes, abolishing the need for a reversal antidote. While preliminary human studies were commenced, the large quantities of aptamer required for continual administration for anticoagulation resulted in suboptimal dosing profile (179).

HD22 is another unmodified DNA aptamer, 29 nucleotides long, that also forms a G-quadruplex. This aptamer, however, binds to exosite II on thrombin to inhibit thrombin-mediated activation of platelets, but has minimal effects on fibrinogen cleavage (180). A very potent DNA aptamer was made by designing a hybrid aptamer joining both HD1 and HD22 with a linker. HD1-22 thus binds to both exosites, effectively shutting down thrombin function (70). A third DNA aptamer, Nu172, is a 26nt single stranded unmodified DNA aptamer, which produced a dose dependent increase of clinical coagulation assays during phase I testing in healthy male volunteers. Since this aptamer has a short half-life, after terminating infusion of Nu172, coagulation values returned to baseline. This aptamer is currently being evaluated in phase II clinical trials for acute cardiovascular surgical procedures (NCT00808964).

While many of the first thrombin aptamers were DNA, several RNA aptamers targeting thrombin have since been developed. Whereas unmodified DNA has a very short half-life in the body, RNA can be modified to be resistant to endonuclease
cleavage, thus greatly increasing an aptamer’s plasma stability. A 25nt 2’F pyrimidine RNA aptamer, Tog25, was selected against thrombin using a “toggle” SELEX method to promote species cross-reactivity. In order to isolate an aptamer that was efficacious in both human and porcine, the selection was toggled back and forth each round with human and porcine thrombin (151). Tog25 binds to exosite II of thrombin, thus inhibiting platelet activation but having a minimal effect on fibrinogen cleavage (158).

In contrast to the G-quadruplex architecture of the DNA aptamers, Tog25 has a traditional stem-loop structure with an internal bulge. A crystal structure of Tog25 in complex with human thrombin shows that the RNA forms an elaborate three-dimensional structure to present an extended molecular surface complementary to the protein. A number of key interactions, including an “A-Arg zipper”, which involves a number of adenine-arginine stacking interactions, as well as hydrogen bonds and van der Walls interactions, contribute to the intricate folding that allows Tog25 to tightly interact with thrombin (Figure 6) (157). While Tog25 is not itself a potent anticoagulant, dual administration with the exosite I binding DNA aptamer, HD-1, results in synergistic anticoagulation, similar to the bivalent DNA aptamer described above (175).
Recently, another 2′F pyrimidine modified RNA aptamer was described. R9d14t is 58 nucleotides and binds to both prothrombin and thrombin at exosite I, thus inhibiting fibrin clot formation, FV feedback activity, and platelet activation mediated by the PAR receptors. In addition, because the aptamer binds to the pro-exosite I on prothrombin, it inhibits thrombin generation by the extrinsic tenase complex. This aptamer is a potent inhibitor of clinical clotting assays. In addition, an oligonucleotide antidote was generated towards R9d14t that can rapidly and stably reverse anticoagulation. While this aptamer binds to the same exosite as the DNA aptamer HD-1, R9d14t is a more potent inhibitor of thrombin due to its increased stability and higher binding affinity (181). Aside from NU172, the other thrombin aptamers described above
have not advanced clinically due to limited anticoagulant ability, rapid clearance, or chemical instability. R9d14t is a promising thrombin aptamer therapeutic with an elegant reversal strategy; however, prothrombin is present at a high concentration of approximately 1.4µM and will therefore require large amounts of compound to fully saturate the target. Further optimization of Rd914t will be warranted before pre-clinical studies can proceed.

FX

FX combines with its cofactor, FVa, on the surface of a platelet to cleave prothrombin to thrombin. While FX has some protease activity itself, the formation of the prothrombinase complex yields a ~10⁵-fold increase in thrombin generation. Since prothrombinase cleavage of thrombin is the only reaction not duplicated in the coagulation pathway, inhibition of this complex would yield a potent anticoagulant. An aptamer, 11F7t, was isolated that binds to FX and FXa. This aptamer works as a potent anticoagulant in clinical coagulation assays by blocking the assembly of the prothrombinase complex (182). Biochemically, 11F7t binds to FX and competes for binding with FVa. Therefore, in the presence of aptamer, the prothrombinase complex cannot form, resulting in a decreased amount of thrombin able to be formed. Interestingly, the aptamer does not affect membrane binding, catalytic site activity, or influence substrate binding. In addition, 11F7t blocks the ability of FXa to activate FVIII in a feedback loop, as well as blocking TFPI from inhibiting FXa (182). As a potent
anticoagulant, this aptamer unfortunately does not exhibit a high amount of cross-reactivity to other species (unpublished data). Optimization of the aptamer, or the isolation of a separate FX aptamer, would be needed in order continue developing this aptamer as a therapeutic.

1.4.4.2 Inhibiting the extrinsic pathway

FVII

The principle activator of the extrinsic pathway, and also the major activator in vivo, is the TF/FVIIa complex. Upon TF exposure, FVIIa binds to TF, allowing FVIIa to then cleave FIX and FX to their active proteases, and thus initiate thrombin generation at the site of injury. An inhibitor against FVIIa would therefore shut down the initiation of thrombin generation. A 2’aminopyrimidine RNA aptamer, termed 16.3, was generated that binds to FVIIa and potently inhibits a prothrombin time clotting assay. This aptamer inhibits the TF/FVIIa mediated activation of FX, at least in part by preventing this complex to form, to function as an anticoagulant (183). Unfortunately, the folding of this aptamer is temperature sensitive, and at 37°C, has decreased binding affinity for FVIIa. Therefore, this aptamer was not further developed.

1.4.4.3 Inhibiting the intrinsic pathway

FIX aptamer

The serine protease FIX is a critical component in coagulation, where it plays a fundamental role in both the initiation and propagation phases leading to thrombin
generation and stable fibrin clot formation. Although a member of the intrinsic pathway, FIX can be activated by both FXI and the TF/FVIIa complex. It then forms a complex with its cofactor, FVIIIa, to activate a large amount of FX on the platelet surface. Inhibiting FIX is thought to be a “safer” target, since current FIX-targeting agents show reduced bleeding risks at their effective doses. However, at higher doses, these agents still have bleeding risks, making an antidote strategy attractive.

A 35 nucleotide, 2′F pyrimidine modified RNA aptamer was isolated that inhibits FIXa activity and prolongs plasma clotting in a dose-dependent manner. Optimal doses of this aptamer induce a transient, Hemophilia A-like state where >99% FIXa activity is inhibited. This aptamer can also be rapidly reversed by a number of short 2′OMe RNA antidote oligonucleotides (164). Biochemical studies indicate that this aptamer blocks an extended substrate binding site so as to inhibit FIX-mediated activation of FX, but it does not inhibit FVIII binding to FIX (184).

This FIXa aptamer-antidote pair was next tested in a porcine cardiopulmonary bypass surgery model, and it was found that this strategy could limit thrombin generation and inflammation more effectively than heparin while exhibiting none of the dehabilitating side effects, such as reduced cardiac function, that are associated with protamine administration (185). Because of its low immunogenicity, this regimen could lend itself well to applications in patients who cannot tolerate heparin/protamine (HIT,
HITT, or sensitization to protamine) and currently have no other option for reversible anticoagulation.

Because of the success in the preclinical development of establishing the FIX aptamer-antidote pair as a nontoxic, predictable, and reversible system in animals, the aptamer-antidote pair was next optimized for use in humans and moved into clinical development as the REG1 Anticoagulation System (Regado Biosciences, Durham, NC). The REG1 system consists of two compounds: RB006 is the FIXa aptamer further modified with active 2′F and 2′OMe nucleotides and a 3′ inverted deoxythymidine cap conjugated to a 40kDa PEG carrier to increase its half life and RB007 is a 2′OMe modified 15 nucleotide RNA oligonucleotide antidote complementary to a portion of RB006 (162) (Figure 7).
Three phase one clinical studies were performed to determine if the REG1 Anticoagulation System would be well tolerated in healthy subjects and patients with stable CAD currently on antiplatelet agents, as well as to determine the relationship between drug dose and clinical monitoring tests (161, 186). Overall, The RB006/RB007 complex was found to be both stable and biologically inactive, with irreversible binding of aptamer to antidote, thus exhibiting no rebound anticoagulation effect due to dissociation of aptamer and antidote. Anticoagulation, either bolus or weight-adjusted,
was rapid and stable for several hours, whereas antidote administration rapidly reversed the aptamer’s activity within minutes (161). While clearance of free RB006 involves mainly intravascular and some renal mechanisms, clearance of RB007 and the RB006/RB007 complex is believed to occur rapidly through endogenous endonuclease degradation, allowing for the re-administration of aptamer with immediate restoration of anticoagulant effects (162, 186). The REG1 system was also shown to be well tolerated and predictable in patients with stable CAD that commonly undergo procedures requiring anticoagulation. These patients tend to be older with reduced drug clearance and are currently on other medications, such as oral antiplatelets, that affect hemostatic factors and can increase the patient’s propensity for bleeding (186). The success of these studies highlight the versatility of the aptamer-antidote platform for use in a wide number of clinical indications, as the pair can be repeatedly administered with highly predictive results and no evidence of toxicity, immunogenicity, or adverse bleeding events. Importantly, drug reversal can be closely controlled by titrating in antidote as needed to neutralize the anticoagulant effects of the aptamer to the necessary degree (187).

Reversal-PCI (NCT00113997) was a phase 2a pilot study that was undertaken to assess the REG1 system as the sole anticoagulant for use in elective PCI in low risk patients with stable CAD. This study represented the first clinical use of the REG1 system and exhibited partial or complete reversal of REG1 to allow for a safe sheath
removal. Overall, the REG1 system exhibited low inter-patient variability, with a rapid onset and stable anticoagulation throughout the procedure. RB006 was either fully or partially reversed upon administration of the appropriate dose of RB007 in a predictable manner. This ability to slowly and partially reverse is useful in clinical settings where incomplete or slow reversal of anticoagulation is desired, such as PCI, where anticoagulation can be slowly reversed in conjunction with sheath removal. This study proved that REG1 could replace heparin/protamine in PCI with stable and predictable anticoagulation, and laid the groundwork for a larger clinical trial in higher risk patients undergoing PCI (188).

A Phase 2b study termed RADAR (A Randomized, Partially Blinded, Multicenter, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System in Patients with ACS) (NCT00932100), was designed to assess the degree of reversal required for early sheath removal and mitigate bleeding following cardiac catheterization (163). A total of 640 non-ST elevated ACS patients from multiple international centers were randomly assigned to one of four REG1 treatment arms, all receiving a weight adjusted dose of RB006 (now termed pegivacogin) with four different RB007 (now termed anivamersen) reversal strategies. Overall, it was determined that at least 50% reversal of pegivacogin is required for safe sheath removal. In addition, full FIX inhibition with pegivacogin, followed by full reversal with anivamersen, did not increase bleeding or subsequent
thrombotic events despite early sheath removal, suggesting that this strategy is efficacious for ACS patients undergoing invasive surgery. While the incidence of bleeding rates and adverse events were similar with REG1 and heparin, enrollment in RADAR was halted after three allergic events thought to be due to exposure to PEG and not the aptamer itself. In addition, all three patients had a history of allergic reactions (163). Overall, the study goals were met, and larger clinical trials determining the efficacy of the REG1 system compared to other anticoagulation strategies are warranted.

While the REG1 system was administered intravenously in these previous studies for rapid onset anticoagulation, a subcutaneous route of injection could be valuable in settings that require chronic anticoagulation, such as VTE. In a phase 1a clinical trial in healthy volunteers, subcutaneous administration of pegnivacogin resulted in anticoagulation beginning at 8-12 hours after injection, with peak anticoagulation at ~48 hours. This effect was durable with a half-life of 6 days. Anivamersin administration successfully neutralized RB006 plasma activity, but did not inhibit further absorption of RB006 in the bloodstream, resulting in only transient reversal (189). A phase 2b trial with multiple dose escalation is planned.

Overall, the REG1 anticoagulation system is the first aptamer-antidote pair to be tested in humans, and it has shown to be safe and effective in the clinical setting of PCI with a number of advantages over the standard of care heparin/protamine. Importantly, REG1 was able to predictably and stably anticoagulate patients and was easily
monitored with routine point of care assays. Antidote reversal allowed for immediate
restoration of FIX function, allowing for repeat administration with stable and
predictable anticoagulation. The hallmark of this system allows for unprecedented
control over drug titratability, with the ability to fully or partially neutralize the aptamer
as needed.

1.4.4.4 Inhibiting platelet pathways

**VWF Aptamer**

VWF is a large, multimeric glycoprotein (ranging from 600 to 20,000 kDa)
expressed in platelets and endothelial cells and mediates platelet adhesion, activation,
and aggregation. Once VWF is exposed on the injured vessel wall, it can then interact
with collagen near the site of injury, as well as adhesion platelet receptors to tether
platelets to the site of injury, allowing them to become activated and aggregate, thus
forming a plug at the site of injury. Inhibiting the interaction of platelets with VWF,
especially in a high flow environment, could severely impair coagulation by not
allowing platelets to adhere to the site of injury. This defect is evident in von
Willebrand’s disease, where patients with deficiencies of VWF have moderate to severe
bleeding phenotypes.

A mixed modified DNA/RNA aptamer against VWF was isolated that binds to
the A1 domain of VWF. This domain is responsible for platelet binding to the
glycoprotein. As such, this aptamer, termed ARC1779, blocks the ability of VWF to
interact with platelet receptors, thus interrupting VWF-mediated aggregation and activation of platelets in clinical platelet aggregation assays. Given as a continuous infusion, this aptamer was efficacious in preventing occlusive thrombi from forming in a cynomolgous monkey arterial thrombosis model (190). A PEGylated version of ARC1779 was subsequently administered in healthy volunteers in a Phase I clinical trial sponsored by Archemix Corporation. While the drug was well tolerated in this study, with high specificity and no reports of excess bleeding or toxicity, further clinical studies with this aptamer were either terminated or halted (190).

A 2’F pyrimidine RNA VWF aptamer was isolated using a convergent SELEX approach by first selecting against the entire plasma proteome. Then, using this focused library, several rounds of purified protein selection against VWF were performed. The lead candidate, R9.14, was shown to bind within the A1 domain that mediates platelet binding to VWF, and therefore, this aptamer was able to inhibit platelet aggregation and activation in a clinical platelet aggregation assay. An antidote was also generated that could potently reverse the aptamer’s action within two minutes (191).

A truncated, cholesterol-modified version of R9.14 was next tested in animal models. These modifications allow for more cost effective synthesis, and increase the half-life of the aptamer in an animal. In a mouse ferric-chloride arterial thrombosis model, administration of R9.14 kept the vessel patent and free of thrombi for up to one hour (192). While there was no spontaneous bleeding in these mice, the aptamer dose-
dependently increased bleeding as measured by a tail transection. However, administration of either a matched oligonucleotide antidote or a universal antidote completely reversed the bleeding phenotype (192). As use of antiplatelets has been limited due to the high risk of hemorrhage, especially from coupling these agents with other anticoagulants, an aptamer-antidote pair could be rapidly controlled by physicians in response to adverse bleeding events in a clinical setting, while still protecting the patient from thrombotic complications. Thus, the VWF aptamer-antidote system is currently undergoing further optimization and subsequent pre-clinical trials.

**GPVI**

The platelet receptor Glycoprotein VI (GPVI) binds collagen to activate platelets, and is a promising target for a thrombosis therapeutic, as inhibition of GPVI impairs stable platelet aggregation without a bleeding phenotype. Regado Biosciences has developed a GPVI aptamer-antidote pair that can inhibit collagen-induced platelet aggregation and activation. While this aptamer is still in preclinical trials, it is expected to enter safety trials in 2013. In addition, a 2’F pyrimidine RNA aptamer was isolated against GPVI by the Sullenger lab (unpublished data). While this aptamer exhibited high affinity binding towards the receptor, the aptamer exhibited agonistic effects by rapidly activating platelets and stimulating aggregation (unpublished data). It is thought that at high concentrations, the aptamer multimerizes and thus mimics other GPVI agonists to activate platelets.
2. Characterization of an anticoagulant aptamer against FXII

Chapter 2 was modified from a manuscript entitled “Inhibiting the intrinsic pathway of coagulation with a FXII-targeting RNA Aptamer” published in the Journal of Thrombosis and Haemostasis in May 2013 (epub ahead of print). The authors were Rebecca Woodruff, Yiming Xu, Juliana Layzer, Weizhen Wu, Martin Ogletree, and Bruce Sullenger.

2.1 Introduction

The hemostatic system maintains the integrity of the vasculature by sequentially activating a series of proteases, culminating in thrombin production and fibrin clot formation. Activation of coagulation can occur by either exposure of TF on the vessel wall at the site of injury (extrinsic pathway) or by activation of blood-borne components (factor XII) in the vasculature (intrinsic, or contact activation, pathway) (10). While the extrinsic pathway is thought to initiate thrombin formation at the site of injury, the intrinsic pathway is thought to mediate continued thrombin generation to stabilize a thrombus (39). Deficiency of FXII in animals is associated with protection from occlusive thrombus formation after arterial injury and stroke models (40, 41, 96). While thrombi can still form in these models, they are unstable and fail to occlude the vessel. Importantly, while offering a protective thrombotic effect, deficiency of FXII did not interrupt normal hemostatic events (40). Thus, pharmacologic inhibition of FXII is an attractive alternative in providing protection from pathologic thrombus formation while minimizing hemorrhagic risk.
Human FXII is an 80kDa glycoprotein consisting of an enzymatic light chain and a heavy chain comprised of several conserved domains that mediate binding to anionic surfaces and other proteins (15, 20). Binding of the FXII heavy chain to an anionic surface induces a conformational change and results in a small amount of activated FXII (FXIIa) formed (21). While a number of negatively charged substances have been shown to autoactivate FXII, several compounds thought to be involved in or associated with thrombosis or inflammation, such as polyphosphates (45), nucleic acids (27, 89), activated platelets (43), protein aggregates (44), collagen (25), and mast cell heparin (28) have been identified as potential autoactivators of FXII in vivo. Once activated, FXIIa can then activate FXI and the intrinsic pathway of coagulation to generate thrombin, leading to fibrin clot formation and stabilization and platelet and cellular activation via protease activated receptors. Additionally, FXIIa can activate plasma kallikrein (PK) to cleave the inflammatory mediator bradykinin (BK) from high-molecular weight kininogen (HK) to facilitate inflammatory responses (193).

Aptamers are single stranded, highly structured oligonucleotides that act as protein antagonists by binding to large surface areas on their target protein to directly inhibit protein-protein interactions. A number of aptamers have been developed as specific and high affinity inhibitors of coagulation proteins (FIX, FVII, VWF, FX, FII) that function as potent anticoagulants by interrupting specific complex macromolecular interactions on their target protease (164, 181-183, 191). The aptamer platform offers a
level of control, as each aptamer can be specifically and effectively reversed by either a 
sequence specific antidote that recognizes and binds to the primary sequence of the 
aptamer to disrupt aptamer-protein binding (160) or a universal antidote that can 
reverse the action of any aptamer independent of its sequence (165). While aptamer 
technology has been successfully applied to downstream coagulation factors, an 
aptamer inhibitor of the upstream contact pathway has not yet been reported. Herein, 
we describe the isolation and characterization of a modified RNA aptamer targeting 
FXII/FXIIa. This aptamer functions as a potent anticoagulant in a number of clinical 
coagulation assays, and mediates its anticoagulant effects by inhibiting not only the 
autoactivation of FXII, but also FXI-mediated intrinsic pathway activation. However, 
this aptamer does not affect FXIIa-mediated PK activation, demonstrating that aptamers 
can selectively interfere with specific protein-protein interactions without inhibiting the 
active site of enzymes.

2.2 Materials and Methods

Materials:

The SELEX DNA template sequence was 5’-

TCTCGGATCCTCAGCGAGTCGTCTG-N40-CCGCATCGTCTCCCTA-3’ and was 
purchased from Oligos, etc. (Wilsonville, OR). The 5’ and 3’ SELEX primer sequence are 
5’-GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG and 5’-

TCTCGGATCCTCAGCGAGTCGTC-3’, respectively, and were purchased from
Integrated DNA Technologies (IDT, Coralville, IA). The 2′Flouro modified cytidine and uridine were purchased from Trilink BioTechnology (San Diego, CA).

Kallikrein, prekallikrein, α-FXIIa, and β-fXIIa, were purchased from Enzyme Research Laboratories (South Bend, IN), and FXII, Corn Trypsin Inhibitor (CTI), and all other coagulation proteins were purchased from Haematologic Technologies (Essex Junction, VT). Human normal pooled plasma was purchased from George King Biomedical, Inc. (Overland Park, Kansas). Bovine serum albumin (BSA) was purchased from EMD Chemicals (Gibbstown, NJ), PEG-8000 was purchased from Fluka Biochemika (Buchs, Switzerland), dextran sulfate was purchased from Pharmacia Biotech (Piscataway, NJ), and kaolin was purchased from Sigma-Aldrich (St. Louis, MO). AMV-RT enzyme was purchased from Roche Applied Science (Indianapolis, IN). Pacific Hemostasis APTT-XL Reagent (Ellagic Acid) was purchased from Thermo Scientific (Waltham, MA), and TriniCLOT aPTT S (micronized silica) was purchased from Trinity BioTech (Bray, Co Wicklow, Ireland). All kinetic assays were performed in 96-well flat bottom microtiter plates (Corning Incorporated, Corning, NY), the absorbance was read at 405nm on a Power Wave XS2 kinetic microplate spectrophotometer (Biotek, Winooski, VT), and the data were analyzed using the Graphpad Prism Software (GraphPad Prism, GraphPad Software, Inc., San Diego, CA).
Convergent SELEX:

Convergent aptamer selection was performed as described previously (191). The sequence of the starting RNA library was 5'-GGGAGGACGAUGCGG-N40-CAGACGACUCGUGAGGAUCC-3', where N40 is a 40 nucleotide randomized region, and D and U represent 2'F modified ribonucleotides, respectively. Complex selection rounds were performed by incubating the modified starting library with diluted normal human plasma in a low salt, Hepes-based binding buffer (20mM Hepes, 50mM NaCl, 2mM CaCl$_2$, and 0.01%BSA). To inhibit non-specific binding of the RNA library to the plasma proteome, yeast tRNA was incorporated into the binding mixture. Bound RNA was separated from unbound RNA by passing the mixture through a 25-mm 0.45µm nitrocellulose filter membrane (Protran BA 85, Whatman, Inc., Piscataway, NJ). The bound RNA was extracted and RT-PCRed to amplify the bound RNA species as previously described (152). After five rounds of selection against unfractionated normal human pooled plasma (George King Biomedical, Inc., Overland Park, KA), four rounds of selection were performed against purified FXII in Hepes-based buffer (20mM Hepes, 150mM NaCl, 2mM CaCl$_2$, and 0.01%BSA). Binding of each round to FXII was monitored by a nitrocellulose filter-binding assay. The final round was cloned and sequenced as previously described to distinguish individual aptamer sequences (152).
RNA Aptamers

For all aptamer sequences, “C” and “U” represent 2’fluorocytosine and 2’fluorouracil.

The 80-nucleotide full length R4cXII-1 sequence is 5’-

GGGAGGACGAUGCGCCAAAUCUCGGCGCCAGCAGGUCACGAGUCGCAAGAUAAC
AGACGACUCGCUGAGGAUCCGAGA-3’. The 51 nucleotide truncated R4cXII-1t sequence is
5’- GGCUCGGCUGCCAGCAGGUGACGUGCGACGUCGCAGUCCGUGAGGAUCCGAG-3’.

The 51-nucleotide scrambled control RNA sequence is
5’GGGGCAGCCGUGGACCGACUGCCGCAUGCCAUUGACAGUCCGAUGCCAGGC-3’.

The sequence for the point mutant control R4cXII-1T22M is
GGCUCGGCUGAAGCAGGUGACGAGUCGACGUGCGACGUGAGGAUCCGAG. All
aptamers were transcribed in vitro as previously described using a modified polymerase (152,
194). Before use, all aptamer preparations were diluted into a Hepes-based buffer with or
without BSA (20mM Hepes, 150mM NaCl, 2mM CaCl₂, and with or without 0.01%BSA) as
indicated. Diluted aptamers were refolded by heating to 65°C for 5 minutes, and then cooled
for 3 minutes at ambient room temperature.

Nitrocellulose filter binding assay:

A double-filter nitrocellulose binding assay was employed to determine the
apparent binding affinity constants (Kₐ values) of aptamer to protein (152). The 5’ end of
the RNA was dephosphorylated using bacterial alkaline phosphatase (Gibco BRL,
Gaithersburg, MD), and subsequently end-labeled with \([\gamma^{32}P]\) ATP (Perkin Elmer, Waltham, MA) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). Varying concentrations of purified protein were incubated with \([\gamma^{32}P]\) RNA in Hepes binding buffer with BSA (20mM Hepes, 150mM NaCl, 2mM CaCl\(_2\), and .01%BSA) at 37°C for 5 minutes. The RNA-protein complexes were then separated from the unbound RNA by passing the mixture through a nitrocellulose filter (Protran BA 85, Whatman Inc., Florham Park, NJ). The levels of bound RNA were quantified using a Storm 825 phosphoimager (GE Healthcare, Piscataway, NJ). Non-specific binding of the radiolabeled RNA to the nitrocellulose filter was subtracted, and the data were fitted using nonlinear regression to determine the apparent binding affinity for the RNA aptamer-protein interaction (GraphPad Prism, GraphPad Software, Inc., San Diego, CA).

Clotting Assays

Activated partial thromboplastin time (aPTT) and prothrombin time (PT) assays were carried out using a model ST4 coagulometer (Diagnostica Stago, Parsippany, NJ). Aptamer was diluted in Hepes buffer without BSA (20mM Hepes, 150mM NaCl, 2mM CaCl\(_2\)), refolded by heating for 5 minutes at 65°C and then cooled to ambient temperature for 3 minutes. For the aPTT, aptamer (5µL) was then added to 50µL normal human pooled plasma (George King Biomedical, Inc., Overland Park, KA) and incubated for 5 minutes at 37°C. 50µL APTT-XL reagent was then added to activate
plasma and incubated for 5 minutes at 37°C. Clotting was initiated by adding 50µL of 25mM CaCl₂ and the time to clot formation was recorded. Aptamer concentrations represent the final concentration in the entire reaction.

For the PT, refolded aptamer (5µL) was added to 50µL plasma and incubated for 5 minutes at 37°C. TriniClot PT Excel (Trinity BioTech, Bray, Co Wicklow, Ireland) was added to initiate clotting.

For FXIIa and FXIa clotting times, refolded aptamer (5µL) was added to 45µL of either 40nM FXIa or 250nM FXIIa and incubated for 5 minutes at 37°C. Aptamer and protein were added to either FXII or FXI-deficient human plasma (Haematologic Technologies, Essex Junction, VT) supplemented with 3µM phospholipid (15% phosphatidylserine, 41% phosphatidylcholine, 44% phosphatidylethanolamine (Avanti Polar Lipids (Alabaster, AL)) and incubated for 30 seconds at 37°C. Clotting was initiated by adding 50µL of 25mM CaCl₂ and the time to clot formation was recorded. Aptamer concentrations represent the final concentration in the entire reaction.

*Thrombin Generation Assay*

In an Immulon 2HB clear U-bottom 96 well plate (Thermo Labsystems, Franklin, MA), CTI- treated (50µg/mL), pooled normal human platelet poor plasma from healthy, consented volunteers (60µL) was mixed with aptamers (3µL) diluted in Hepes-based buffer without BSA and incubated for 5 min at 37°C. Ellagic acid reagent (final
concentration 0.1µM, diluted 1:200 with 4µM phospholipid vesicles (20% phosphatidylserine, 60% phosphatidylcholine, 20% phosphatidylethanolamine) in Hepes-based buffered saline (15µL) was added to the plasma-aptamer mixture, and incubated for 5 minutes at 37°C. Flu-Ca (Diagnostica Stago) (15µL) was added to start the assay and thrombin generation was measured using a Fluroskan Ascent Reader (Thermo Scientific, Waltham, MA). A thrombin calibrator reagent (Diagnostica Stago, Parsippany, NJ) was used to quantify the amount of thrombin generated in the samples. Data analysis was performed using Thrombinoscope software (Thrombinoscope BV, the Netherlands). Aptamer concentrations represent the final concentration in the entire reaction. The amount of ellagic acid used was standardized to produce a similar curve to a TF-activated TGA. In addition, the amount of CTI present was standardized to inhibit contact activation of the plasma sample, while still allowing for robust FXII-dependent activation upon administration of ellagic acid.

**FXIIa small peptide substrate cleavage**

FXIIa (final concentration 10nM) was incubated with varying concentrations of either aptamer or CTI for 10min at 37°C in a Hepes-based reaction buffer (20mM Hepes pH 7.4, 150mM NaCl, 2mM CaCl₂, .01% BSA). The chromogenic substrate Spectrozyme FXIIa (American Diagnostica Inc. – now Sekisui Diagnostics, Stamford, CT) was added to a total volume of 100µL. Substrate cleavage was monitored at an absorbance of
405nm using a kinetic microplate spectrophotometer at 37°C, and rates of substrate cleavage were determined using linear regression analysis.

FXII autoactivation assays

FXII (final concentration 0.2μM) was incubated with varying concentrations of aptamer, dextran sulfate, or buffer for 1 hour at 37°C in a Hepes-based buffer with BSA and with or without 0.1% PEG. To determine if the aptamer could block autoactivation of FXII, 1μM aptamer or buffer was pre-incubated with FXII for 5 minutes prior to the addition of an autoactivator, and the mixture was incubated for 1 hour at 37°C. The final concentrations of the autoactivators were: dextran sulfate (1μg/mL), kaolin (100μg/mL), micronized silica (30x-diluted), and ellagic acid (30x-diluted). In both experiments, the FXIIa chromogenic substrate Spectrozyme FXIIa (American Diagnostica Inc. – now Sekisui Diagnostics, Stamford, CT) was added to a total volume of 100μL (final concentration 0.2mM). Substrate cleavage was monitored at an absorbance of 405nm using a kinetic microplate spectrophotometer at 37°C, and rates of substrate cleavage were determined using linear regression analysis.

FXIIa-mediated FXI activation:

Conversion of zymogen FXI to activated FXIa by FXIIa was measured in a two stage chromogenic assay performed at 37°C in a Hepes-based buffer with BSA. Aptamer
or buffer was incubated with FXIIa (final concentration 5nM) for 5 minutes at 37°C, and reactions were initiated with the addition of FXI (final concentration 25nM). At timed intervals after the initiation of the reaction, samples of the reaction mixture were removed, FXIIa activity was quenched by addition of 1μM CTI, and FXIa activity was assayed by the addition of 1mM Pefachrome FXIa (Centerchem, Inc., Norwalk, CT). The rate of substrate hydrolysis was recorded at 405nM using a kinetic microplate spectrophotometer at 37°C. FXIa cleavage rates of substrate were then used to determine the amount of FXIa formed by extrapolating from a standard curve prepared using purified FXIa.

To determine the inhibition constant (Kᵢ), FXI activation reactions were performed as described above in the presence of varying concentrations of aptamer. The initial rate of FXI activation by FXIIa was determined by linear regression of the amount of FXIa formed versus time for the first 10 minutes of the reaction. Fractional activity (V₁/V) was calculated by dividing the initial rate of FXI activation in the presence of aptamer by the initial rate of FXI activation in the absence of aptamer. The Kᵢ was determined using nonlinear regression analysis.

FXIIa-mediated Prekallikrein activation

Conversion of prekallikrein to kallikrein by FXIIa was measured in a two stage chromogenic assay performed at 37°C in a Hepes-based buffer with BSA and 0.1% PEG.
Aptamer or buffer was incubated with FXIIa (final concentration 4nM) for 5 minutes at 37°C and reactions were initiated with the addition of prekallikrein (final concentration 20nM). At timed intervals after the initiation of the reaction, samples of the reaction mixture were removed and FXIIa activity was quenched by addition of 1µM CTI. Kallikrein activity was assayed by the addition of 0.25mM Pefachrome PK (Centerchem, Inc., Norwalk, CT), and the rate of substrate hydrolysis was recorded at 405nM using a kinetic microplate spectrophotometer at 37°C. Kallikrein cleavage rates of substrate were then used to determine the amount of kallikrein formed by extrapolating from a standard curve prepared using purified kallikrein.

2.3 Results

2.3.1 SELEX Pool Analysis and Lead Clone Selection

High affinity aptamers targeting human FXII were isolated from a convergent selection approach, whereby a nucleic-acid-based combinatorial library containing approximately 10¹⁴ RNA species was first enriched for binding against the entire human plasma proteome, and then further enriched for binding against purified FXII. To confer greater stability in human plasma, the library contained 2'F pyrimidines (159). Five rounds of complex selection were performed against unfractionated human plasma to obtain a focused library containing aptamers that theoretically bind to all plasma components. Using this focused library, four rounds of selection to purified FXII
yielded further enrichment for a pool of aptamers targeting FXII as determined by a nitrocellulose filter-binding assay (Figure 8).

![Graph showing binding affinity of SELEX rounds against purified FXII](image)

**Figure 8. Binding affinity of SELEX rounds against purified FXII**
Nitrocellulose filter binding assay of the plasma proteome enriched starting library (black circles), round 2 of selection against purified FXII (black squares), and round 4 of selection against purified FXII (red diamonds). Data courtesy of Juliana Layzer.

The selection process was ended by cloning and sequencing the individual RNA sequences present in the round 4 pool, and these sequences were then organized into families based upon their primary sequences (Table 4).
Table 4. RNA aptamer sequences from FXII convergent SELEX

<table>
<thead>
<tr>
<th>Clone ID</th>
<th>Variable Region Sequence</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>R4cXII-12</td>
<td>ACTCCGCCATGGACCATGCATCTTCACAGCTAAACCACCGCA</td>
<td>26.1%</td>
</tr>
<tr>
<td>R4cXII-15</td>
<td>TCAAAAATCAACGAGTCACAT-CTAGCATGGACGTT</td>
<td>17.4%</td>
</tr>
<tr>
<td>R4cXII-1</td>
<td>CAAATCTCAGGTGCCAGGTCAGGTCGAGTTAACGATGAA</td>
<td>13.0%</td>
</tr>
<tr>
<td>R4cXII-7</td>
<td>CCCTCTGACACACTCTCGCTGCCAGGACACGAGTTAC</td>
<td>13.0%</td>
</tr>
<tr>
<td>R4cXII-8</td>
<td>CATGACCTCTCTTCTCAGGTGCCAGGAGATCGAGT</td>
<td>8.7%</td>
</tr>
<tr>
<td>R4cXII-16</td>
<td>TTCGATCTCCCTCCGCTTACCAACAGAGTTTCCGAGTCTT</td>
<td>8.7%</td>
</tr>
<tr>
<td>R4cXII-11</td>
<td>TCGCTGACGAATAGAGGTTCATCCAGGGTGATCATCTTAG</td>
<td>4.3%</td>
</tr>
<tr>
<td>R4cXII-21</td>
<td>ACNCCGACAGAGATTACNNTATTAGTCACCACNAGAGTGNGA</td>
<td>4.3%</td>
</tr>
</tbody>
</table>

In order to determine the binding affinity of each family of isolated clones, a nitrocellulose filter-binding assay was performed with a representative clone from each family. A number of aptamers bound to FXII with affinities (measured by their dissociation constants, or $K_d$'s) in the low nanomolar range. Binding to $\alpha$FXIIa was also tested, and each clone bound with approximately 10-fold increased affinity to the activated form (Table 5). The $B_{max}$, or the percentage of RNA present that is folded correctly in order to bind to the target protein, was also determined for each individual aptamer.
Table 5. RNA aptamer binding to soluble FXII and FXIIa as determined by a nitrocellulose filter-binding assay

<table>
<thead>
<tr>
<th>Aptamer</th>
<th>FXII</th>
<th></th>
<th>FXIIa</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kd approx (nM)</td>
<td>Bmax approx (%)</td>
<td>Kd approx (nM)</td>
<td>Bmax approx (%)</td>
</tr>
<tr>
<td>R4cXII-1</td>
<td>8.9</td>
<td>75</td>
<td>0.31</td>
<td>58</td>
</tr>
<tr>
<td>R4cXII-7</td>
<td>2.8</td>
<td>53</td>
<td>0.22</td>
<td>28</td>
</tr>
<tr>
<td>R4cXII-8</td>
<td>17.9</td>
<td>47</td>
<td>0.52</td>
<td>20</td>
</tr>
<tr>
<td>R4cXII-11</td>
<td>20</td>
<td>58</td>
<td>0.24</td>
<td>24</td>
</tr>
<tr>
<td>R4cXII-12</td>
<td>9.3</td>
<td>47</td>
<td>0.13</td>
<td>46</td>
</tr>
<tr>
<td>R4cXII-15</td>
<td>463</td>
<td>46</td>
<td>0.08</td>
<td>4</td>
</tr>
<tr>
<td>R4cXII-16</td>
<td>29</td>
<td>44</td>
<td>0.25</td>
<td>21</td>
</tr>
<tr>
<td>R4cXII-21</td>
<td>5.9</td>
<td>45</td>
<td>0.05</td>
<td>8</td>
</tr>
</tbody>
</table>

Although several clones bound with high affinity to FXII and FXIIa, the nitrocellulose filter-binding assay does not examine the functionality of these aptamers as anticoagulants. Therefore, we next tested each aptamer for anticoagulant activity in a common clinical coagulation test, the activated partial thromboplastin time (aPTT). This assay measures the time it takes for a fibrin clot to occur in plasma, and is sensitive to deficiencies or inhibition of the intrinsic and common pathways of coagulation. This assay uses a negatively charged substance, such as kaolin or ellagic acid, to activate FXII and prime the cascade, and, upon addition of Ca^{2+} to initiate clotting, records the time for a fibrin clot to form. Because initial tests using normal human plasma and a micronized silica activator did not show any affect of the FXII aptamers over control RNA at the concentration used on altering the clotting time, the assay was performed in 99% FXII deficient plasma and 1% normal plasma, affectively lowering the amount of
FXII present and allowing for a lower concentration of aptamer to show an effect (Figure 9).

![Figure 9. Screen of FXII aptamers in a functional clotting assay, the aPTT](image)

Selected aptamers (0.5µM) were screened for prolongation of clotting time in 1% Normal/99% FXII deficient human plasma. Aptamer clotting times were compared against a buffer control (WBF), library RNA (Sel2), 100% FXII deficient plasma (XII/-/- + WBF) and 100% normal human plasma (Normal + WBF). The dotted line represents the clotting time of library RNA and serves as a baseline clotting time to compare to aptamer clotting time.

The clone R4cXII-1 was chosen as the lead aptamer due to its greater effect in the aPTT assay, as well as its superior binding profile compared to all other aptamers. While R4cXII-1 did not necessarily have the lowest $K_d$, it did have the highest $B_{\text{max}}$, meaning a larger proportion of the RNA is in a folded state that is able to bind to FXII or
FXIIa compared to the other aptamers. This is reflected in the functional clotting assay, where R4cXII-1 outperformed all other aptamers.

2.3.2 Lead aptamer binding affinity and specificity

The full length, 80 nucleotide, 2′F pyrimidine modified RNA R4cXII-1 was chosen as the lead aptamer out of the convergent selection against FXII (Figure 10).

![M-fold predicted secondary structure of the full-length aptamer R4cXII-1](image)

Figure 10. The M-fold predicted secondary structure of the full-length aptamer R4cXII-1
In depth binding of R4cXII-1 was analyzed by a nitrocellulose filter-binding assay and the aptamer was found to bind to both the zymogen and active form of FXII. R4cXII-1 bound to FXII with a $K_d$ of $8.9 \pm 1.0\text{nM}$ and a $B_{\text{max}}$ of $74.8 \pm 4.7\%$ and to $\alphaFXIIa$ with a $K_d$ of $0.5 \pm 0.2\text{nM}$ and a $B_{\text{max}}$ of $58 \pm 3.2\%$ to $\alphaFXIIa$ (Figure 11).

![Graph showing corrected fraction bound of R4cXII-1 as a function of protein concentration.](image)

**Figure 11.** Aptamer R4cXII-1 binds with high affinity to FXII and FXIIa

Nitrocellulose filter binding assays of aptamer to A) FXII (■) and FXIIa (▲) and B) indicated proteins. C) Linear sequence and dissociation constants of full length R4cXII-1 and truncated R4cXII-1 (R4cXII-1t). In A, the data represent the mean ± SEM of triplicate measures and in B, the data are representative of at least two independent experiments.

This high affinity binding of R4cXII-1 to FXII and FXIIa was also found to be specific, as R4cXII-1 binding to a number of other structurally and functionally related coagulation factors, including thrombin, FXIa, FIXa, FXa, FVIIa, urokinase plasminogen activator, and tissue plasminogen activator, was shown to be non-existent or very weak,
with dissociation constants greater than 1000nM and no different from a random RNA library (data not shown). In addition, R4cXII-1 exhibited greatly reduced binding to β-fXIIa (dissociation constant $K_d$ of 51.4 ± 9.0nM and a $B_{\text{max}}$ of 34.7 ± 2.3%), a cleaved form of FXIIa which is missing part of the heavy chain (Figure 12).

![Figure 12. Aptamer R4cXII-1 binds with reduced affinity to β-fXIIa](image)

Nitrocellulose filter binding assay of aptamer to β-fXIIa. The data represent the mean ± SEM of triplicate measures.

### 2.3.3 Biochemical Characterization of aptamer inhibition

*Assessment of aptamer activity on FXII active site function*

A number of purified protein assays were performed to characterize the mechanism of aptamer binding and inhibition. First, we studied the impact of aptamer binding on active site function of αFXIIa by monitoring the cleavage of a small peptide
chromogenic substrate in the presence of a range of concentrations of aptamer, size matched scrambled control RNA, and a known FXIIa active site inhibitor, corn trypsin inhibitor (CTI). While CTI potently and dose dependently inhibited the ability of FXIIa to cleave the small peptide chromogenic substrate, both the control RNA and R4cXII-1 did not affect small-substrate cleavage (Figure 13). These data indicate that the anticoagulant effect of the aptamer is not due to the inhibition of the active site on FXIIa. Because aptamers tend to impede protein-protein interactions without affecting the active site (157), the ability of the aptamer to inhibit FXII/XIIa-mediated macromolecular interactions was next evaluated.

Figure 13. Aptamer R4cXII-1 does not inhibit FXIIa cleavage of a small peptide substrate

αFXIIa (10nM) was incubated with varying amounts of R4cXII-1 (■), size matched scrambled control RNA (▲), and CTI (▼), and active site activity was measured by an αFXIIa-specific chromogenic substrate. The data were normalized to the rate in the absence of compound and represent the mean ± SEM of duplicate measures.
Assessment of aptamer activity on FXII autoactivation

Since a range of anionic compounds, including unmodified nucleic acids (27, 89), have been found to autoactivate FXII, aptamer and size matched scrambled control RNA were tested to determine if relatively short 2′F pyrimidine modified RNAs could also autoactivate FXII. While a known FXII autoactivator, dextran sulfate, was able to convert FXII to FXIIa with the characteristic bell-shaped concentration curve of a template-related mechanism (195), neither the control RNA nor R4cXII-1 could autoactivate FXII over a wide range of concentrations (Figure 14A).

Next, the ability of R4cXII-1 to block the autoactivation of FXII by various known activators was tested. Dextran sulfate, as well as purified kaolin, and standardized aPTT reagents including micronized silica (TriniClot S) and ellagic acid (APTT-XL) were all tested and found to activate FXII at widely different rates (data not shown). The final concentration of each activator that yielded an optimal rate of autoactivation of FXII was used for further studies. R4cXII-1 (1μM) was able to greatly inhibit the ability of dextran sulfate (1μg/mL) and micronized silica (30x) to autoactivate FXII, and partially inhibit the ability of kaolin (100μg/mL) and ellagic acid (30x-diluted) to autoactivate FXII (Figure 14B). In contrast, a size matched scrambled control RNA was not able to inhibit autoactivation by any activator. Autoactivation assays conducted with physiologic activators, such as polyphosphates, were hampered by the necessity for the aptamer
buffer to contain divalent ions, which assist in proper aptamer folding but inhibit the ability of these physiologic activators to measurably autoactivate FXII with a cofactor present (data not shown).

Figure 14. Aptamer R4cXII-1 does not induce autoactivation of FXII but blocks the activities of several autoactivators of FXII

A) FXII (200nM) was incubated for 1 hour with varying amounts of dextran sulfate (■), R4cXII-1 (▲), or size matched scrambled control RNA (▼), and assayed for the amount of FXIIa formed by an FXIIa-specific chromogenic substrate. The data represent the mean ± SEM of triplicate measures. B) FXII (200nM) was incubated for 5 min with R4cXII-1 (black bars) or size matched scrambled control RNA (grey bars) prior to the addition of autoactivators, and the amount of FXIIa formed after 1 hour was assayed. The data were normalized to the rate in the absence of any RNA and represent the mean ± SEM of triplicate measures.

Assessment of aptamer activity on FXIIa-mediated activation of biologic substrates

Once activated, FXIIa can subsequently activate FXI to propagate the intrinsic pathway of coagulation. The ability of R4cXII-1 to inhibit FXIIa-mediated FXI activation was assessed by monitoring the amount of FXIa formed in a purified system containing FXIIa as an activator in the absence of aptamer, or in the presence of R4cXII-1 or control
RNA. R4cXII-1 reduced the initial rate of FXI activation by greater than ~90%, while the presence of size matched scrambled control RNA did not (Figure 15A). To determine the potency of inhibition, the initial rate of FXI activation by FXIIa was measured in the presence of varying concentrations of R4cXII-1. As shown in Figure 15B, R4cXII-1 concentration-dependently decreased the amount of FXIa formed. An apparent equilibrium inhibition constant ($K_i$) of $3.0\text{nM} \pm 0.3\text{nM}$ was obtained by plotting the fractional rates of FXI activation versus the concentration of R4cXII-1 used (Figure 15C).
Figure 15. Aptamer R4cXII-1 dose dependently inhibits FXIIa-catalyzed activation of FXI

FXI (25nM) was activated by FXIIa (5nM), the reaction was quenched at various time-points by the addition of 1 µM CTI, and the amount of FXIa was quantified using a chromogenic substrate. A) The amount of FXIa formed at various time points was determined in the presence of 1µM R4cXII-1 (■), 1µM size matched scrambled control aptamer (▲), or buffer (▲). Lines represent linear regression fits of the data. The data represent the mean ± SEM of triplicate measures. B) Dose dependent response on FXIa generation with increasing concentrations of R4cXII-1. The amount of FXIa formed was determined in the presence of R4cXII-1 at final concentrations of 0nM (■), 1nM (■), 3nM (●), 6nM (●), 10nM (▲), 20nM (□), and 50nM (○). Lines represent linear regression fits of the data. The data are representative of three independent measures. C) Fractional activity of R4cXII-1 versus the ratio of R4cXII-1 to FXII present in the reaction. Fractional activity of R4cXII-1 was calculated by dividing the initial rate of FXI activation in the presence of R4cXII-1 by the initial rate of FXI activation in the absence of aptamer. The Ki was calculated by nonlinear regression analysis. The data represent the mean ± SEM of triplicate measures.
Aside from activating the intrinsic pathway through FXI activation, FXIIa can also activate plasma kallikrein (PK), which in turn reciprocally activates more FXII in a feedback loop that amplifies the activation of the contact pathway (23). PK is involved in the initiation of the kallikrein-kinin system by cleaving the small peptide bradykinin (BK) from high molecular weight kininogen (HK), leading to activation of various inflammatory processes, including vasodilation and vascular permeability (115). The ability of R4cXII-1 to inhibit prekallikrein activation by FXIIa was examined by monitoring the amount of kallikrein formed in a purified system using FXIIa as an activator. In contrast to the ability of R4cXII-1 to inhibit the generation of activated FXI (Figure 15), the aptamer did not affect prekallikrein activation by FXIIa compared to buffer or size matched scrambled control RNA (Figure 16). This indicates that R4cXII-1 does not bind to FXIIa in a manner that inhibits FXIIa-PK interactions, while it does inhibit FXIIa-FXI interactions. Collectively, these data suggest that R4cXII-1 is a potent inhibitor of both the autoactivation of FXII and FXIIa-mediated activation of FXI, while having no effect on prekallikrein activation.
Figure 16. Aptamer R4cXII-1 does not inhibit the ability of FXII to activate prekallikrein
Prekallikrein (20nM) was activated by FXIIa (4nM), the reaction was quenched at various time points by the addition of 1μM CTI, and the amount of kallikrein was quantified using a chromogenic substrate. The amount of kallikrein formed was determined in the presence of 1μM R4cXII-1 (▼), 1μM size matched scrambled control aptamer (▲), or buffer (■). Lines represent linear regression fits of the data. The data represent the mean ± SEM of triplicate measures.

2.3.4 Truncation of aptamer
In order to facilitate optimal transcription yields and reduce background noise due to RNA length, R4cXII-1 was truncated by systematic nucleotide deletion. Three to five constructs were tested at a time, with deletions beginning on each end of the aptamer, and then internally to shorten stems and loops as much as possible without losing binding affinity or functionality. Table 6 depicts the truncation strategy, where each possible truncate was tested for binding affinity and functionality.
Table 6. Truncation strategy for R4cXII-1

$K_d$’s and $B_{max}$’s were determined using a nitrocellulose filter-binding assay. FXIa generation inhibition was determined using a chromogenic assay.

<table>
<thead>
<tr>
<th>Aptamer Name</th>
<th>Length (nt)</th>
<th>$K_d$ approx. (nM)</th>
<th>$B_{max}$ approx (%)</th>
<th>Inhibits FXIa Generation</th>
</tr>
</thead>
<tbody>
<tr>
<td>R4cXII-1</td>
<td>80</td>
<td>4.0</td>
<td>85</td>
<td>Yes</td>
</tr>
<tr>
<td>T1</td>
<td>67</td>
<td>8.9</td>
<td>86</td>
<td>Yes</td>
</tr>
<tr>
<td>T2</td>
<td>58</td>
<td>109.5</td>
<td>106</td>
<td>Yes</td>
</tr>
<tr>
<td>T4</td>
<td>60</td>
<td>5.5</td>
<td>55</td>
<td>Yes</td>
</tr>
<tr>
<td>T6</td>
<td>63</td>
<td>9.9</td>
<td>57</td>
<td>Yes</td>
</tr>
<tr>
<td>T7</td>
<td>65</td>
<td>120</td>
<td>84</td>
<td>No</td>
</tr>
<tr>
<td>T8</td>
<td>60</td>
<td>308</td>
<td>67</td>
<td>No</td>
</tr>
<tr>
<td>T9</td>
<td>50</td>
<td>203</td>
<td>70</td>
<td>No</td>
</tr>
<tr>
<td>T10</td>
<td>59</td>
<td>38.5</td>
<td>88</td>
<td>Yes</td>
</tr>
<tr>
<td>T11</td>
<td>59</td>
<td>60.2</td>
<td>98</td>
<td>Yes</td>
</tr>
<tr>
<td>T12</td>
<td>57</td>
<td>4.2</td>
<td>74</td>
<td>Yes</td>
</tr>
<tr>
<td>T13</td>
<td>56</td>
<td>28.2</td>
<td>80</td>
<td>Yes</td>
</tr>
<tr>
<td>T14</td>
<td>52</td>
<td>5.8</td>
<td>73</td>
<td>Yes</td>
</tr>
<tr>
<td>T15</td>
<td>55</td>
<td>277</td>
<td>113</td>
<td>No</td>
</tr>
<tr>
<td>T16</td>
<td>55</td>
<td>289</td>
<td>106</td>
<td>No</td>
</tr>
<tr>
<td>T17</td>
<td>55</td>
<td>350</td>
<td>123</td>
<td>No</td>
</tr>
<tr>
<td>T18</td>
<td>51</td>
<td>50</td>
<td>65</td>
<td>Yes</td>
</tr>
<tr>
<td>T19</td>
<td>54</td>
<td>279</td>
<td>104</td>
<td>Yes</td>
</tr>
<tr>
<td>T20</td>
<td>50</td>
<td>20.5</td>
<td>72</td>
<td>Yes</td>
</tr>
<tr>
<td>T21</td>
<td>48</td>
<td>116</td>
<td>88</td>
<td>No</td>
</tr>
<tr>
<td>T22</td>
<td>51</td>
<td>13.2</td>
<td>80</td>
<td>Yes</td>
</tr>
<tr>
<td>T23</td>
<td>51</td>
<td>71</td>
<td>101</td>
<td>No</td>
</tr>
</tbody>
</table>

When a truncation lost binding (generally a $K_d$ of over 100nM) and/or functionality, those deleted portions/nucleotides were considered to be essential in either facilitating the proper folding and final structure of the aptamer or directly involved in binding to the target protein. The most optimal truncation that retained binding affinity to both FXII (apparent $K_d$ of 12.9 ± 2.06nM) and FXIIa (apparent $K_d$ of 0.4
± 0.02 nM), as well as the ability to block FXIIa-mediated FXIa generation, was the 51-nucleotide truncate 22 (R4cXII-1T22). The predicted secondary structure of the aptamer features an “L” shaped aptamer, with several bulge regions and two lengthy stems (Figure 17).

![M-fold predicted secondary structure of the truncated aptamer R4cXII-1T22](image)

**Figure 17.** The M-fold predicted secondary structure of the truncated aptamer R4cXII-1T22

For ongoing functional studies, a 51 nucleotide scrambled RNA that had no binding or functional activity against FXII was also employed as an aptamer control.
2.3.5 Functional Characterization of aptamer inhibition

Biochemical characterization of R4cXII-1 suggests that the aptamer acts as an anticoagulant by specifically inhibiting FXII activation and FXIIa-mediated FXI activation. However, the functionality of this aptamer as an anticoagulant in a plasma setting is not certain, as several redundant pathways, including a feedback loop whereby thrombin can directly activate FXI, can contribute to thrombin activation with minimal or no FXII involvement.

We next tested aptamer R4cXII-1 for anticoagulant activity in two common coagulation tests, the activated partial thromboplastin time (aPTT) and the thrombin generation assay (TGA). The aPTT assay uses a negatively charged substance, such as kaolin or ellagic acid, to strongly activate FXII and thus initiate clotting through the intrinsic pathway. Therefore, this test is highly sensitive to deficiencies or inhibition of the intrinsic pathway of coagulation. A 51-nucleotide truncated version of R4cXII-1 (R4cXII-1t) that retained binding affinity to both FXII (apparent Kd of 12.9 ± 2.06nM) and FXIIa (apparent Kd of 0.4 ± 0.02 nM) dose dependently anticoagulated human plasma in an aPTT activated with ellagic acid. This inhibition was specific to the intrinsic pathway, as the aptamer had no effect on PT, which measures the function of the extrinsic pathway of coagulation (Figure 18). A size matched scrambled control RNA that does not retain binding to FXII/FXIIa had minimal impact on clotting time (Figure 18). R4cXII-1t also dose-dependently increased clotting time when a micronized silica
based reagent was utilized, indicating that inhibition of the intrinsic pathway of coagulation occurs regardless of the FXII activator (data not shown).

**Figure 18.** Aptamer R4cXII-1t dose dependently anticoagulates human plasma in an aPTT, but not a PT clotting assay

Effect of the 51-nucleotide R4cXII-1t (■) and size matched scrambled mutant control (▲) in an aPTT clotting assay activated with ellagic acid, and R4cXII-1t (▼) in a PT clotting assay activated with tissue factor. The data were normalized to the baseline clot time without aptamer present and represent the mean ± SEM of duplicate measures.

In addition, this prolongation was specific to FXII/FXIIa inhibition, as the aptamer dose-dependently prolonged FXIIa clotting times, with no effect on the FXIa clotting time (Figure 19).
Figure 19. Aptamer R4cXII-1t dose dependently inhibits FXIIa clotting times, but not FXIa clotting times.

Effect of the 51-nucleotide R4cXII-1t in a clotting assay activated with 250nM FXIIa (■) or 40nM FXIa (▲). The data were normalized to the baseline clotting time of a size-matched control RNA and represent the mean ± SEM of duplicate measures.

The TGA is a coagulation assay that measures the amount of thrombin generated in human plasma in real-time by monitoring cleavage of a thrombin-specific fluorogenic substrate (196). Using a TGA allows for several more parameters to be analyzed in addition to the lag time (the time when thrombin begins to appear), including the peak (maximal amount of thrombin formed), the endogenous thrombin potential (ETP, the total amount of thrombin formed), and the rate of thrombin generation (the slope of the line from no thrombin generation to peak thrombin generation). While a standard TGA is initiated using various concentrations of TF to activate the extrinsic pathway, an assay using ellagic acid as an activator was developed with our colleagues at Merck Research.
Labs to study effects on thrombin generation during inhibition of the intrinsic pathway. Similar to its activity in an aPTT, R4cXII-1t dose-dependently increased the lag time, as well as decreased peak thrombin generation, ETP, and the rate of thrombin generation in a TGA initiated with ellagic acid (Figure 20). Overall thrombin generation was decreased to background levels, with a clear saturation point of aptamer inhibition (3.75µM), while the peak amount of thrombin generated and the rate of thrombin generation were robustly inhibited. In contrast, a size matched scrambled control RNA did not inhibit thrombin generation (Figure 20). These data suggest that R4cXII-1 acts as an anticoagulant by specifically inhibiting FXII function to effectively shut down intrinsic pathway activation and thus impair thrombin generation triggered by ellagic acid.
Figure 20. Aptamer R4cXII-1t dose dependently impairs thrombin generation in a TGA assay initiated with ellagic acid

Thrombograms of normal pooled plasma activated with 200x-diluted ellagic acid with various concentrations of A) R4cXII-1t and B) a size matched scrambled RNA. C) Lag time, D) Peak thrombin generation, E) Endogenous thrombin potential, and F) Rate of thrombin generation of R4cXII-1t (■) and a size matched scrambled RNA (▲). Data are representative of three independent experiments.

While the FXII aptamer was isolated solely against the human form of the coagulation factor, analysis for cross reactivity in animal plasma is a must before proceeding into in vivo models of thrombosis. In general, aptamers have exhibited some
efficacy in a variety of species; with the FIX aptamer cross-reacting in every species tested except for rabbit (data not shown). However, other aptamers exhibit limited cross-reactivity. R4cXII-1 was tested in a number of animal plasmas in an aPTT assay, as well as with different activating reagents. Activation with ellagic acid gave the most reproducible data, with less background control aptamer activity. Aside from human plasma, R4cXII-1t did not exhibit robust anticoagulation above control aptamer in any of the plasma’s tested at a fixed concentration (Figure 21). However, there was slight anticoagulant activity over control aptamer in canine, bovine, rat, rabbit, and baboon. Importantly, the plasma samples used here were not treated with CTI, thus contact activation of the plasma sample may already be present.
Figure 21. Analysis of R4cXII-1t cross-reactivity utilizing the aPTT across select animal species

Effect of buffer, R4cXII-1t, a point mutant, and a size matched scrambled mutant control in an aPTT clotting assay activated with ellagic acid. None of the plasmas were treated with CTI to inhibit contact activation during the blood drawing process. The data represent the mean ± SEM of duplicate measures.

2.4 Discussion

Herein, we describe the isolation and characterization of a novel FXII/FXIIa inhibitor (Figure 22). A nuclease resistant, 2’F pyrimidine modified RNA aptamer was isolated using in vitro iterative selection methods. This aptamer binds with high affinity to both FXII and FXIIa and is a potent anticoagulant in common clinical coagulation assays. Although the aptamer does not inhibit the active site of FXIIa, it functions as an anticoagulant by both inhibiting the autoactivation of FXII and inhibiting FXIIa-mediated activation of FXI. Additionally, the aptamer does not impede the ability of FXIIa to activate PK.
Figure 22. A schematic depicting the role of the FXII aptamer, R4cXII-1, in inhibiting FXII/FXIIa function

The aptamer R4cXII-1 inhibits FXII autoactivation by negatively charged surfaces as well as FXIIa-mediated FXI activation to effectively shut down thrombin generation in a plasma setting. However, the aptamer does not affect the ability of FXIIa to activate the inflammatory mediator prekallikrein. Predicted secondary structure of aptamer adapted from M-fold.

Taken together, the data indicate that the aptamer binds to a region on FXII/FXIIa implicated in anionic and FXI binding, which is spatially separate from where PK binds to FXII. Although a crystal structure of FXII is not available, domain mapping has suggested a closely located binding site for FXI and anionic surfaces in the N-terminus fibronectin type II domain (197-199). Studies on thrombin aptamers have determined that an aptamer binds by presenting an extended surface complementary to the protein.
binding site (157) and subsequently sterically interferes with macromolecular interactions formed between the aptamer binding region and large protein substrates. While aptamer binding can thus disrupt a specific exosite’s function, it can still allow other distant exosites and active sites to function (181). Interestingly, other putative binding sites on FXII for anionic molecules exist in separate domains (200). As distinct anionic compounds bind discretely to FXII and autoactivate FXII at different rates, this binding to different, and possibly partially overlapping, domains could explain why the aptamer was not able to inhibit the autoactivation of FXII by various autoactivators to the same degree. Continued studies into aptamer binding and function using FXII mutant proteins could help to further delineate the regions involved in macromolecular substrate interaction (197), especially the differential binding of anionic molecules to FXII.

The ability to inhibit the intrinsic pathway of coagulation while leaving the kallikrein-kinin system intact will be beneficial in parsing out the importance of FXIIa functions in vivo. While all members of the contact pathway (FXII, FXI, PK, HK, BK) have been implicated in thrombosis through studying various knockdown or knockout animal models, it is not entirely clear which FXIIa-mediated process, inflammation or coagulation, plays the primary part in contributing to thrombosis (40, 41, 72, 91, 94, 95, 201). Targeted inhibition or animal knockout models have suggested that FXIIa-mediated FXI activation is responsible for thrombotic protection in injury models due to
the similar thrombotic protection profiles of FXI and FXII deficient animals (40, 78, 201).

Currently, studies using FXIIa inhibitors to assess thrombosis have employed active site inhibitors, which thus inhibit all amidolytic functions of FXIIa, including PK activation (41, 202). Utilizing a specific inhibitor of the intrinsic pathway, while leaving the kallikrein-kinin system intact, would be valuable in parsing out the various functions of FXIIa in thrombosis.

The development of a TGA assay triggered by contact activation is instrumental for studying the functions of contact pathway and intrinsic cascade proteins in plasma thrombin generation. While autoactivation of FXII serves as the mechanism to initiate the aPTT, and is oftentimes the diagnostic test used to detect FXII deficiencies in the clinic during routine preoperative screening, the TGA is commonly triggered by the extrinsic pathway activator TF, and is thus not sensitive to deficiencies or inhibitors of FXII (203). Both the aPTT and TGA assays showed a dose-dependent increase in the time it takes for thrombin or a clot to form with aptamer R4cXII-1 present. However, the TGA also showed the ability of the aptamer to decrease the total amount of thrombin formed, the peak amount of thrombin generation, and the overall rate of thrombin generation. Importantly, the rate of thrombin generation has previously been shown to be a key contributor in influencing clot stability, with a slower rate of thrombin generation associated with less stable clots (64, 204). The finding that FXII inhibition decidedly decreases the rate of thrombin generation in this assay is consistent with
observations that FXII inhibition or deficiency is antithrombotic, potentially due to formation of unstable clots that can easily break up in thrombosis models under flow (39, 41).

In addition to its role in thrombosis, activation of the contact pathway through FXII occurs upon exposure to foreign substances, such as on the surface of a catheter in invasive surgery or even during the process of drawing blood into a collection tube (205, 206). In these situations, the irreversible FXIIa inhibitor CTI has been effective in inhibiting contact activation (207); however, inhibition of the autoactivation of FXII might result in a better antithrombotic profile. In addition, the ability to fully reverse aptamer activity by addition of a matched oligonucleotide antidote (164) or a universal antidote (165) may be beneficial in these and other settings, especially for allowing further studies into the contact pathway after drawing blood.

Through *in vitro* and animal studies, FXII has been well established as an important mediator of thrombotic effects while not affecting normal hemostatic function. In thrombosis, it is hypothesized that aggregated proteins, activated platelets, and polyphosphate, among other compounds present at a developing thrombus, can contribute to the continued activation of FXII and the intrinsic pathway, leading to excessive thrombin generation to exacerbate the growth of the thrombus (101). Inhibition of the autoactivation of FXII, as well as a significant decrease in the rate of thrombin generated at the site of a growing thrombus through targeted inhibition of the
intrinsic pathway of coagulation, could be a viable antithrombotic strategy in a number of clinical settings. While clinical studies have not always mirrored the results seen in FXII deficient animal models, further analysis into the utility of targeted inhibition of the intrinsic pathway of coagulation is warranted. Currently, an aptamer generated against FIXa and its matched oligonucleotide antidote is making their way through clinical development (163, 164). We anxiously await the clinical evaluation of other aptamers targeting upstream coagulation factors, such as FXII, that may not require antidotes to be safe and effective antithrombotic agents.
3. Characterization of an anticoagulant aptamer targeting FXI

3.1 Introduction

There is a large unmet need for antithrombotics that are efficacious enough to treat both arterial and venous thrombotic disorders while safe enough to not induce severe bleeding. While currently approved antithrombotics target mainly the common pathway of coagulation, whose action is imperative for hemostasis to occur, human and animal data have suggested that inhibition of the upstream intrinsic pathway proteins, FXI and FXII, have a role in pathological thrombus formation but not hemostasis. This is supported by the fact that humans deficient in FXII and FXI have either no bleeding phenotype or a mild bleeding phenotype, respectively. In addition, genetic mouse knockouts of FXII and FXI do not exhibit prolonged bleeding times, but these mice are protected in several models of thromboembolism (40, 41, 72, 91). Because FXII also has an initiating role not only in coagulation, but also in the inflammatory kallikrein-kinin system, FXI might be a safer target to managing thrombosis without a risk of undesired side effects.

Human FXI is a 160-kDa serine protease glycoprotein that circulates as a disulfide linked dimer of two identical subunits. Each subunit consists of a 35-kDa C-terminal light chain containing the catalytic domain, and an N-terminal 45-kDa heavy chain with four ~90 amino acid tandem repeats termed apple domains (82). The four apple domains confer binding to other proteins: A1 contains binding sites to thrombin
A2 to HK (209), A3 to FIX (51), the platelet receptor GP1bα (52), and heparin (210), and A4 to FXIIa (211). Dimerization occurs at the interface between the two A4 domains (54). The four apple domains form a disk-like structure that supports the catalytic domain (54). In plasma, FXI can be activated by XIIa (49), thrombin and thrombin intermediates (88, 212), as well as autoactivated by FXIa (88). Platelet polyphosphates can potently accelerate the activation of FXI by thrombin, thrombin intermediates, and FXIa, and are thus thought to amplify thrombin generation in a FXI-mediated fashion after extrinsic pathway activation in the hemostatic process (111, 203). In contrast, FXII-mediated FXI activation is not thought to be relevant for hemostasis, but can enhance thrombin generation at the site of a thrombus, thus contributing to pathological thrombosis (96).

All activators of FXI cleave the zymogen at the same activation loop site in the catalytic domain. Activation proceeds through an intermediate structure, 1/2FXIa, with one activated subunit, and is thought to possibly be the primary form of activated FXIa in plasma (56). Dimerization seems to be required for FXI activation, as it is thought that the proteases bind to one subunit while activating the other (60). In addition, dimerization might be important in tethering FXI to the site of injury, as the zymogen subunit can bind to the platelet receptor GP1bα, and leave the active subunit free to bind to and activate FIX. Zymogen FXI binds to platelets better than FXIa, with approximately 1500 binding sites per platelet (61). Whereas optimal binding requires
HK, zinc ions, residues in the apple 3 domain of FXI, and the N-terminal domain of GP1bα, recent data has suggested that FXI binds to the platelet receptor ApoER2, which colocalizes with GP1bα (55). FXIa also binds to platelets, but with a much lower frequency of 250 binding sites per platelet (62). FXI and FXIa bind to platelets through a separate binding site and mechanism, as FXIa binding to platelets seemingly requires the catalytic domain, but not the apple 3 domain as does FXI (55).

FXI deficiency was first described as hemophilia C in 1953, and is a rare bleeding disorder that affects approximately one in 10,000 people worldwide, but is more common in distinct populations, such as Ashkenazi Jews (65). While hemophilia C does not normally result in spontaneous bleeding, it is a mild to moderate bleeding disorder with increased bleeding tendencies in tissues with high fibrinolytic activity. Historically, it has been difficult to predict bleeding tendency in FXI deficient patients as there has been a poor correlation between bleeding phenotype and plasma FXI levels. For example, some patients with severely low levels of FXI will not bleed after surgery, while patients with normal levels of FXI do bleed, suggesting that bleeding risk may be modified by the levels of other coagulation factors (213). With over 190 reported mutations in the F11 gene (www.factorxi.com), there are two main types of mutation: CRM- (Type I) are mutations causing low FXI plasma levels while CRM+ (Type II) are mostly functional mutations correlating with normal FXI levels but reduced coagulant activity. Treatment is usually not necessary for patients undergoing mild procedures,
but antifibrinolytic agents, as well as fresh frozen plasma or human FXI concentrate is effective in reducing bleeding events.

While the function of FXI in hemostasis may depend on the setting, the potential uncoupling of FXI’s role in thrombosis and hemostasis is supported by observations from thrombosis models in FXI- deficient mice. Several studies using a ferric chloride model of arterial injury demonstrated that FXI deficiency protected mice from thrombus occlusion at a level comparable to FIX deficiency or high concentrations of unfractionated heparin (40, 72, 73). Attenuation of thrombus development was also observed following arterial injury from mechanical damage to the vessel or ligation (40). This protection was not limited to arterial thrombosis models, as FXI deficiency also conferred a thromboprotective effect in a transient middle cerebral artery stroke model (tMCAO), with a lower volume of infarcted brain tissue and less fibrin deposition in distal microvessels compared to wild type mice without any detectable hemorrhage (41).

The potential antithrombotic effect of FXI depletion or inhibition has also been observed in species other than mice. Antibody-mediated FXI inhibition in rabbits increased clot lysis in jugular veins and reduced thrombus propagation on injured neointima of the iliac artery (74, 75), while infusion of FXI antibodies in baboons prevented growth of occlusive thrombi in arterio-venous shunt and vascular graft occlusion models (76, 77). Administration of a FXI specific antisense oligonucleotide in mice reduced levels of FXI while conferring an antithrombotic effect similar to warfarin without abnormal bleeding.
times (78). The same technology has been applied to non-human primates, as antisense mediated depletion of FXI in cynomolgus moneys results in a prolongation of clotting times (214). Overall, the *in vivo* evidence strongly suggests that FXI contributes to fibrin formation and platelet activation, stabilizing occlusive thrombi under high flow conditions. This differs from its participation in hemostasis, where FXI-driven fibrin formation is not needed to prevent blood loss following vascular injury in most tissues (215). The effect appears to be mediated primarily through FXII’s activation of FXI and not via thrombin activation, as FXII deficiency shows similar protective effects in thrombosis models.

A number of anticoagulant aptamers have been isolated targeting various proteases of the coagulation cascade. Aptamers are short, single-stranded oligonucleotides that bind over large surface areas on the target protein and tend to act as anticoagulant by blocking specific macromolecular interactions. Herein, we describe the isolation and characterization of aptamers targeting FXI. These aptamers can partially inhibit FXIa active site cleavage, as well as greatly reduce the ability of FXIa to activate FIX. In addition, one of these aptamers acts as an anticoagulant to decrease thrombin generation in a modified thrombin generation assay activated through the intrinsic pathway.

### 3.2 Materials and Methods

*Materials*
The SELEX DNA template sequence was 5’-TCGGCGAGTCGTCTG-N_{40}-CCGCATCGTCCCTCCA-3’ and was purchased from Oligos, etc. (Wilsonville, OR). The 5’ and 3’ SELEX primer sequence are 5’-GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG-3’ and 5’-TCGGGCGAGTCGTCTG-3’, respectively, and were purchased from Integrated DNA Technologies (IDT, Coralville, IA). The 2’Flouro modified cytidine and uridine were purchased from Trilink BioTechnology (San Diego, CA). FXIIa and prekallikrein were purchased from Enzyme Research Laboratories (South Bend, IN). FXI, FXIa, and all other coagulation proteins were purchased from Haematologic Technologies (Essex Junction, VT). Human normal pooled plasma was purchased from George King Biomedical, Inc. (Overland Park, Kansas). AMV-RT enzyme was purchased from Roche Applied Science (Indianapolis, IN). Bovine serum albumin (BSA) was purchased from EMD Chemicals (Gibbstown, NJ), ethylene glycol was purchased from Sigma-Aldrich (St. Louis, MO) and lima bean trypsin inhibitor was purchased from USB Corporation (Cleveland, OH). The Ellagic Acid-based Pacific Hemostasis APTT-XL Reagent was purchased from Thermo Scientific (Waltham, MA), and micronized silica-based TriniCLOT aPTT S was purchased from Trinity BioTech (Bray, Co Wicklow, Ireland). All kinetic assays were performed in 96-well flat bottom microtiter plates (Corning Incorporated, Corning, NY), the absorbance was read at 405nm on a Power Wave XS2 kinetic microplate spectrophotometer (Biotek, Winooski, VT), and the data were
analyzed using the Graphpad Prism Software (GraphPad Prism, GraphPad Software, Inc., San Diego, CA).

**SELEX**

Solution based SELEX was performed as previously described (164). The sequence of the starting RNA library was 5'-GGGAGGACGAU-CAGACGACUCGCGCA-3', where N40 is a 40 nucleotide randomized region, and C and U represent 2'F modified ribonucleotides, respectively. A modified RNA library was transcribed *in vitro* using a modified polymerase that can incorporate 2'F cytidine triphosphates and 2'F uridine triphosphates (194). Selection rounds were performed by incubating the modified starting library with FXIa and passing the mixture through a 25-mm 0.45µµm nitrocellulose filter membrane (Protran BA 85, Whatman, Inc., Piscataway, NJ) to separate the bound RNA from the unbound RNA. The bound RNA was extracted and RT-PCR ed to amplify the bound RNA species. For rounds 1-6, 1 nmol RNA was incubated with FXIa in a low salt Hepes buffer E/F (20mM Hepes, 100mM NaCl, 2mM CaCl$_2$, and 0.01%BSA). For rounds 6-14, 1 nmol RNA was incubated with FXIa in a physiologic salt-Hepes buffer (20mM Hepes, 150mM NaCl, 2mM CaCl$_2$, and 0.01%BSA). Rounds 11, 12 and 14 were cloned and sequenced as previously described to distinguish individual aptamer sequences (152).
RNA Aptamers

For all aptamer sequences, “C” and “U” represent 2’fluorocytosine and 2’fluorouracil. The 70 nucleotide Xla7 (11.7) aptamer sequence is 5’ –

GGGAGGACATGCGCTCGACTATATTCCGGATCAGCAGATCACCCCCTCCCCC TCAGACGACTCGCCCGA-3’ and the 71 nucleotide sequence for Xla9 (12.7) is 5’-

GGGAGGACATGCGGTAACGCCACGCTCGACAACGCGT CGAGTGTCCTCCGCC CCCAGACGACTCGCCCGA-3’. All aptamers were transcribed in vitro as previously described using a modified polymerase that can incorporate 2’F cytidine triphosphates and 2’F uridine triphosphates (194). Before use, all aptamer preparations were diluted into a Hepes-based buffer with or without BSA (20mM Hepes, 150mM NaCl, 2mM CaCl$_2$, and with or without .01%BSA) as indicated. Diluted aptamers were refolded by heating to 65°C for 5 minutes, and then cooled for 3 minutes at ambient room temperature.

FXIa small peptide substrate cleavage

FXIa (final concentration 25nM) was incubated with 500nM aptamer, library, or buffer for 5min at 37°C in a Hepes-based reaction buffer (20mM Hepes pH 7.4, 150mM NaCl, 2mM CaCl$_2$, .01% BSA). The chromogenic substrate Pefachrome FXIa (Centerchem, Inc., Norwalk, CT) (final concentration 1mM) was added to a total volume
of 100µL. Substrate cleavage was monitored at an absorbance of 405nm using a kinetic microplate spectrophotometer at 37°C, and rates of substrate cleavage were determined using linear regression analysis.

**Restriction Fragment Length Polymorphism**

Library and SELEX round DNA (50pmoles) were end-labeled with [γ³²P] ATP (Perkin Elmer, Waltham, MA) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). [γ³²P] DNA was digested with AluI, HhaI, and HaeIII (New England Biolabs, Beverly, MA) for 3 hours at 37°C. Digested radiolabeled DNA was then separated on an acrylamide gel and visualized using a Storm 825 phosphoimager (GE Healthcare, Piscataway, NJ).

**Nitrocellulose filter binding assay**

A double-filter nitrocellulose binding assay was employed to determine the apparent binding affinity constants (Kₐ values) of aptamer to protein (152). The 5’ end of the RNA was dephosphorylated using bacterial alkaline phosphatase (Gibco BRL, Gaithersburg, MD), and subsequently end-labeled with [γ³²P] ATP (Perkin Elmer, Waltham, MA) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). Varying concentrations of purified protein were incubated with [γ³²P] RNA in Hepes binding buffer with BSA at 37°C for 5 minutes. The RNA-protein complexes were then
separated from the unbound RNA by passing the mixture through a nitrocellulose filter (Protran BA 85, Whatman Inc., Florham Park, NJ). The levels of bound RNA were quantified using a Storm 825 phosphoimager (GE Healthcare, Piscataway, NJ). Non-specific binding of the radiolabeled RNA to the nitrocellulose filter was subtracted, and the data were fitted using nonlinear regression to determine the apparent binding affinity for the RNA aptamer-protein interaction (GraphPad Prism, GraphPad Software, Inc., San Diego, CA).

**FXIa-mediated FIX activation**

Conversion of zymogen FIX to activated FIXa by FXIa was measured in a two stage chromogenic assay performed at 37°C in a Hepes-based reaction buffer (20mM Hepes pH 7.4, 150mM NaCl, 2mM CaCl$_2$, .01% BBF). Aptamer or buffer was incubated with FXIa (final concentration 5nM) for 5 minutes at 37°C, and reactions were initiated with the addition of FIX (final concentration 1µM). At timed intervals after the initiation of the reaction, samples of the reaction mixture were removed and FXIa activity was quenched by addition of lima bean trypsin inhibitor (final concentration 1mg/mL) suspended in EDTA (final concentration 2.1mM). FIXa activity was assayed by the addition of 1mM Pefachrome FIXa 3107 (Centerchem, Inc., Norwalk, CT) suspended in Hepes-based reaction buffer supplemented with ethylene glycol (20mM Hepes pH 7.4,
150mM NaCl, 2mM CaCl₂, .01% BBF, 30% ethylene glycol). The rate of substrate hydrolysis was recorded at 405nM using a kinetic microplate spectrophotometer at 37°C.

To determine the inhibition constant (Kᵢ), FIX activation reactions were performed as described above in the presence of varying concentrations of aptamer. The initial rate of FIX activation by FXIa was determined by linear regression of the rate of FIXa formed versus time for the first 10 minutes of the reaction. Fractional activity (V1/V) was calculated by dividing the initial rate of FXI activation in the presence of aptamer by the initial rate of FXI activation in the absence of aptamer. The Kᵢ was determined using nonlinear regression analysis.

Cell-based model of thrombin generation

The cell-based model system has been described in detail (64). Briefly, human monocytes from one individual were isolated and cultured overnight in a 96-well microtiter plate in 500ng/mL lipopolysaccharide-containing macrophage serum free media (Gibco, Invitrogen Life Technologies, Grand Island, NY) to induce TF expression. Platelets were obtained and purified from a normal healthy individual, and diluted to a final concentration of ~150x10⁹ L⁻¹. TF expression on cultured monocytes were checked, and determined to be on the order of 1pM. Final concentrations of proteins were approximately at normal plasma levels: antithrombin (3.0µM), TFPI (3nM), FII (1.4µM), FIX (70nM), FX (135nM), FVIIa (0.2nM), FXI (25nM), FV (20nM), and FVIII (0.3nM).
Aptamers were incubated with FXI for 5 minutes at room temperature. This mixture was added to the culture monocytes, as well as platelets, the purified coagulation proteins, and 3mM calcium chloride. At timepoints, 10µL of the reaction mixture was added to 1mM FIIa Chromozyme (Aniara, West Chester, Ohio) in 1mM EDTA. After 10 minutes, 50% acetic acid was added to stop the reaction, and the rate of substrate hydrolysis was recorded at 405nM using a kinetic microplate spectrophotometer at 37°C.

Clotting Assays

Activated partial thromboplastin time (aPTT) and prothrombin time (PT) assays were carried out using a model ST4 coagulometer (Diagnostica Stago, Parsippany, NJ). Aptamer diluted in Hepes buffer without BSA (20mM Hepes, 150mM NaCl, 2mM CaCl₂) was refolded by heating for 5 minutes at 65°C and then cooled to ambient temperature for 3 minutes. Pooled normal human platelet poor plasma was prepared by drawing blood into sodium citrate tubes. For the aPTT, aptamer (5µL) was then added to 50µL pooled normal human platelet poor plasma and incubated for 5 minutes at 37°C. 50µL APTT-XL Reagent was then added to activate plasma and incubated for 5 minutes at 37°C. Clotting was initiated by adding 50µL of 25mM CaCl₂ and the time to clot formation was recorded. Aptamer concentrations represent the final concentration in the entire reaction.
For the PT, refolded aptamer (5µL) was added to 50 µL pooled normal human platelet poor plasma and incubated for 5 minutes at 37°C. TriniClot PT Excel (Trinity BioTech, Bray, Co Wicklow, Ireland) was added to initiate clotting.

**Thrombin Generation Assay**

In an Immulon 2HB clear U-bottom 96 well plate (Thermo Labsystems, Franklin, MA), CTI- treated (50µg/mL), pooled normal human platelet poor plasma from healthy, consented volunteers (60µL) was mixed with aptamers (3µL) diluted in Hepes-based buffer without BSA and incubated for 5 min at 37°C. Ellagic acid reagent (final concentration 0.1µM, diluted 1:200 with 4µM phospholipid vesicles (20% phosphatidylserine, 60% phosphatidylcholine, 20% phosphatidylethanolamine) in Hepes-based buffered saline)(15µL) was added to the plasma-aptamer mixture, and incubated for 5 minutes at 37°C. Flu-Ca (Diagnostica Stago)(15µL) was added to start the assay and thrombin generation was measured using a Fluroskan Ascent Reader (Thermo Scientific, Waltham, MA). A thrombin calibrator reagent (Diagnostica Stago, Parsippany, NJ) was used to quantify the amount of thrombin generated in the samples. Data analysis was performed using Thrombinoscope software (Thrombinoscope BV, the Netherlands). Aptamer concentrations represent the final concentration in the entire reaction. The amount of ellagic acid used was standardized to produce a similar curve to a TF-activated TGA. In addition, the amount of CTI present was standardized to inhibit
contact activation of the plasma sample, while still allowing for robust FXII-dependent activation upon administration of ellagic acid.

*Thromboelastogram*

Blood was drawn from healthy, consented volunteers under a Duke University Institutional Review Board Protocol into tubes with 3.2% sodium citrate. Whole blood (320 µL) was mixed with aptamer (10 µL) and incubated at room temperature for 5 minutes. Kaolin (10 µL) (Haemonetics, Niles, IL) was added, and the entire reaction (340 µL) was added to 20 µL CaCl₂ in a disposable, plain TEG cup (Haemonetics). Clot formation was measured at 37°C with a Thromboelastograph Analyzer (Haemonetics) until a stable clot was formed. Parameters were automatically calculated using the TEG® Analytical Software version 4.2.3 (Haemonetics).

### 3.3 Results

3.3.1 SELEX Pool Analysis and Lead Clone Selection

To isolate aptamers targeting FXIa, we utilized a traditional solution based SELEX against purified FXIa. A library of approximately $10^{14}$ 2'Fpyrimidine modified RNA sequences were incubated with FXIa and screened for high affinity binding and active site inhibition. Because binding of the pool RNA was initially weak, the selection was begun in a binding buffer with a lower salt concentration (100 mM NaCl), and
subsequently increased to physiologic salt concentration (150mM NaCl) once higher binding affinity was established. After 6 rounds of selection in a lower salt buffer, the binding affinity of the pool RNA began to increase as high affinity binding sequences began to dominate the pool. The final rounds were performed at physiological salt conditions.

Fourteen total rounds of SELEX were performed, with progression monitored in several ways. First the binding affinity of each round was determined by a nitrocellulose filter-binding assay; however, this assay was often inconsistent, perhaps because of the dimer formation of FXIa. Thus, the evolution of the selection was additionally assessed for functionality and diversity (Figure 23). The functionality of the pool RNA was monitored by its ability to reduce the active site cleavage rate of a small substrate. As shown in Figure 23A, the pool began to include a higher number of sequences that could decrease the rate of active site cleavage of FXIa as early as round 4, and these sequences were maximally present in rounds 11 and 12. Later rounds began to slightly lose this functionality, indicating the loss of functional aptamers as stringency towards tighter binders was increased. Lastly, the diversity of sequences present in the pool was examined using a restriction fragment length polymorphism (RFLP) assay (Figure 23B). In this assay, the oligonucleotide pool is digested with a set of restriction enzymes and separated according to length by gel electrophoresis. The emergence of separate bands from the starting library RNA was apparent from the
earliest round tested, round 8. Rounds 13 and 14 exhibited an additional band, suggesting the further evolution of the pool. For comparison of diversity, and to isolate the more frequent functional sequences present in the earlier pools, rounds 11, 12 and 14 were chosen to clone and sequence.
Figure 23. Analysis of FXIa SELEX rounds active site functionality and sequence diversity

A) Chromogenic assay for active site activity. FXIa (25nM) was incubated with SELEX RNA rounds (500nM), and active site activity was measured by a FXIa specific chromogenic substrate. The data were normalized to the rate in the absence of compound and represent the mean ± SEM of duplicate measures. B) RFLP analysis of SELEX rounds. Radiolabeled DNA from each round was digested with the same set of restriction enzymes and separated by gel electrophoresis. The labels above the lanes indicate the round: “R8“ means round 8.
The seventy clones selected to sequence from all three rounds were organized into families based upon their primary sequences (Table 7). There was considerable diversity in the pool, with the highest frequency clone present only in 20% of the pooled sequences. While many of the conserved sequences were found in two or all three of the sequenced pools, there were many “orphan” sequences, or sequences that do not fit into a family, but are present at a low frequency in the final pool. The functional data and progression of the SELEX rounds indicate that there is some loss of functional binders, therefore, several of the orphan sequences from rounds 11 and 12 were analyzed, and indicated by their individual clone name.

### Table 7. RNA aptamer sequences from FXIa solution-based SELEX

<table>
<thead>
<tr>
<th>Clone ID</th>
<th>Variable Region Sequence</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xla1</td>
<td>ACCGCATCCGTGAAGATCCCTCTCTGCCCTCCCCCTCCCCC</td>
<td>20.0%</td>
</tr>
<tr>
<td>Xla8</td>
<td>GCCGTCTGAGTCGTATGAATTCCGCATGGTCGTGTGTG</td>
<td>12.9%</td>
</tr>
<tr>
<td>Xla2</td>
<td>AATTACCCCGCTCTGTAGTACACATGCTATCCCCTCCCCC</td>
<td>8.6%</td>
</tr>
<tr>
<td>Xla7</td>
<td>CAAAACCATTTCCGCCGCGAGGCTCTTCCCTCCCCC</td>
<td>8.6%</td>
</tr>
<tr>
<td>Xla4</td>
<td>ATCGTGCAATTATTTCTGCTACCAGCCAACGGTGCCC</td>
<td>5.7%</td>
</tr>
<tr>
<td>Xla5</td>
<td>ATGTCTGGGTAATCACACACCACACTGCTCCAGCTCCCTCCCCC</td>
<td>5.7%</td>
</tr>
<tr>
<td>Xla3</td>
<td>CACTACGAGGGTGTCATGCTTCCGCGACATCACCCTCCCCCC</td>
<td>2.9%</td>
</tr>
<tr>
<td>Xla6</td>
<td>AGCACATAAACCCTGGTGTTCACACCACCACCTCCCCC</td>
<td>2.9%</td>
</tr>
<tr>
<td>11.7</td>
<td>CTGCCTACTATTCCGGATCGCAGATCACCCCCCTCCCCC</td>
<td>2.9%</td>
</tr>
<tr>
<td>11.23</td>
<td>TATCAGCAGCCGTCTCGACTCTAGAGTGTCGCCCTCCCCC</td>
<td>1.4%</td>
</tr>
<tr>
<td>12.7</td>
<td>TAACGCCACGCTCGACAACCGTGTCGTCGTCGTCGTCGTCGTCG</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

Sequence analysis of the clones indicated a conserved region near the end of the random region, found in most families, consisting of a string of C’s. Predicted structural
analysis indicated that this region bound to the 5’ constant region, resulting in a similar structure for many of the sequence families (Figure 24). This structure is hallmarked by a central loop with two stem loops emerging from it, as well as a stem and the un-base-paired 3’ constant region. Outside of the constant regions and the string of C’s, no sequence similarity was found between families.

Figure 24. Representative secondary structures of clone families
The M-fold predicted secondary structures of A) Xla1, B) Xla2, C) 11.7 and D) 12.7.

In order to select a lead aptamer for further analysis, a representative clone from each of family was screened in three separate assays: binding affinity utilizing the nitrocellulose filter binding assay, functionality of active site cleavage, and functionality of FXIa-mediated FIXa activation. A summary of these results is found in Table 8. While not found in a high frequency in the selection pool, two of the most potent aptamers, 11.7 and 12.7, were further characterized.
**Table 8. FXI aptamer screening results**

Aptamers were screened in a binding affinity assay, and two chromogenic assays to determine the rates of active site cleavage of FXIa and FXIa-mediated FIXa generation. For the chromogenic assays, all aptamers were tested at 0.5µM. Data represents one independent experiment.

<table>
<thead>
<tr>
<th>Aptamer</th>
<th>FXIa Binding affinity $K_a$ approx (nM)</th>
<th>Active Site Cleavage Rate (A405/msec)</th>
<th>FIXa generation rate (A405/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xla1</td>
<td>753.9</td>
<td>2.346</td>
<td>0.618</td>
</tr>
<tr>
<td>Xla2</td>
<td>394.9</td>
<td>2.021</td>
<td>0.419</td>
</tr>
<tr>
<td>Xla3</td>
<td>303.5</td>
<td>4.100</td>
<td>1.314</td>
</tr>
<tr>
<td>Xla4</td>
<td>73.1</td>
<td>4.481</td>
<td>1.177</td>
</tr>
<tr>
<td>Xla5</td>
<td>65.5</td>
<td>4.436</td>
<td>0.526</td>
</tr>
<tr>
<td>Xla6</td>
<td>362.3</td>
<td>2.302</td>
<td>0.823</td>
</tr>
<tr>
<td>Xla7</td>
<td>2,182.0</td>
<td>3.974</td>
<td>ND</td>
</tr>
<tr>
<td>11.7</td>
<td>27.5</td>
<td>1.603</td>
<td>0.259</td>
</tr>
<tr>
<td>11.23</td>
<td>75.6</td>
<td>2.235</td>
<td>1.312</td>
</tr>
<tr>
<td>12.7</td>
<td>21.0</td>
<td>1.511</td>
<td>0.178</td>
</tr>
<tr>
<td>Library</td>
<td>461.7</td>
<td>4.375</td>
<td>1.81</td>
</tr>
<tr>
<td>Buffer</td>
<td>N/A</td>
<td>3.966</td>
<td>1.682</td>
</tr>
</tbody>
</table>

### 3.3.2 Lead Aptamer Biochemical Characterization

While several of the aptamer clones did not affect active site cleavage, a number of aptamers were able to slow the rate of active site cleavage of FXIa to varying degrees. For all FXI biochemical assays, a non-binding, size-matched control RNA was used to assess the non-specific effects of RNA activity on FXI. Clones 11.7 and 12.7 were maximally able to slow active site cleavage rates by ~65% compared to library control RNA or non-functional aptamers (Figure 25).
Figure 25. Active site activity assay to determine lead clone candidates
FXIa (25nM) was incubated with FXIa aptamer clones (500nM), and active site activity was measured by a FXIa specific chromogenic substrate. The data were normalized to the rate in the absence of compound and represent the mean ± SEM of at least duplicate measures.

Both of these clones were next analyzed using nitrocellulose filter binding assays to determine their binding affinity to both zymogen FXI and FXIa (Figure 26). Binding in general to FXI and FXIa was quite variable and inconsistent, even with control RNA, compared with binding studies on other proteins, resulting in widely changing disassociation constants. A compilation of all binding studies suggested that 11.7 binds to only FXIa, while 12.7 binds to both zymogen FXI and FXIa (Table 9). For both clones, the $B_{\text{max}}$, or the percentage of RNA present that is folded correctly in order to bind to the target protein, was also very low, suggesting that only a small fraction of the RNA is able to bind the protein. Additional nitrocellulose filter binding assays to other proteins
were employed to determine specificity of aptamer binding. Both aptamers did not exhibit binding toward a panel of coagulation factors, including the structurally related prekallikrein (data not shown). However, 11.7 did exhibit weak binding to the enzymatically inactive HK, a protein that circulates in complex with FXI or PK.

Figure 26. Aptamer 11.7 binds preferentially to FXIa while aptamer 12.7 binds to both zymogen FXI and FXIa
Representative nitrocellulose filter binding assay of 11.7 (■), 12.7 (▼), and library control RNA (●) to A) FXI and B) FXIa.
Table 9. RNA aptamer binding to soluble FXI and FXIa as determined by a nitrocellulose filter-binding assay

Data represent at least duplicate measures.

<table>
<thead>
<tr>
<th>Aptamer</th>
<th>FXI K_d approx (nM)</th>
<th>FXI B_max approx (%)</th>
<th>FXIa K_d approx (nM)</th>
<th>FXIa B_max approx (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.7</td>
<td>671.6 ± 265.9</td>
<td>21.3 ± 4.3</td>
<td>52.0 ± 13.5</td>
<td>24.7 ± 2.0</td>
</tr>
<tr>
<td>12.7</td>
<td>139.2 ± 81.9</td>
<td>10.45 ± 1.7</td>
<td>84.9 ± 32.5</td>
<td>9.1 ± 2.5</td>
</tr>
</tbody>
</table>

In the coagulation cascade, FXI functions to activate FIX to amplify thrombin generation. Thus, the ability of the lead aptamers to inhibit this reaction was next determined. This reaction was assessed by monitoring the amount of FIXa formed in a purified system using FXIa as an activator in the presence or absence of aptamer or control RNA. The presence of either aptamer in this reaction impaired the initial rate of FIX activation by greater than ~80%, while the presence of control RNA did not (Figure 27A). To determine the potency of inhibition, the initial rate of FIX activation by FXIa was measured in the presence of varying concentrations of either 11.7 or 12.7, and was shown to dose dependently decrease the amount of FIXa formed. An apparent equilibrium inhibition constant (K_i) of 82.4 ± 12.8nM for 11.7 or 190.1 ± 27.3nM for 12.7 was obtained by plotting the fractional rates of FIX activation versus the concentration of aptamer used (Figure 27B and C). While 11.7 could maximally inhibit 90% of FIXa generation, 12.7 had slightly less potency while able to inhibit 75% of FIXa generation.
Figure 27. Both lead aptamers reduce FXIa-catalyzed activation of FIX

FIX (1µM) was activated by FXIa (5nM), the reaction was quenched at various timepoints by the addition of 1mg/mL LBTI, and the amount of FIXa was quantified using a chromogenic substrate. A) The rate of FIXa generation at various timepoints was determined in the presence of 500nM 11.7 (▼), 12.7 (▲), control library RNA (◆), or buffer (■). Lines represent nonlinear regression fits of the data. The data are representative of two independent measures. Fractional FXIa activity of B) 11.7 and C) 12.7. Fractional activity was calculated by dividing the initial rate of FXI activation in the presence of R4CIII-1 by the initial rate of FXI activation in the absence of aptamer. The Kᵢ was calculated by nonlinear regression analysis. The data represent the mean ± SEM of at least duplicate measures.

Since both aptamers can reduce FXIa active site cleavage and FIXa generation, they were next tested to see if they could reduce thrombin generation in a reconstituted cell-based model of coagulation. This assay was developed to assess thrombin...
generation using cultured monocytes as a source of tissue factor, and purified platelets as a surface for physiologic amounts of procoagulant proteins to generate thrombin (64, 216). Preliminary results suggest that both aptamers are potent inhibitors of thrombin generation in this assay (Figure 28). This assay does not include FXII, thus any FXI activity is thought to occur from the thrombin feedback loop.

![Graph](image)

**Figure 28. Both aptamers inhibit thrombin generation in a reconstituted cell-based model**

Purified platelets and physiologic amounts of procoagulant factors are added to human monocytes induced to express tissue factor and thrombin generation is determined by a chromogenic substrate. The amount of thrombin formed with pre-incubation of FXI with 11.7(●), and 12.7 (▼) with control library RNA (■) was determined. The data are representative of two independent experiments.

### 3.2.3 Lead Aptamer Functional Analysis

While both aptamers exhibit biochemical inhibition of FXIa function and downstream thrombin generation, we next tested each aptamer for anticoagulant
activity in a plasma-based common clinical coagulation test, the activated partial thromboplastin time (aPTT). This assay measures the time it takes for a fibrin clot to form in plasma, and is sensitive to deficiencies or inhibition of the intrinsic and common pathways of coagulation. This assay uses a negatively charged substance, such as kaolin or ellagic acid, to activate FXII and prime the cascade, and, upon addition of Ca^{2+} to initiate clotting, records the time for a fibrin clot to form. Aptamer 12.7 shows a slight increase of clotting time over control RNA in an aPTT activated with ellagic acid (Figure 29A), although this increase plateaus once aptamer saturation of target protein is reached. In addition, 11.7 does not show activity in this assay. As a control, both aptamers do not inhibit clotting time in a PT, which measured extrinsic pathway inhibition (Figure 29B). Use of a different activator (micronized silica), abolished the ability of 12.7 to prolong clotting time in an aPTT (data not shown).
Figure 29. Lead aptamer screening in functional clotting assays
Dose titration of 11.7 (■) and 12.7 (▲) in A) an aPTT clotting assay activated with ellagic acid or B) a PT clotting assay activated with TF. The data were normalized to the clot time of a control library RNA.

Because of the minimal prolongation of clot time seen in an aPTT, 12.7 was examined in the more sensitive thrombin generation assay (TGA) to determine functionality in plasma. This is a coagulation assay similar to the cell-based model system that measures thrombin generation in human plasma in real-time by monitoring cleavage of a thrombin-specific chromogenic substrate. While the cell-based model system used cultured macrophages to initiate thrombin generation through the extrinsic pathway, a TGA was developed with our colleagues at Merck Research Labs using ellagic acid as an activator to study thrombin generation during inhibition of the intrinsic pathway. Using a TGA allows for several more parameters to be analyzed in addition to the lag time (the time when thrombin begins to appear), including the peak (maximal amount of thrombin formed), the endogenous thrombin potential (ETP, the total amount of thrombin formed), and the rate of thrombin generation (the slope of the
line from the lag time to peak thrombin generation). Contrary to the aPTT data, 12.7 exhibited potent inhibition of thrombin generation in this assay, including prolongation of the lag time by several minutes (Figure 30). Importantly, in contrast to the aPTT, which uses sodium citrate pooled human plasma, this assay uses human plasma that has been treated with corn trypsin inhibitor (CTI), a FXIIa inhibitor that is added during the blood drawing process to inhibit any contact activation that may occur. While 12.7 dose dependently inhibited thrombin generation and all analyzed parameters, including the ETP, the peak amount of thrombin formed, and the rate of thrombin generation, size matched library control RNA exhibited agonist activity and dose dependently increased the rate of thrombin generation and the peak amount of thrombin formed. While the mechanism of this is undetermined, other control RNA with no inhibitory characteristics also exhibited this trend (data not shown). However, control RNA had no effect on the ETP of the sample, indicating that the same amount of thrombin was generated across doses. In contrast, 12.7 completely abolished ETP, with no thrombin formed at the two highest concentrations tested (Figure 30D).
Figure 30. Aptamer 12.7 dose dependently impairs thrombin generation in a TGA assay initiated with ellagic acid

Thrombograms of normal pooled plasma activated with ellagic acid with various concentrations of A) 12.7 and B) size-matched library control RNA. C) Lag time, D) Endogenous thrombin potential E) Peak thrombin generation, and F) rate of thrombin generation of 12.7 (■) and library control RNA (▲). Data are representative of one independent experiment.

While the aPTT and TGA indirectly measure thrombin generation in a plasma-based setting, an assay that uses whole blood, and thus also platelets, was utilized to measure clot strength kinetics. This assay, the thromboelastogram, uses kaolin to
activate citrated blood, and measures the time it takes for a clot to form (lagtime), the rate of clot formation (angle) and the strength of the clot (maximum amplitude). Both lead aptamers were tested in this assay, and both 11.7 and 12.7 could prolong the time it takes for a clot to form over size-matched control RNA (Figure 31). Aptamer 12.7 also significantly decreased the angle, or the rate of clot formation.

![Figure 31. FXI aptamers can impair clot strength parameters in a thromboelastogram activated with kaolin](image)

Thromboelastogram tracings for A) 12.7 (green) and size-matched control scrambled RNA (black) and B) 11.7 (green) and size-matched control scrambled RNA (black). The data are representative of two independent observations.

While the FXI aptamer was isolated solely against the human form of the coagulation factor, analysis for cross reactivity in animal plasma is a must before proceeding into in vivo models of thrombosis. In general, aptamers have exhibited some efficacy in a variety of species; with the FIX aptamer retaining binding in every species tested except for rabbit (data not shown). However, other aptamers exhibit limited cross-reactivity. Both lead FXI aptamers were tested in a number of animal plasmas in an aPTT assay, as well as with different activating reagents. Unfortunately, no
anticoagulant effect was seen in any of the plasmas tested (data not shown). Importantly, the animal plasma samples were not treated with CTI, thus contact activation of the plasma sample may already be present, and subsequent aptamer inhibition may not be detected. This experiment will be repeated once we obtain CTI-treated, non-contact activated plasma from each animal species.

3.4 Discussion

We utilized a solution based SELEX to isolate aptamers that bound to FXIa and inhibited coagulant function. A number of aptamers were characterized that could reduce the rate of FXIa active site cleavage of a small chromogenic substrate, as well as inhibit FXIa-mediated FIX activation (Figure 32). All of these functional aptamers evolved a similar predicted secondary structure, however, binding affinities varied widely, and were generally low compared to other aptamer selections. Two lead aptamers exhibited a robust decrease in thrombin generation in a reconstituted cell based model system. Plasma or blood based assays utilizing the FXIa aptamers did not initially have a robust affect on thrombin generation; however, contact activation during a blood draw could decrease the function of these aptamers in plasma or blood that was not treated with a contact pathway inhibitor. Addition of a FXIa aptamer in a plasma assay using contact-inhibited plasma during the blood draw showed potent inhibition of thrombin generation.
Figure 32. A schematic depicting the role of the FXI aptamer, 12.7, in inhibiting FXI/FXIa function

The aptamer 12.7 inhibits FXIa active site cleavage as well as FXIa-mediated FIX activation to effectively shut down thrombin generation in a plasma setting. Predicted secondary structure of aptamer adapted from M-fold.

Initial binding of the starting RNA library to FXIa was low at physiologic salt concentrations; therefore, SELEX was initially started in a lower salt containing buffer in which the library RNA exhibited binding (data not shown). After six rounds, the pool had evolved with a higher affinity binding than the starting library in both lower salt and physiologic salt buffers; thus, the selection was then continued at physiologic salt concentrations. Throughout the selection, background binding varied widely in separate experiments and in separate lots of FXIa. While each lot of FXIa was believed
to be >95% pure by the company it was purchased from, during the preparation process, the zymogen protein is activated by FXIIa, a protein that can bind to library RNA fairly easily. While there are not any of the original lots of protein available to subsequently test for purity, contamination of a high nucleic acid binding protein could have been responsible for the varied background binding. Subsequent lots showed much reduced and more consistent background bindings, suggesting that purification methods have been optimized.

Because of the inconsistencies with the nitrocellulose filter-binding assay, the SELEX rounds were also monitored functionally in a simple chromogenic assay determining the rate of FXIa active site cleavage. While aptamers do not normally bind within and inhibit the active site, some aptamers have been found to reduce this activity (184). It is thought that the aptamer either binds in such a way to partially occlude or allosterically affect the active site, thus reducing rates of substrate cleavage. Beginning with Round 4, the selection pool contained sequences that could slightly reduce FXIa active site cleavage. Further evolution of the pool resulted in further reduction of active site cleavage. However, as stringency in binding was increased in later rounds, the pool began to lose the frequency of functional binders. Analysis of individual clones identified the most functional aptamers from the two most potent rounds in this assay.

Cloning and sequencing three rounds from this selection led to identification of numerous aptamer families and orphan sequences. While some selections are driven
nearly to completion, with the identification of one or two closely related sequences that
tend to dominate the pool (152, 191), this selection had many aptamer families present to
screen for functionality. Testing these aptamers in a panel of biochemical assays
identified several of the most potent aptamers, and several aptamers that had no
functionality. Interestingly, all of the functional aptamers contained the same predicted
structure, while the non-functional aptamer structures varied. In analyzing the
sequences of the aptamer families, most sequences evolved a string of C’s near the end
of the variable region that bound to the 5’ constant region. The library used for this
selection was shorter than previous libraries (71 nucleotides versus 80 nucleotides).
While both libraries contained 40 nucleotide random regions, the shorter library
contained a truncated 3’ constant region. In another selection using this library, the
same string of C’s near the end of the variable region was also evolved. This suggests
that the constant regions in this shorter library may not exhibit stable binding, and thus
the selection had to evolve stable aptamer structures first before then selecting for high
affinity binders. Since the binding affinity was so low in this selection, and this was the
first selection using this library to isolate aptamers against coagulation factors, the initial
library may not have been able to exhibit high structural diversity due to low stability
binding of the constant regions, especially at physiologic salt concentrations.

Similar to the selection rounds, binding analysis of the two most potent
functional clones exhibited lower binding affinities (high nanomolar range) and $B_{\text{max}}$
percentages (10-20%) than normally seen with other aptamers to coagulation factors (152, 162). As most coagulation proteins are not dimers, the nitrocellulose filter-binding assay may not be a suitable assay to determine binding with a dimerized protein. It is possible that the protein could fall apart, or bound RNAs could be eluted off the protein due to a structural change upon binding to the nitrocellulose filter. Separate binding assays to compare aptamer binding to FXIa are currently planned, as well as binding assays to a non-dimeric form of the protein, as well as the isolated catalytic domain. In addition, the predicted secondary structure of the RNA’s present a large un-basepaired 3’ region. While no other structures are predicted, it is our experience that un-basepaired regions are not very stable. A native gel binding assay with 11.7 to FXIa showed three aptamer states, where only one of those states were able to bind to FXIa, corresponding with the determined $B_{\text{max}}$ where only 30% of the aptamer is folded correctly to bind to FXIa. Truncation of the aptamers, especially eliminating the 3’ un-basepaired region, could lead to further stabilization of the aptamer structure capable of binding to FXIa, thus increasing the $B_{\text{max}}$ of the aptamer.

The crystal structure of FXIa has been solved, along with the locations of the binding site of the proteins that FXIa interacts with. These binding sites are located in four apple domains, on top of which the catalytic site sits. The decision to perform SELEX on FXIa rather than FXI preceded from the observation that zymogen FXI does not bind FIX. Cleavage of the activation loop by FXIIa or thrombin in the catalytic
domain results in significant conformational changes. Specifically, an arginine residue which is normally buried in the A3 domain near the FIX binding site is subsequently exposed upon FXI activation, acting as a switch to shift the position of the apple domain disk relative to the catalytic domain, thus exposing the FIX binding site (54). As both lead aptamers reduce active site cleavage and block FIX activation, they most likely bind near or in this region, as aptamers tend to home in on sites that mediate protein-protein interactions (157). Interestingly, 11.7 binds only to FXIa and is a more potent inhibitor of FIX activation in a purified protein setting than 12.7, which can bind to both FXI and FXIa. This suggests that 11.7 binds more directly than 12.7 in the FIX binding site that is occluded in zymogen form. Other proteins bind the regions surrounding the FIX binding site, such as GP1ba, which binds in the same apple domain, and thrombin and HK, which bind in separate apple domains. As aptamers tend to bury large surface areas, biochemical analysis to determine if these aptamers block the function of these other proteins would help to map the aptamer binding site, as well as further elucidate the mechanism of aptamer inhibition.

Functionally, there was initially a discrepancy between the lack of potency in plasma-based assays versus the potent inhibition of FXI function in biochemical assays or the reconstituted cell-based model of thrombin generation. This could be due to prior contact pathway activation in the plasma samples. The process of drawing blood can activate the contact pathway through the exposure and subsequent activation of FXII to
foreign surfaces. Therefore, FXIa can already be present and bound to FIX in a plasma preparation from a blood draw without an inhibitor of FXIIa present, and subsequent inhibition of FXIa in these samples might not be viable or as potent as inhibition in CTI-treated samples, where presumably no FXI has been activated. CTI is an irreversible FXIIa inhibitor, and inclusion has been shown to inhibit contact pathway activation during the blood drawing process. This discrepancy can be seen when comparing the results from the aPTT and TGA with 12.7. While 12.7 has minimal activity in the aPTT, which uses plasma without CTI, there is robust inhibition of thrombin generation in the TGA, including the lag time, using plasma prepared with CTI. Further analysis to determine if CTI-treated plasma would have a great aptamer effect in the aPTT is warranted. In addition, 11.7 has not been evaluated in a CTI-based plasma assay; thus, its functionality in plasma is unknown, although it was able to decrease thrombin generation in the cell-based model. However, 11.7 could also be less potent in plasma than 12.7 because it only binds to activated FXI while 12.7 binds to both FXI and FXIa. Therefore, 12.7 would already be bound to FXI in plasma and able to immediately block FIX activation. In addition, several aptamers that bind to the zymogen as well as the activated protein have been shown to not only inhibit downstream function of their target protein, but also to inhibit their protein’s activation (181, 184). While it has not been directly studied if these aptamers can block FXIIa-mediated FXI activation, the aptamer would presumably be more potent if it could block these two subsequent
stages. In addition, the aPTT and TGA used here only measures FXI as a function of the contact activation pathway, and does not incorporate feedback activation by thrombin or interactions with platelets. The cell based model system, however, does not include FXII, thus the inhibition of thrombin generation seen in this system indicates that the aptamer does affect either or both of these functions. Further biochemical assays, as well as a TGA assay run with platelet-rich plasma, can determine the extent of inhibition of either of these functions.

Overall, we have isolated an aptamer inhibitor of FXIa that is a potent inhibitor of thrombin generation. Additional biochemical assays would assist in mapping the binding site of the aptamer, as well as give additional information into the mechanism of thrombin inhibition. As the conditions for plasma preparation are continually being determined for each species, further assessment of aptamer activity in plasma and blood based assays, as well as assessment of cross-reactivity of the aptamer in animal plasmas will be necessary in order to determine if this aptamer is potent enough to move forward into clinical trials. As FXI may have a slightly more prominent role in coagulation than FXII, as evident by FXI deficiency being accompanied with a mild bleeding disorder, the development of a specific FXIa inhibitor is promising step in finding a therapeutic to inhibit thrombosis. An aptamer inhibitor of FXI is attractive, as any potential bleeding effects due to therapy could be quickly reversed with an aptamer
antidote, thus increasing the safety and providing an effective therapeutic to treat thromboembolism.
4. Comparing the sensitivity of coagulation assays for target validation

The results in this chapter were performed as part of a collaboration with the scientists at Merck Research Labs in Rahway, NJ.

4.1 Introduction

Clinically, a number of hemostatic tests are available that serve as a simple indicator of the clotting function of blood in a human being by determining the time that it takes for a plasma sample to clot. These tests are used to identify or assess bleeding risk in patients with genetic clotting factor defects or those under anticoagulant therapy. In reality, these clotting times, while commonly used, do not always correlate with bleeding phenotypes and cannot detect the use of all anticoagulants (196, 217).

Thrombin is the pivotal step in the coagulation cascade; thus, any alteration in any of the components responsible for making thrombin can greatly affect bleeding rates. Aside from the clotting time, the rate of thrombin generation or the peak amount of thrombin generated can have a profound affect on the stability of a clot (64). Thus, a more comprehensive view of thrombin dynamics could more predictably predict bleeding rates in patients with genetic defects or under anticoagulant therapy.

The thrombin generation assay (TGA) offers this more comprehensive and global assessment of thrombin formation, as it uses a small chromogenic substrate to detect thrombin generation in a plasma sample. While the analysis of thrombin generation has been around for decades, the development of an automated system has been hampered...
by the difficulties of measuring optical density (thrombin formation) during a change in turbidity of the plasma sample due to clot formation (196). The introduction of a slow-reacting thrombin-specific fluorogenic substrate circumvented this problem, and the fluorescence signal is converted to the amount of thrombin generated as a function of time by comparing thrombin generation in a calibrated parallel sample (196). In this way, several thrombograms, the graph that measures thrombin generation overtime, can be measured simply and reliably in many samples at the same time with minimal manpower, thus making it an excellent candidate for use in the clinic.

In general, a thrombogram in normal plasma follows the same trend: after activation of the plasma sample, there is a lagtime during which the coagulation cascade is generating undetectable amounts of thrombin and priming the cascade for a large burst of thrombin. Once detectable amounts of thrombin have formed and the burst of thrombin generation has begun, the lagtime has ended, and is generally correlated with the formation of a fibrin clot or the clotting times that are measured in the mechanical aPTT and PT assays. During the burst of thrombin generation, thrombin is formed very quickly, with a steep rate of reaction, culminating in a peak amount of thrombin being formed. After the peak is reached, thrombin generation slowly tails off, as coagulation factors in the sample have been used or are inactivated. These measurable parameters (lagtime, peak thrombin generated, total amount of thrombin formed, etc.) are
dependent upon the type of activator used; commonly, low amounts of TF (1pmol) are used and are generally thought to be the most physiological setting for activation (196).

While the TGA has been slowly making its way into the clinic, it has found a home in research settings, as it can easily be used to study the contribution of clotting factors to thrombin generation. In addition, this assay is well suited for in vitro drug development to identify drugs that affect thrombin dynamics for antithrombotic therapy. Analysis of current anticoagulant drugs have determined that inhibition of the ETP to approximately 20-40% of normal results in stable anticoagulation (218), while inhibition of the ETP to less than 20% of normal is correlated with bleeding phenotypes (217). Therefore, this assay has been used to determine a target therapeutic window of 20-40% ETP for efficacious and safe antithrombotic administration.

While the above studies have primarily been carried out with deficiencies or drugs that target the common or extrinsic pathway of coagulation, recent insight into the actions of the intrinsic pathway, primarily FXIIa-mediated FXI activation, have led to the hypothesis that these factors may be involved in pathological thrombus formation, but not hemostasis (40). While the common TGA is activated through the extrinsic pathway without the contribution of FXII, a standardized TGA activated through the intrinsic pathway would be beneficial to determine the effects on thrombin generation during inhibition of these factors, as well as identify potential therapeutics.
Here, we developed a standardized modified TGA (mTGA) assay that is activated by ellagic acid. We use a panel of anticoagulant RNA aptamers that specifically target five clotting factors (FII, FX, FIX, FXI, and FXII) to assess inhibition of the intrinsic and common pathways of coagulation in this assay, as well as compare thrombin inhibition in the mTGA to the standard, TF-activated TGA. Aptamers are single stranded, highly structured oligonucleotides that act as protein antagonists by binding to large surface areas on their target protein to directly inhibit protein-protein interactions (157). The aptamer platform is a promising tool for anticoagulant therapy, as aptamer administration can be rapidly and effectively reversed by a sequence specific or universal aptamer antidote (160, 165). Currently, an aptamer generated against FIXa and its matched oligonucleotide antidote are making their way through clinical development (163, 164). Using these aptamers as specific anticoagulant tools, it was found that this assay can detect inhibitors of the intrinsic and common pathway, and will be useful in target validation for analysis of an anticoagulant in human as well as animal plasmas.

4.2 Materials and Methods

Materials

The 2’F modified cytidine and uridine were purchased from Trilink BioTechnology (San Diego, CA). CTI collection tubes were purchased from
Haematologic Technologies (Essex Junction, VT). Human normal pooled plasma was purchased from George King Biomedical, Inc. (Overland Park, Kansas). The ellagic Acid-based Pacific Hemostasis APTT-XL Reagent was purchased from Thermo Scientific (Waltham, MA).

**RNA Aptamers**

For all aptamer sequences, “C” and “U” represent 2’fluorocytosine and 2’fluorouracil. The FII aptamer sequence (58nt) is 5’-

GGCGGUCGAUCACACAGUUCAAACGUAAUAAGCCAAUGUACGAGGAGAGACG
ACUCGCC-3’ (181), the FX aptamer sequence (80nt) is 5’-

GGGAGGACGATGCGGACATCTCCGCACATCGAGTTTGAGCACCACAACGAGC
CCCAGAGCAGACTCTGCTGAGGATCAGAGA-3’, the FIX aptamer sequence (80nt) is 5’-

GGGAGGACGATGCGGACTTGTCGGATAGGCCCTGATCCTAGTACACAAGAC
AGCAGACGACTCGCTGAGGATCAGAGA-3’, the FXI aptamer sequence (71nt) is 5’-

GGGAGGACGATGCGGTAACGCCGCCGCTCGGACGCTCGAGGTCTGACGAG
AGGTCTCCTCCGCCCAGACGACTCGCTGAGGATGAG-3’

The FII and FXII control aptamer sequence (51nt) is 5’-

GGGGGCAACGGCCCATCGCACGATGCTGATGAGCTCGAGCGACTCCTGATGAGGAGG-3’.

The FIII and FXII control aptamer sequence (51nt) is 5’-

GGGGGCAACGGCCCATCGACGATGCTGATGAGCTCGAGCGACTCCTGATGAGGAGG-3’.

The FIII and FXII control aptamer sequence (51nt) is 5’-

GGGGGCAACGGCCCATCGACGATGCTGATGAGCTCGAGCGACTCCTGATGAGGAGG-3’.

The FIII and FXII control aptamer sequence (51nt) is 5’-GGGAGGACGAGUGCGG-N10-
CAGACGACUCGCGGAGGAAUCCGAGA-3' and the FXI control aptamer sequence (71nt) is 5'-
GGGAGGACGATGCGG-N₄₀-CAGACGACTCGCCCGA-3'.

All aptamers were transcribed \textit{in vitro} as previously described using a modified
polymerase that can incorporate 2'F cytidine triphosphates and 2'F uridine
triphosphates (194). Before use, all aptamer preparations were diluted into a Hepes-
based buffer (20mM Hepes, 150mM NaCl, 2mM CaCl₂). Diluted aptamers were refolded
by heating to 65°C for 5 minutes, and then cooled for 3 minutes at ambient room
temperature.

\textit{Clotting Assays}

Activated partial thromboplastin time (aPTT) and prothrombin time (PT) assays
were carried out using a model ST4 coagulometer (Diagnostica Stago, Parsippany, NJ).
Pooled normal human platelet poor plasma was prepared by drawing blood into
sodium citrate tubes. For the aPTT, aptamer (5µL) was then added to 50µL pooled
normal human platelet poor plasma and incubated for 5 minutes at 37°C. 50µL APTT-
XL Reagent was then added to activate plasma and incubated for 5 minutes at 37°C.
Clotting was initiated by adding 50µL of 25mM CaCl₂ and the time to clot formation was
recorded. Aptamer concentrations represent the final concentration in the entire
reaction.
For the PT, refolded aptamer (5µL) was added to 50 µL pooled normal human platelet poor plasma and incubated for 5 minutes at 37°C. TriniClot PT Excel (Trinity BioTech, Bray, Co Wicklow, Ireland) was added to initiate clotting.

**Thrombin Generation Assay**

In an Immulon 2HB clear U-bottom 96 well plate (Thermo Labsystems, Franklin, MA), CTI- treated (50µg/mL), pooled normal human platelet poor plasma from healthy, consented volunteers (60µL) was mixed with aptamers (3µL) diluted in Hepes-based buffer without BSA and incubated for 5 min at 37°C. Ellagic acid reagent (final concentration 0.1µM, diluted 1:200 with 4µM phospholipid vesicles (20% phosphatidylinerine, 60% phosphatidylcholine, 20% phosphatidylethanolamine) in Hepes-based buffered saline)(15µL) was added to the plasma-aptamer mixture, and incubated for 5 minutes at 37°C. Flu-Ca (Diagnostica Stago)(15µL) was added to start the assay and thrombin generation was measured using a Fluroskan Ascent Reader (Thermo Scientific, Waltham, MA). A thrombin calibrator reagent (Diagnostica Stago, Parsippany, NJ) was used to quantify the amount of thrombin generated in the samples. Data analysis was performed using Thrombinscope software (Thrombinscope BV, the Netherlands). Aptamer concentrations represent the final concentration in the entire reaction. The amount of ellagic acid used was standardized to produce a similar curve to a TF-activated TGA. In addition, the amount of CTI present was standardized to inhibit
contact activation of the plasma sample, while still allowing for robust FXII-dependent activation upon administration of ellagic acid.

*Thromboelastogram*

Blood was drawn from healthy volunteers into standard sodium citrate tubes. Whole blood (320µL) was mixed with aptamer (10µL) and incubated at room temperature for 5 minutes. Kaolin (10µL)(Haemonetics, Niles, IL) was added, and the entire reaction (340µL) was added to 20µL CaCl₂ in a disposable, plain TEG cup (Haemonetics). Clot formation was measured at 37°C with a Thromboelastograph Analyzer (Haemonetics) until a stable clot was formed. Parameters were automatically calculated using the TEG® Analytical Software version 4.2.3 (Haemonetics).

### 4.3 Results

#### 4.3.1 Modified TGA assay validation

In order to evaluate inhibition of the intrinsic pathway of coagulation, as well as the common pathway in the TGA, the standard TF-activated TGA was modified so that plasma samples were activated with diluted ellagic acid aPTT reagent, thus autoactivating FXII to stimulate thrombin generation through the intrinsic pathway. During the development of this assay, it was recognized that activation of the plasma sample occurs relatively easily during the blood drawing or plasma preparation process,
as samples with only added phospholipids and calcium were able to generate thrombin without an activator present (data not shown). Activation of the plasma sample is thought to occur through the contact pathway, as FXII can be readily autoactivated upon exposure to foreign surfaces, resulting in activated FXII and FXI in the plasma sample. While this does not pose a problem in the standard TF-activated assay, as calcium is needed for extrinsic pathway reactions, as well as the activation of FIX by FXI, prior activation of the intrinsic pathway in the plasma sample will confound results in an intrinsic pathway based assay. Therefore, a standardized amount of corn trypsin inhibitor (CTI), an irreversible FXIIa inhibitor, was used to inhibit any FXIIa that may become activated during the blood draw or plasma preparation process. Importantly, only enough CTI was used to inhibit activation of FXII in this process, and not further inhibit FXII during activation in the assay.

To assess inhibition in the mTGA assay, a panel of RNA aptamers was used to determine thrombin generation during inhibition of each coagulation factor in the intrinsic and common pathways. Each of these aptamers have slightly different binding properties to their respective target (Table 10); however, each is specific for binding to only their specific protease. Although the exact mechanisms of all of these aptamers have not been evaluated, aptamers tend to bind to exosites on the surface of their protein, and thus inhibit protein-protein interactions that are essential for their coagulant function (157, 181).
Table 10. Summary of aptamer properties

<table>
<thead>
<tr>
<th>Aptamer Target</th>
<th>Length (nt)</th>
<th>$K_d$ Zymogen (nM)</th>
<th>$K_d$ Protease (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FII</td>
<td>58</td>
<td>10.0</td>
<td>1.0</td>
</tr>
<tr>
<td>FX</td>
<td>80</td>
<td>136.0</td>
<td>39.0</td>
</tr>
<tr>
<td>FIX</td>
<td>80</td>
<td>0.7</td>
<td>0.4</td>
</tr>
<tr>
<td>FXI</td>
<td>71</td>
<td>139.2</td>
<td>84.9</td>
</tr>
<tr>
<td>FXII</td>
<td>51</td>
<td>12.9</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Inhibition of each coagulation factor in the common (FII and FX) and intrinsic (FIX, FXI, FXII) pathways were detected in the modified TGA (mTGA) upon administration of aptamers. Dose titrations of each aptamer exhibited a distinct inhibition profile: full inhibition of FII, FX, and FIX completely abolished thrombin generation while inhibition of FXI and FXII reduced, but did not completely inhibit thrombin generation (Figure 33). Further analysis and comparison of individual TGA parameters during aptamer inhibition is discussed below.
Figure 33. Dose titrations of the panel of aptamers in the mTGA
Thrombograms of normal pooled plasma activated with 200x-diluted ellagic acid with indicated concentrations of A) FII Aptamer, B) FX Aptamer, C) FIX aptamer, D) FXI Aptamer, and E) FXII Aptamer. Preliminary data represent one assay.

Comparison of the mTGA versus the standard TF-activated TGA was analyzed by comparing parameters of both assays during inhibition of either FX (common pathway) or FIX (intrinsic pathway). As a common pathway coagulation factor, inhibition of FX in both assays gave comparable results, with the FX aptamer in TF-activated (Figures 34A,C,E) and ellagic acid activated (Figure 34B,D,F) exhibiting similar
potency in thrombograms (Figure 34A,B), ETP (Figure 34C,D) and the peak amount of thrombin generated (Figure 34E,F). Both assays were able to detect a complete inhibition of thrombin generation at saturating concentrations of the FX aptamer, with a slightly steeper dose response curve in the modified TGA versus the low TF activated TGA.
Figure 34. Comparison of the inhibition of the common pathway with the FX aptamer during the standard TF-activated TGA versus the modified ellagic acid-activated TGA

Normal pooled plasma was mixed with the FX aptamer and activated with either low (1pM) TF (A,C,E) or 200x-diluted ellagic acid (B, D, F). A) and B) represent thrombograms of the FX aptamer at indicated concentrations. C) and D) are the ETP and E) and F) are the peak thrombin generated of the FX aptamer (■) and a library size-matched control RNA (▲). Preliminary data represent one assay.

Comparison of the standard and mTGA assays during inhibition of the lower intrinsic pathway of coagulation was assessed using an aptamer targeting FIX. FIX can be activated through FXI (intrinsic pathway) or at a smaller extent through the TF/FVIIa
complex (extrinsic pathway). Activating the TGA with ellagic acid forces thrombin
generation to proceed mainly through the intrinsic pathway, thus analyzing FXI
activation of FIX, while activating the TGA with TF allows for the TF/FVIIa to activate
FIX as well as activate the common pathway directly through FX. The mTGA was more
sensitive to FIX inhibition, as saturating concentrations of the aptamer were able to
completely inhibit thrombin generation (Figure 35B,D,F). In contrast, high amounts of
aptamer were not able to fully inhibit thrombin generation in the TF-activated assay
(Figure 35A, C, E).
Figure 35. Comparison of the inhibition of the intrinsic pathway during the standard TF-activated TGA versus the modified ellagic acid-activated TGA
Normal pooled plasma was mixed with the FIX aptamer and activated with either low (1pM) TF (A,C,E) or 200x-diluted ellagic acid (B, D, F). A) and B) represent thrombograms of the FX aptamer at indicated concentrations. C) and D) are the ETP and E) and F) are the peak thrombin generated of the FIX aptamer (■) and a library size-matched control RNA (▲). Data represent one assay.
4.3.2 Modified TGA parameter analysis upon aptamer inhibition

Analysis of thrombogram parameters can further validate the modified TGA assay, as well as give insight into the mechanisms of inhibition of each individual coagulation factor when thrombin generation is initiated by the intrinsic pathway. First, the ETP for each aptamer was analyzed (Figure 36). The ETP represents the total amount of thrombin generated over time, and is determined by calculating the area under the thrombin generation curve. Full inhibition of the common pathway, as well as FIX and FXI, completely inhibited thrombin generation in this assay, as the ETP of each sample was zero or a negligible amount. Inhibition of FXII with the RNA aptamer, however, only decreased the ETP, but did not completely shut down thrombin generation.
Figure 36. Comparison of the endogenous thrombin potential (ETP) during aptamer inhibition in the modified ellagic acid-activated TGA

Normal pooled plasma was mixed with either the indicated aptamer (■) or a size-matched control RNA (▲) and activated with 200x-diluted ellagic acid. The ETP was calculated using the Thrombinsoscope software.  A) FII Aptamer,  B) FX Aptamer,  C) FIX Aptamer,  D) FIX Aptamer,  E) FXII Aptamer. The preliminary data represent one or more assays.

Next, the peak amount of thrombin formed was analyzed during aptamer administration. The peak is measured by calculating the maximum amount of thrombin formed, which is the peak of the thrombin generation curve. Analysis of this parameter in the mTGA behaves similarly to the ETP with aptamer inhibition of FIX, FX, and FII
exhibiting a steep dose response curve (Figure 37A,B,C). Inhibition of FXI and FXII more slowly reduced the peak, with maximal inhibition able to severely diminish the peak without completely abolishing thrombin generation (Figure 37D,E). This is in contrast to the ETP, as the FXII aptamer was able to greatly reduce the peak amount of thrombin formed without having such affect on the ETP (Figure 37E).
Figure 37. Comparison of the peak amount of thrombin formed during aptamer inhibition in the modified ellagic acid-activated TGA

Normal pooled plasma was mixed with either the indicated aptamer (■) or a size-matched control RNA (▲) and activated with 200x-diluted ellagic acid. The peak amount of thrombin generated was calculated using the Thrombinscope software. A) FII Aptamer, B) FX Aptamer, C) FIX Aptamer, D) FIX Aptamer, E) FXII Aptamer. The preliminary data represent one or more assays.

Next, the rate of thrombin generation upon aptamer administration was analyzed. This parameter measures the slope of the amount of thrombin formed from the first amount of thrombin generated (lagtime) to the maximum amount of thrombin
generated (peak). Similarly to the ETP and peak amount of thrombin generated, inhibition of the common pathway (FII and FX) exhibited a steep dose-response inhibition, as smaller aptamer doses had no effect on the rate of thrombin generation, but the rate of thrombin generation was suddenly abolished at higher doses (Figure 38). Inhibition of the intrinsic pathway (FIX, FXI, FXII) exhibited a much slower rate of reduction of thrombin generation. For every aptamer, administration of the control aptamer was able to increase the rate of thrombin generation dose-dependently, while having differing affects on the other parameters.
Figure 38. Comparison of the rate of thrombin generation during aptamer inhibition in the modified ellagic acid-activated TGA
Normal pooled plasma was mixed with either the indicated aptamer (■) or a size-matched control RNA (▲) and activated with 200x-diluted ellagic acid. The rate of thrombin generation was calculated using the Thrombinscope software. A) FII Aptamer, B) FX Aptamer, C) FIX Aptamer, D) FIXI Aptamer, E) FXII Aptamer. The preliminary data represent one or more assays.
The lagtime measures the time it takes for the first amount of thrombin to be formed, thus it is considered to be the time at which clotting first occurs. Full inhibition of the common pathway does not form thrombin, thus, the lagtime cannot be computed at the higher aptamer concentrations and these data points are missing (Figure 39A and B). Inhibition of FIX greatly increases the lagtime, while inhibition of FXI and FXII does not prolong the lagtime as severely compared to the other aptamers (Figure 39).
Figure 39. Comparison of the lagtime during aptamer inhibition in the modified ellagic acid-activated TGA

Normal pooled plasma was mixed with either the indicated aptamer (■) or a size-matched control RNA (▲) and activated with 200x-diluted ellagic acid. The lagtime was calculated using the Thrombinscope software. A) FII Aptamer, B) FX Aptamer, C) FIX Aptamer, D) FIX Aptamer, E) FXII Aptamer. The preliminary data represent one or more assays.
4.3.3 Comparison of aptamer inhibition and mTGA validation in human plasma and blood-based coagulation assays

Two common coagulation tests, the activated partial thromboplastin time (aPTT) and the thrombin generation assay (TGA), also measure the lagtime of clot formation in plasma. The aPTT assay uses the same activator, ellagic acid, to activate FXII and thus initiate clotting through the intrinsic pathway. The PT uses TF to activate the extrinsic pathway, and thus measures the function of the extrinsic pathway of coagulation. All aptamers prolonged the clotting time in the aPTT, with inhibition of the common pathway having a maximum effect (Figure 40A). Similar to the mTGA, inhibition of the intrinsic pathway could prolong clot time maximally with FIX, intermediately with FXII, and only slightly with FXI (Figure 40A). In the PT, inhibition of the intrinsic pathway did not have an effect, while inhibition of the common pathway produced a robust effect in clot time, with the FII aptamer inhibiting clot formation past the assay maximum (Figure 40B).
Figure 40. Comparison of clotting times during aptamer inhibition in an aPTT and PT with human plasma

Normal pooled plasma was mixed with the indicated aptamer and activated with either A) aPTT reagent or B) PT reagent. The data represent one or more assays.

In addition to the plasma based assays, an experiment utilizing whole blood and the presence of platelets would also give detailed information about the dynamics of inhibition in a complete setting. Thromboelastography uses whole blood to study the kinetics of clot formation by using mechanical motion to analyze clot strength. The two parameters studied included the lagtime (the time until clot formation) and the maximum amplitude (the strength of the clot formed). Table 11 summarizes the data from aptamer dose-titrations performed with kaolin as the intrinsic pathway activator.
Whereas all of the aptamers except the FXII aptamer could prolong the lag time, none of the aptamers had a large effect on the maximum amplitude of the system.

Table 11. Summary of preliminary TEG parameters with the panel of aptamers in human whole blood

<table>
<thead>
<tr>
<th>Aptamer Target</th>
<th>FII</th>
<th>FX</th>
<th>FIX</th>
<th>FXI</th>
<th>FXII</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lagtime (Doubling Time)</td>
<td>4μM</td>
<td>2.6μM</td>
<td>0.17μM</td>
<td>5.1μM</td>
<td>No effect</td>
</tr>
<tr>
<td>Maximum Amplitude</td>
<td>No effect</td>
<td>Slightly reduced</td>
<td>No effect</td>
<td>Slightly reduced</td>
<td>No effect</td>
</tr>
</tbody>
</table>

In order to determine the most sensitive coagulation assay for target and inhibitor validation, the panel of aptamers were compared in the TGA, the aPTT/PT, and the TEG for either doubling time (aPTT/PT and TEG) or IC50 (calculated from the peak amount of thrombin generated in the modified TGA) (Table 12). Importantly, the modified TGA was the only assay in which CTI was added to the collection tube during the blood draw so as to inhibit contact activation of the sample, resulting in more sensitivity to aptamer inhibition with all but the FII aptamer.
### Table 12. Summary of aptamer effects in clinical coagulation assays on human plasma or blood

<table>
<thead>
<tr>
<th>Aptamer Target</th>
<th>FII (Doubling Time)</th>
<th>FX (Doubling Time)</th>
<th>FIX (Doubling Time)</th>
<th>FXI (Doubling Time)</th>
<th>FXII (Doubling Time)</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>0.7μM</td>
<td>0.4μM</td>
<td>0.1μM</td>
<td>5μM</td>
<td>1μM</td>
</tr>
<tr>
<td>PT</td>
<td>0.15μM</td>
<td>0.5μM</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
<tr>
<td>TEG</td>
<td>4μM</td>
<td>2.6μM</td>
<td>0.17μM</td>
<td>5.1μM</td>
<td>No effect</td>
</tr>
<tr>
<td>mTGA (IC50)</td>
<td>3.0μM</td>
<td>0.3μM</td>
<td>&lt;0.1μM</td>
<td>&lt;1.0μM</td>
<td>0.2μM</td>
</tr>
</tbody>
</table>

#### 4.3.4 Comparison of aptamer inhibition and mTGA validation in animal plasma and blood-based coagulation assays

Before a drug can proceed into human clinical trials, it must first be extensively studied in animals for safety and efficacy. Because most coagulation assays are blood or plasma based, they are easily adapted for assessing drug inhibition with animal plasmas. All of the aptamers used here are isolated solely against the human form of the coagulation factor; thus, analysis for cross reactivity in animal plasma is a must before proceeding into pre-clinical trials. In general, aptamers have exhibited some efficacy in a variety of species; however, the cross-reactive species varies from aptamer to aptamer. The panel of aptamers was tested in rabbit plasma or blood in the aPTT/PT, TEG, and mTGA assays for cross-reactivity (Table 13). Only the FII and FX aptamers were able to exhibit cross reactivity in rabbit plasma as determined by the aPTT and the mTGA; however, these aptamers did not exhibit high efficacy in either the PT or the TEG.
Aptamers targeting the intrinsic pathway (FIX, FXI and FXII) did not show reproducible efficacy in rabbit plasma.

**Table 13. Summary of aptamer effects in clinical coagulation assays on rabbit plasma or blood**

*Doubling time was not reached at the highest concentration tested.

<table>
<thead>
<tr>
<th>Aptamer Target</th>
<th>FII (Doubling Time)</th>
<th>FX (Doubling Time)</th>
<th>FIX</th>
<th>FXI</th>
<th>FXII</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>1.5µM</td>
<td>1.5µM</td>
<td>No effect</td>
<td>No effect</td>
<td>8µM</td>
</tr>
<tr>
<td>PT</td>
<td>&gt;8µM*</td>
<td>&gt;4µM*</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
<tr>
<td>TEG</td>
<td>2.7µM (IC50)</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
<tr>
<td>mTGA</td>
<td>5µM</td>
<td>1.2µM</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
</tbody>
</table>

**4.4 Discussion**

The standard TF-activated TGA offers a comprehensive view of thrombin dynamics, generating more information on how deficiencies or drug-inhibition of coagulation factors affect thrombin generation than any other common clinical coagulation test. However, the standard TGA proceeds without contribution of the intrinsic pathway of coagulation (FXII). While physiologic hemostasis is thought to occur mainly through the extrinsic pathway, thus mirroring the standard TGA, intrinsic pathway activation is thought to occur through continued thrombin generation at the site of the growing thrombus (39). To this end, a modified TGA assay that stimulates thrombin generation through the intrinsic pathway was developed in order to study
thrombin generation during intrinsic pathway inhibition as well as identify potent inhibitors of this pathway.

Aptamers targeting both the common pathway (FII and FX) and the intrinsic pathway (FIX, FXI, and FXII) were used to validate the modified TGA, compare the inhibition of thrombin generation in both assays, as well as compare thrombin generation during inhibition of each pathway and individual clotting factor. First, the strength of activator used to initiate the intrinsic pathway was calibrated to exhibit a similar pattern of thrombin generation seen in the standard TF-activated TGA. The mTGA was able to detect significant decreases in thrombin generation upon inhibition of all targets tested, in both the intrinsic and common pathways. Inhibition of FII and FX of the common pathway completely abolished thrombin generation as expected since these factors are essential for thrombin and fibrin clot formation (1). Thrombin generation during inhibition of the intrinsic pathway varied depending upon the target. While inhibition of FIX and FXI severely reduced thrombin generation to negligible amounts, inhibition of FXII could only lower the amount of thrombin formed. Like FXII, FXI has been shown to be autoactivated upon contacting certain negative surfaces, such as dextran sulfate. While it was not tested whether ellagic acid could autoactivate FXI itself, some FXI activation would bypass the need for FXII to generate thrombin. In addition, some contact activation of the plasma sample, as occurs during the blood
drawing process, could also contribute to downstream activation of clotting factors that would affect thrombin generation upon inhibition of FXII.

The standard TF-activated TGA was compared to the ellagic acid-activated mTGA during inhibition of the common pathway (FX) and the intrinsic pathway (FIX). Comparison of the ETP and peak amount of thrombin formed during inhibition of FX was similar between the two assays. As the intrinsic and extrinsic pathway converge upon activation of FX, this result suggests that both assays proceed similarly once the common pathway is activated. On the other hand, there were differences in thrombin generation upon inhibition of FIX. FIX is thought to be primarily activated by FXI, however, the TF/FVIIa complex can activate small amounts of FIX in the initiation phase of thrombin generation as well as directly activating FX. This was mirrored during comparison of the two assays, as the TF-activated TGA only lowered thrombin generation, with a substantial amount of thrombin still able to be formed. In the mTGA, which is activated through the intrinsic pathway, thrombin generation was essentially abolished, as only negligible amounts of thrombin were able to be detected upon full FIX inhibition. This result highlights the differences in the two assays, and validates the mTGA in proceeding primarily through the intrinsic pathway.

Further analysis into the individual parameters of the mTGA upon inhibition with each aptamer exhibited certain trends consistent with the roles of each factor in thrombin generation. Inhibition of FII and FX of the common pathway was able to
completely abolish thrombin generation to the point where no parameters could be computed. Both of these aptamers exhibited a steep dose titration curve, as thrombin generation seemingly was either all-on or all-off. This result was in part mirrored in an assay utilizing a cell-based model of thrombin generation, an in vitro system using cultured macrophages as a source of tissue factor, physiologic amounts of purified proteins, and platelets that serve as the surface for thrombin generation to occur. In this assay, only small levels of FX were needed to normalize parameters, similar to the steep dose titration seen here as well as previous data using the extrinsic activated TGA (64) (217).

As FIX has roles in both the intrinsic and extrinsic pathway, its thrombin generation profile was comparatively “in the middle” between common pathway inhibitors and other intrinsic pathway inhibitors. Inhibition of FIX led to a marked increased in the lagtime, and high concentrations of the aptamer were able to completely inhibit thrombin generation. However, this aptamer had a slightly slower onset of action compared to the FII and FX aptamers. In contrast, inhibition of FXI and FXII could not completely inhibit thrombin generation, although both aptamers severely impaired the peak and rate of thrombin generation, consistent with the finding that inhibition of factors contributing to tenase complex formation primarily affects these parameters (64). While FXI could also greatly inhibit the ETP, FXII had a much smaller effect on the ETP, perhaps reflecting that FXI could be activated in the plasma sample by
several ways. In contrast to the other aptamers, inhibition of FXI and FXII only slightly increased the lagtime of the sample, the parameter that is solely measured in the aPTT. Thus, it seems that inhibition of FXI and FXII is better analyzed in the mTGA than traditional clotting time assays, as both of these aptamers could maximally affect other thrombin generation parameters with minimal disturbance of the lagtime.

Because of the sensitivity of this assay to contact activation, a standardized amount of CTI was included in the collection tube during the blood draw in order to inhibit contact activation during the blood drawing and plasma preparation process. While human blood is easily activated during the blood drawing process, rodent blood is highly attune to contact activation as well. In our experience, each animal species requires a certain amount of CTI present during the blood draw to inhibit contact pathway activation. Rabbit was chosen as the species of choice due to quantity of blood drawn and regularity in the blood drawing process, so as to obtain a decent number of plasma samples that have not been contact activated. In comparison, it is difficult to obtain the volume of plasma needed that is not contact activated in rats, as more than half of the samples drawn are contact activated (verbal communication).

In comparing aptamer efficacy across the panel of coagulation assays performed with rabbit blood or plasma, only the common pathway inhibitors (FII or FX) were able to exhibit cross-reactivity. Intriguingly, both aptamers were only able to inhibit thrombin generation effectively in the aPTT or mTGA in rabbit plasma - both assays that
are activated by ellagic acid. Inhibition of FII in the kaolin-activated TEG was able to prolong the time for a clot to occur, but did not reach doubling time at the concentrations tested. The FX aptamer, however, did not show any effect in the TEG in rabbit plasma. In addition, both aptamers did not have an effect in the TF-activated PT assay. This suggests that rabbit plasma may act differently than humans, with the extrinsic system perhaps not being as important in initiating coagulation. In addition, the fact that none of the three intrinsic pathway aptamers were able to cross react in this species suggests that these proteins may be quite different from the human proteins, and perhaps act in a different manner. Studies of cross-reactivity with the entire panel of aptamers in rat and non-human primates are currently underway.

Overall, the modified TGA is the most sensitive and informative assay used to study both intrinsic and common pathway inhibition. Inhibition of any of these coagulation factors can affect a number of parameters that are easily analyzed using the mTGA, while each of the other assays tested here primarily measure the lagtime. While this study focused on the use of RNA aptamers targeting each specific coagulation factor, data with small molecule and antibody inhibitors also exhibited similar trends, albeit with different mechanisms of inhibition (data not shown). Further analysis and comparison between thrombin inhibition patterns and mechanism of small molecules versus aptamer could give insight into coagulation target validation for the type of therapy being developed. In addition, further validation and analysis of coagulation
factor inhibitors in animal models versus mTGA assessment will also aide in the ability of this assay to identify potent antithrombotics.
5. Conclusions and Perspectives

5.1 The rationale behind developing aptamer inhibitors of the intrinsic pathway of coagulation

Traditionally, the hemostatic system of proteins and zymogens involved in maintaining the integrity of the vasculature has been organized into a cascade model hallmarked by two converging pathways initiated by either the extrinsic or the intrinsic pathway and resulting in thrombin and fibrin clot formation. While the extrinsic pathway is triggered by the binding and subsequent activation of circulating FVII to exposed TF on a damaged vessel wall and thought to be the dominant cause of coagulation, the intrinsic, or ‘contact’ pathway, is activated when FXII is exposed to any number of artificial or physiologic negatively charged surfaces circulating in the blood and subsequently activates FXI to initiate the cascade.

Although the intrinsic pathway can activate clotting efficiently in vitro, such as in clotting assays that use glass to activate FXII and initiate clotting, these tests do not necessarily correlate with in vivo observations from hemophilic or factor deficient patients. While patients with hemophilia A or B (FVIII or IX deficiency) or common factor deficiencies (X, V, or II) have severe bleeding phenotypes or are incompatible with life (77), patients with deficiencies of FXII and FXI either have no bleeding tendencies or an injury-related variable bleeding tendency, respectively (219), suggesting that FXII and FXI are not required in hemostasis. Mice lacking FXI or FXII exhibit no bleeding phenotype, and, interestingly, both are protected against thrombus formation in several
models of arterial thrombotic injury. These studies suggest that, while thrombus initiation is not interrupted on the vessel wall after injury in both FXI and FXII deficient mice, thrombi that are formed are unstable and break up before occlusion of a blood vessel can occur (40, 72, 73, 91). Protection from thrombosis is not limited to arterial injury, as FXII or FXI deficiency also confer a thromboprotective effect in a transient middle cerebral artery stroke model (MCAO) (41, 92). The antithrombotic effect of FXI deficiency is also apparent across species, as inhibition of FXI with antibodies in rabbits and baboons resulted in reduced thrombus propagation and prevented growth of occlusive thrombi in either injured arteries or on arterio-venous shunts, respectively (74-77, 93). Taken together, this work increasingly suggests that inhibition of the upstream, intrinsic coagulation factors XI and XII can hinder thrombosis without affecting normal hemostatic events (220). It then follows that the pharmacological inhibition of FXI and FXII in humans could produce a safe and effective anticoagulant to treat and prevent thromboembolic disorders (Figure 41).
Figure 41. Decoupling hemostasis and thrombosis
While the extrinsic pathway is essential for initiating hemostasis at the site of blood vessel wall injury, continued thrombin generation on the clot surface due to the intrinsic pathway contributes to the stability of the blood clot. Pharmacologic inhibition of FXI and FXII of the intrinsic pathway could lead to a safe and effective antithrombotic that interrupts thrombosis without interrupting hemostasis.

The overall goal of this project was to develop potent and specific inhibitors of the intrinsic pathway utilizing the aptamer platform of therapeutics and evaluate this inhibition as a potential anticoagulant strategy. Currently approved anticoagulants inhibit either downstream or multiple members of the coagulation pathway. While these drugs are effective anticoagulants, they are not always safe, and drug
administration without a direct antidote can require constant monitoring and confer a higher risk of bleeding complications. Striking the correct balance between inhibiting thrombus formation (efficacy) and reducing the risk of severe bleeding (safety) is crucial in developing a novel anticoagulant. This ratio of efficacy to safety can be achieved by two ways: targeting factors that cause bleeding, but having the ability to reverse the drug’s action, or targeting factors involved in pathological thrombus formation that do not play a major part in hemostasis. While aptamer-antidote pairs targeting downstream members of the coagulation pathway (including FII, FX, and FIX) have previously been described to be effective anticoagulants yet will require antidotes to be safely administered, this project was successful in isolating effective aptamer inhibitors of two upstream members of the intrinsic pathway, FXI and FXII, which may not require antidotes to be safe and effective anticoagulants.

5.2 Discovery and pre-clinical development of intrinsic pathway aptamer inhibitors

The discovery and initial development phase of aptamer therapeutics includes performing a directed evolution selection to isolate a specific, high affinity aptamer, and subsequently testing this aptamer in a number of biochemical assays to identify its mode of action, as well as plasma or blood based assay to assess its anticoagulant potential. Both aptamers described in this process were able to be initially biochemically characterized, as well as demonstrated anticoagulant ability and reduction of thrombin generation in a plasma-based assay (Figure 42).
Inhibiting the intrinsic pathway of coagulation with RNA aptamers.

Figure 42. Inhibiting the intrinsic pathway of coagulation with RNA aptamers.
Both FXII and FXIa aptamers specifically inhibit their respective targets to decrease thrombin generation and fibrin clot formation.

While this strategy has been used successfully to identify aptamer anticoagulants specifically targeting a number of other coagulation factors, the plasma-based characterization of intrinsic pathway inhibitors was hindered by several circumstances. The first issue has been discussed at length in the above chapters: the ability of the contact pathway to be readily activated during the blood drawing process. This property hindered the use of in vitro, plasma-based assays to be utilized to screen a large
number of intrinsic pathway inhibitory aptamers for anticoagulant activity. Instead, more time intensive biochemical assays were employed to screen these aptamers for functionality before moving into more complex plasma-based assays. It was not until the introduction of the use of CTI, which inhibits contact activation in the sample during the blood drawing process, that we were able to see potent inhibitory effects upon aptamer administration in a plasma-based setting. It was hypothesized that previous contact activation of the plasma sample led to downstream activation of coagulation factors, perhaps culminating with FXIa binding to FIX. It has been determined that only a small amount of thrombin formed can lead to the fibrin clot formation measured in clotting time assays. Upon re-calcification, any residual FXIa bound to FIX can now activate FIX; however, inhibition of FXII/FXIIa or FXI/FXIa would not have a large effect on clotting times in a plasma sample that can already produce a small amount of thrombin due to basal activation. Further studies into the difference of using contact pathway inhibited plasma versus untreated plasma will continue to clarify these differences and allow us to better screen and characterize our aptamer libraries against FXI, FXII and kallikrein.

Aside from hindrances during the blood drawing process, in vitro plasma or blood-based assays that closely mimic physiologic responses are lacking in the laboratory and the field. While it is widely accepted that the extrinsic pathway is the main contributor to coagulation in vivo, the aPTT and PT use extreme amounts of either intrinsic or extrinsic pathway activators in order to reach a standardized clotting time.
utilized in the clinic for reproducibility. These activators are mostly non-physiologic substances or are more concentrated than in any physiologic setting; thus, they fully and quickly activate the clotting cascade. As these assays were primarily based off the initial cascade model of coagulation, they do not take into account the importance of surfaces for clotting to occur, as platelets are replaced by phospholipids and endothelial cells are presumably not present. It is our observation that inhibition of the common pathway proteases (FII and FX) can completely disrupt clotting in these assays, while intrinsic pathway inhibitors have a lesser effect on clotting times, with clots eventually being able to form. Therefore, while this assay can easily identify common pathway inhibitors, the use of intrinsic pathway inhibitors may not cause a large effect on clotting times, and thus it might be harder to identify inhibitors of these targets.

In addition, the traditional clotting assays and other plasma or blood based \textit{in vitro} assays used in this study do not take into account the influence of blood flow on the system. Blood flow continuously supplies the area of clotting with new material, including zymogens, platelets, and inhibitors, as well as carrying away activated proteases, platelets, and inhibitors. Blood flow is a currently underexplored but important mediated of fibrin deposition and can greatly influence the stability of the clot (5). As it is hypothesized that FXI and FXII might play a larger role in continued thrombin generation than initial clot formation, inhibitors of these two proteases in a flow-based system might play a larger role than indicated using non-flow assays. As
more is known about the difference between thrombotic environments versus hemostatic environments, *in vitro* assays need to be developed to mimic these settings.

In addition to choosing the most physiologic *in vitro* assays to more effectively examine thrombosis versus hemostasis, the choice of animal species and animal model during pre-clinical drug development can greatly influence the result. Because aptamers bind tightly over a large surface area on the protein’s surface, they do not always exhibit a high rate of cross-reactivity to other species, where even one amino acid change over the binding region can disrupt aptamer-protein binding. Anecdotally, it is thought that if the aptamer inhibits an established coagulation reaction found across species, such as the binding of FV to FX to form the prothrombinase complex, then this reaction, and thus the specific exosites on each protein, should be highly conserved. Therefore, an aptamer that binds to that exosite and inhibits that reaction theoretically has a higher chance of cross-reacting with different species. In general, aptamers tend to target exosites on the surfaces of proteins. We found (summarized in Chapter 4, as well as unpublished data) that aptamers targeting the downstream coagulation factors (FII, FX and FIX), all which block exosites on their target protein, have a higher rate of cross-reactivity over the animal species tested than the intrinsic pathway-targeting aptamers. This mirrors what is thought to have occurred evolutionarily – with the emergence of the common pathway proteases first, followed by the more recent emergence of the intrinsic pathway. Thus, our data indirectly hints that the protein exosites on proteins
higher up the cascade may not be as conserved across species. Further biochemical studies, including crystal structures of aptamers bound to proteins, would be needed to examine this theory.

Because the proteins for FXI and FXII may not be as conserved across species, established animal models of thrombosis or hemostasis used to evaluate inhibition of FXI and FXII are brought into question. If the function of FXI and/or FXII are slightly different in an animal than a human, then determination of the therapeutic potential of an inhibitor may not correlate. Animals may not be “small humans” where the pathways are identical between the two species. In this instance, it has been observed that different species have different clotting times, with rabbits and rats clotting very quickly compared with humans or non-human primates. This indicates that the coagulation system may have some very real differences, if not just the concentration of protein present in the blood. Both of these species need to have higher amounts of CTI present in order to prevent the contact pathway from becoming activated, indicating that this pathway might play a greater role in coagulation than in humans. Therefore, the use of these animal models to characterize inhibitors, as well as the murine data using FXI or FXII deficient mice, may not replicate what is or will be seen in humans. The selection of the right animal model is key in developing these aptamers further as therapeutics. Currently, the FXI and FXII aptamers do not potently cross react in any animal species besides human. Additional experiments using correct blood drawing
processes are underway to test these aptamers in more closely related species where the
cost to do animal model experiments have been decreasing, including non-human
primates.

Aside from testing the aptamers against different animal serums, strategies to re-
design the aptamer to be cross-reactive can be undertaken. The human binding aptamer
can be partially randomized and re-selected against the animal protein in a “doped-
pool” SELEX. The goal of this SELEX would be that slight changes in the final aptamer
sequence will bind to the same exosite on the human protein and with a higher affinity
to the animal protein. This selection assumes that high-quality, purified animal proteins
are available. Unfortunately, these are not currently available commercially for FXI or
FXII.

In subsequent selections, the consideration of cross-reactivity can be included in
the selection protocol, therefore considering pre-clinical studies during the drug
discovery process. The first instance of this was demonstrated using a toggle selection
approach, whereby a thrombin aptamer was isolated that could bind to both human and
pig thrombin by alternating selection rounds with each purified protein (151). Again,
while this strategy is effective, it is limited with the ability to obtain highly purified
animal protein.

Aside from toggle SELEX, there are other strategies that can be employed to
increase cross-reactivity. If no purified protein is available, a complex convergent toggle
selection may be employed. The complex SELEX approach has previously been utilized to select for a library of aptamers that bind to a mixture of proteins including the plasma proteome (152). Theoretically, a complex toggle approach would alternate selection rounds between human and animal plasma proteomes, with a resulting pool of aptamer sequences that can bind to both proteomes. This strategy can be employed in several different ways to increase the probability of isolating an aptamer that can bind to both species – the plasma proteomes can be combined to form a mixture of human and animal proteins, or a complex selection can be performed on the animal proteome followed by a convergent selection with the purified human target protein. Any number of these selections could 1) increase the chance of obtaining a species cross-reactive aptamer and 2) not require the use of high quantities of purified animal proteins.

5.3 Clinical development of aptamer therapeutics

Before aptamers begin preclinical and clinical trials, several optimization steps must occur in order to make the compound cost-effective and able to be stably administered. First, in order to decrease manufacturing and material costs, as well as potentially decrease any non-specific, RNA length dependent issues, the aptamer is truncated to the shortest length possible that retains binding affinity and anticoagulant function. The FXII and FXI aptamers were isolated using an 80 and 71 nucleotide modified RNA library, respectively. While these libraries are able to isolate functional aptamers, the functional portion of the aptamer may not include all nucleotides.
Truncation is aided by comparing each family of aptamer sequences within a selection. While these families differ considerably in base composition, there may be conserved strings of bases found throughout several different families. Using this strategy, the FXII aptamer was truncated from 80 nucleotide to 52 nucleotide while keeping intact a conserved string of bases. Previously, 40 nucleotides was the maximum length for a cost-effective aptamer, that length has gone up as manufacturing costs have been reduced, and a 50-mer is possible for cost-effect, large scale production. The FXI aptamer has not yet been truncated.

In addition to truncation, the aptamer is further optimized by replacing as many 2'F pyrimidine modifications and 2'hydroxyl nucleotides to a 2'O-methyl modification in order to further increase stability as well as reduce the likelihood of activating innate immune responses. This reduces production costs while still protecting the aptamer from endonuclease cleavage. In addition, stabilization of the aptamer by optimizing the stems present in the RNA structure, such as switching a U-A base pair to the more stable G-C base pair, can also be performed if needed. Oftentimes, this can aid in truncation, as two consecutive U-A base pairs making up a stem can sometimes be altered to one G-C base pair without disrupting the stability of the aptamer.

In preparation for animal or human administration, a high molecular weight moiety, such as PEG, will be appended to the end of the aptamer in order to increase the size of the aptamer and thus reduce clearance time facilitated by the kidneys. While this
modification does not usually alter the structure of the aptamer, there have been instances where addition of a PEG can partially disrupt aptamer binding. While this is rare, the PEG can be appended to the other end of the aptamer, or a longer linker can be added to retain proper aptamer folding and function. In this way, the half-life of the aptamer can be increased from minutes to days. Overall, this strategy has been successful in optimizing aptamers for animal studies, and an anticoagulant aptamer targeting FIX modified with this scheme is currently in Phase 2 clinical trials.

5.4 Applications and the therapeutic potential of an intrinsic pathway inhibitor

Overall, inhibition of the intrinsic pathway could be the “holy grail” of anticoagulant therapy, as inhibition of either FXI or FXII seems promising in inhibiting thrombosis without affecting hemostasis. There is some debate that FXI may be the preferred target, as it is thought to be primarily a coagulation protein with no known large roles in other physiologic processes. FXII, on the other hand, has emerging roles in inflammation as well as potential basal growth factor activity stemming from low levels of zymogen activity. In this setting, an aptamer therapeutic might be beneficial, as aptamers can block distinct functions based on the binding site location on the target protein. To this end, while the FXII aptamer described here inhibits FXI activation, it does not effect prekallikrein activation, and thus potentially might affect coagulation but not inflammatory processes. As other roles of FXII are elucidated, aptamer effects can be studied, including FXII’s emerging role as a growth factor. Because of the low risk of
bleeding and central role as a contact activator, inhibition of FXI or FXII can be utilized a
derug therapy in many ways, including long term therapy to prevent thrombosis in at-
risk patient populations or in combination therapy to inhibit blood contact activation
when using artificial surfaces, such as catheters or a heart-lung machine.

The development of an intrinsic pathway aptamer as a long-term anticoagulant
has several benefits and drawbacks. Although inhibition of FXI or FXII is not anticipated
to be correlated with major bleeding events, some bleeding events associated with
surgical procedures in specific tissues have been reported in FXI-deficient patients.
Aptamers inherently have the ability to be reversed, and this technology has been tested
in humans to be fast-acting and effective (163). While minimal events are expected with
intrinsic pathway inhibition, a readily available antidote can further increase the safety
of these drugs by rendering the target protein completely functional within minutes of
antidote administration.

While long-term anticoagulation has traditionally been effectively administered
orally, aptamers are currently only parentally available, which limits their use to
injections or intravenous use, especially during surgical procedures. Preliminary data
has suggested that aptamers can also be administered subcutaneously with a longer
onset of action, which is an acceptable mode of administration for a long-term
anticoagulant (189). However; while aptamer effects can be seen for weeks after
subcutaneous administration, a rebound anticoagulant effect is exhibited after antidote
use. However, this should not be a hindrance to an intrinsic pathway inhibitor where antidote use is expected to be minimal or for acute settings where re-dosing of antidote is possible.

Aptamers inhibitors of other major coagulation proteases have previously been described (164, 181, 182). While all are functional inhibitors of their protease target and can independently anticoagulate blood or plasma, their concurrent administration synergizes with greatly increased anticoagulant effects (data not published). Current studies are ongoing to determine an effective anticoagulant strategy for use in cardio-pulmonary bypass, with preliminary data suggesting that inhibiting two sequential steps in the coagulation cascade is the most potent anticoagulation combination. The addition of an intrinsic pathway aptamer inhibitor could also be beneficial in this highly thrombogenic, artificial setting, where blood flows through tubing and over an oxygenator. Use of the FXII aptamer to inhibit contact activation by these materials could lead to reduced activation of coagulation factors, and potentially lower dosing requirements for other aptamers. Currently, the use of two highly potent, non-aptamer anticoagulants is limited, as synergy can oftentimes result in uncontrollable hemorrhage. Importantly, concomitant use of several aptamers is ultimately safer, as you can quickly reverse all aptamers using an universal antidote, or reverse the action of just one aptamer by using a sequence specific antidote. In addition, full or partial reversal of aptamer function can be reproducibly performed. This level of control with an
anticoagulant therapeutic is unparalleled, and can lead to multiple applications in the surgical field.

In the laboratory, aptamers are useful tools to examine diverging functions of a protease, as they can inhibit specific functions while leaving others intact. The FXII aptamer described in this project inhibits coagulation (FXI activation) but not inflammation (prekallikrein activation). While in vivo the aptamer may effect both functions of FXII because it inhibits the first step of FXII autoactivation, this aptamer can be used to examine the difference between FXIIa-mediated reactions in the laboratory. As FXII and FXIIa has increasingly been shown to be involved in a number of different processes, this aptamer could be valuable in discerning the influence of its separate functions. Similarly, FXI has binding sites for multiple coagulation proteins, including the platelet receptor GP1bα, and can be activated by other proteases other than FXII. While aptamer effects on these interaction has not yet been assessed, further biochemical characterization will allow for detailed mechanisms in aptamer inhibition, and the potential to aid in further discerning the biologic function of FXI.

5.5 Summary

Overall, the novel aptamer inhibitors of FXII and FXI described here are promising as potential therapeutics. As both of these aptamers can decrease thrombin generation in plasma-based assays, further in vivo analysis will determine if these aptamers can affect the FXII-mediated FXI activation that contributes to attenuated
thrombin generation in a thrombotic environment. As a class of drugs, aptamers lend themselves well to anticoagulation, as they can inhibit specific protein-mediated reactions, thus eliminating off target effects for a protein, especially FXII, whose role in several pathways is not yet elucidated. In addition, aptamers have the ability to be quickly reversed while leaving their target protein intact, thus increasing their safety during potential bleeding events. In the setting of FXII and FXI, this is attractive not only for FXI aptamer therapy, where mild bleeding events may occur, but also for potential combination therapy with a more potent antiplatelet agent or antithrombotic agent, which, while effective, has been hindered by a lack of safety due to increased bleeding events. Lastly, this project highlights the need for better physiologic laboratory assays in which to study potential drug therapeutics. We were successful in developing a standardized assay that can detect changes in thrombin generation during inhibition of the common or intrinsic pathway of coagulation. As many common coagulation tests were based off of outdated coagulation models, the introduction of new or updated tests should be welcomed to the laboratory.
Appendix A

Throughout this project, it was noticed that the aptamer controls could exhibit nonspecific effects in plasma-based assays, notably the aPTT and TGA. These effects, however, were completely opposite in each assay, as control RNA acted as an anticoagulant in an aPTT and an agonist in a TGA. The data and some speculation as to why this occurs are found here.

In an aPTT, 2’F pyrimidine modified, nonspecific RNA can dose-dependently increase clotting times in an aPTT activated by either micronized silica or ellagic acid (Figure 43). This activation is also length dependent, as shorter RNA’s exhibit less of an effect on clotting times, with a steep drop off in nonspecific prolongation for RNAs less than 70 nucleotides. Therefore, our aptamers were truncated whenever possible to less than 70 nucleotides to decrease nonspecific effects.

![Graph](image)

**Figure 43.** Control RNA comparison in an aPTT assay
Normal plasma was incubated with indicated control aptamers, and activated with micronized silica to obtain clotting times. The data represent the mean ± SEM of duplicate measures.

It was quickly noticed that the same RNA constructs used in the aPTT acted as agonists in the modified TGA, as they also could dose-dependently increase the rate and peak amount of thrombin generated (Figure 44). This agonist effect, however, did not alter the ETP of the sample. Anecdotally, the control RNA had a larger effect when the baseline peak thrombin generation of the sample was low (around 100nM), and it also seems that size has an inverse effect, with the longer RNA’s exhibiting less of an effect than the shorter RNA’s. This data, however, needs to be repeated.

Figure 44. An RNA control exhibits antagonistic effects in a modified TGA assay
A 50 nucleotide scrambled control RNA was incubated with plasma at the indicated concentrations before addition of diluted ellagic acid activator to begin thrombin generation. The data are representative of three independent measures.
It was determined that these opposite, nonspecific effects depend on the potency of the activator (data not shown). The TGA uses 200x diluted ellagic acid to initiate thrombin generation with the aPTT uses “full strength” ellagic acid. As tested by an aPTT analyzing lag times, as the concentration of ellagic acid increases, less agonistic effects of control RNA were seen, with a switch to a prolongation of lag time as the reagent neared full strength (personal communication with Merck). This hints at possibly two different mechanisms of nonspecific interactions.

Control aPTT experiments looking at FXIIa and FXIa activated clotting times suggested that the agonist effect may be mediated by FXIa. It is known that polyanions, such as polyphosphates, can act as a cofactor to enhance FXI activation by thrombin (111). Similarly, incubation of either purified protein or plasma with control aptamer or polyphosphate accelerated clotting times in a FXIa-dependent manner, while no difference in lag time was seen in FXIIa-initiated clotting times (Figure 45). As a control, the FXII aptamer inhibited clotting times in FXIIa activated plasma, but acted similarly to nonspecific RNA in FXIa activated plasma.
Figure 45. Analysis of polyanions on FXIIa or FXIa clotting times
The effect of R4cXII-1(■), scrambled control RNA (▲) or polyphosphates (▼) in a clotting assay activated with A) 250nM FXIIa or B) 40nM FXIa. The data represent the mean ± SEM of duplicate measures.

While the general mechanism on why these nonspecific effects occur is not known, the data hints at two different mechanisms that depend on the concentration of activation reagent used. At high concentrations of activator where activation is forced to proceed through the intrinsic pathway, nonspecific RNA could interfere with binding properties of the activator to FXII (it is well established that nonspecific RNA binds to FXII), and thus slightly inhibit clotting. When the activator is diluted, perhaps allowing for other feedback mechanisms to contribute to thrombin generation, nonspecific RNA could be acting as an agonist in a FXI-dependent manner. Further analysis will help to determine the specifics of these nonspecific, yet assay-specific, RNA effects.
References


34. LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate


89. Pavlov V, Zorn M, Kramer R. Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood


104. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic


Biography

Rebecca Leigh Smock Woodruff was born on July 9, 1985 in Richmond, Virginia. She attended the University of North Carolina at Chapel Hill from 2003 through 2007 and obtained a Master’s of Science in Biology and a minor in Chemistry. During her time there, she was a varsity swimmer for all four years, and team captain during the 2006 and the ACC-Champion 2007 seasons. In addition, Rebecca began her research career at UNC in Ralph Baric’s lab studying the SARS coronavirus. Rebecca initiated her graduate studies at Duke University in the fall of 2007 under the Cell and Molecular Biology Department. After choosing to conduct her studies under the mentorship of Bruce Sullenger, she affiliated with the University Program in Genetics and Genomics, and designed her thesis work on developing the aptamer technology as an anticoagulant therapy.

Publications


